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Abstract	
Protein	arginine	methylation	is	a	common	post-translational	modification	where	methyl	groups	are	added	to	the	arginine	residues	of	peptide	chains.	It	is	carried	out	by	a	group	of	enzymes	known	as	protein	arginine	methyltransferases	in	eukaryotic	cells.	Protein	arginine	methylation	plays	an	important	role	in	many	cellular	functions	both	in	the	nucleus	and	in	the	cytoplasm	such	as	the	regulation	of	signal	transduction,	RNA	export,	and	cell	proliferation.	However,	the	exact	role	arginine	methylation	plays	in	neurons	is	not	yet	fully	understood.	
Previously,	CRMP-2	was	suggested	to	be	asymmetrically	di-methylated	in	mouse	primary	cortical	neurons	during	Honour	study.	Therefore,	the	major	aim	of	this	study	was	to	explore	the	role	of	arginine	methylation	of	CRMP-2	and	its	binding	partner,	tubulin.	Another	aim	was	to	investigate	the	enzymes	that	are	involved	in	the	methylation	of	the	identified	proteins.	
The	results	showed	that	CRMP-2	and	tubulin	α	and	β		are	asymmetrically	di-methylated	using	immunoprecipitation	and	Western	blotting.	Mass	spectrometry	analysis	identified	two	methylated	arginine	residues	in	CRMP-2	(R63	and	R173)	along	with	one	in	CRMP-1	(R226)	and	two	methylated	arginines	in	CRMP-3	(R238	and	R270)	in	primary	cortical	neurons.	In	addition,	two	novel	methylated	arginines	in	tubulin	α	(R79	di-methylated	and	R390	mono-methylated)	and	six	novel	arginines	in	tubulin	β	(R241	and	R390	mono-methylated	and	R62,	R156,	R276	and	R282	di-methylated)	in	both	primary	cortical	neurons	and	in	the	Neuro2a	cell	line	were	identified.		
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Inhibition	of	methylation	using	the	general	methylation	inhibitor	AdOx	in	primary	neurons	caused	a	significant	decrease	in	neurite	length	without	any	change	in	cell	body	area	suggesting	that	protein	arginine	methylation	is	important	for	neurite	outgrowth.	Further,	the	amount	of	tubulin	heterodimers	co-immunoprecipitated	with	CRMP-2	using	an	anti-CRMP-2	antibody	column	was	decreased	after	AdOx	treatment	indicating	that	CRMP-2/tubulin	binding	is	regulated	by	protein	arginine	methylation.		
The	effect	of	methylation	on	the	cell	cycle	was	studied	in	the	Neuro2a	cell	line	using	flow	cytometry.	Inhibition	of	methylation	by	AdOx	resulted	in	a	significant	increase	in	the	S	phase	of	the	cell	cycle.	Furthermore,	the	effect	of	Taxol,	an	anti-cancer	drug	that	binds	to	tubulin	and	results	in	G2	arrest	of	cells,	was	increased	when	methylation	was	inhibited	suggesting	that	methylation	of	tubulin	interferes	with	Taxol	binding.	
The	novel	PRMT1/8	inhibitor	(trans-2,3-dimethoxy-ß-nitrostyrene)	as	well	as	esiRNA	were	employed	as	two	independent	methods	to	determine	whether	PRMT	1	and/or	PRMT8	are	involved	in	asymmetrically	di-methylating	tubulin	α	in	Neuro2a	cells.	Results	suggest	tubulin	α	as	a	possible	substrate	of	PRMT1	and	8	which	contributes	to	the	current	understanding	of	microtubule	dynamics.	
In	summary,	methylated	arginine	residues	in	3	members	of	the	CRMP	family	of	proteins	and	in	tubulin	α	and	β	in	mouse	cortical	neurons	have	been	identified	and	their	functional	impact	was	demonstrated.	The	newly	gained	insight	into	the	effects	of	protein	arginine	methylation	of	CRMP	and	tubulin	has	placed	PRMTs	to	be	one	of	the	key	regulators	of	neuronal	differentiation	and	survival	and	may	open	new	drug	targets	for	the	treatment	of	neuronal	diseases	and	cancer.	
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Chapter	1 Introduction		
1.1 Definition	of	protein	methylation	
Protein	methylation	is	a	widespread	post-translational	modification	(PTM)	of	proteins	where	methyl	groups	are	added	to	positively	charged	amino	acids	including	arginines,	lysines	or	histidines	(Yang	and	Bedford,	2013).		Methylation	is	found	on	both	nuclear	and	cytoplasmic	proteins	(Yang	and	Bedford,	2013).	Just	like	other	PTMs	such	as	phosphorylation	and	acetylation,	methylation	increases	the	functional	and	structural	diversity	of	the	twenty	amino	acids	used	by	the	cell	for	synthesizing	proteins.	It	generates	distinct	chemical	interactions	that	play	a	major	role	in	numerous	regulatory	pathways	in	cells	(reviewed	by	Bedford	and	Clarke,	2009,	Yang	and	Bedford,	2013,	Paik	et	al.,	2007).	
1.2 The	chemistry	of	arginine	methylation	
Arginine	is	a	positively	charged	amino	acid	that	mainly	mediates	hydrogen-bonding	reactions	(Luscombe	et	al.,	2001).	It	carries	a	unique	guanidino	nitrogen	that	has	five	hydrogen	bonds,	which	are	potential	sites	for	interaction	with	a	biological	hydrogen	acceptor	(Calnan	et	al.,	1991).	In	protein-DNA	complexes,	arginine	can	form	hydrogen	bonds	with	the	nitrogenous	base	of	the	DNA	molecule,	the	phosphate	group	or	the	sugar	backbone	(Luscombe	et	al.,	2001).	Another	well-known	function	of	arginine	is	the	formation	of	stable	hydrogen	bonds	in	arginine-aspartate	interactions	in	proteins	(Mitchell	et	al.,	1992).	The	addition	of	a	methyl	group	to	arginine	causes	changes	in	the	shape	of	the	arginine	molecule	as	well	as	in	the	position	of	the	hydrogen	bond,	which	can	inhibit	some	arginine	interactions	(Bedford	et	al.,	2000).	When	a	methyl	group	
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is	added	to	the	guanidino	nitrogen	of	the	arginine	residue,	the	result	is	mono-methyl	arginine	or	di-methyl	arginine,	if	two	methyl	groups	are	added	(Zobel-Thropp	et	al.,	1998).	In	eukaryotic	cells	there	are	three	types	of	methylated	arginines;	ω-	NG,	mono-methylarginine	(MMA),	ω-NG,	NG-asymmetric	di-methylarginine	(ADMA);	and	ω-	NG,	NG	-symmetric	di-methylarginine	(SDMA)	(see	Figure	1.1)	(Zobel-Thropp	et	al.,	1998).	Methylation	is	an	energetically	expensive	biological	reaction,	as	it	costs	the	cell	12	ATP	per	methyl	group	added	to	proteins	(Atkinson,	1977).	
	
Figure	1.1	Protein	arginine	methylation.	The	formation	of	mono-methyl,	symmetric	di-methyl	and	asymmetric	di-methyl	arginine,	is	the	result	of	adding	methyl	group(s)	(shown	in	yellow	circles)	to	the	guanidino	nitrogen	of	an	arginine	residue	by	the	action	of	protein	arginine	methyltransferases	(PRMTs).	Adapted	from	(Paik	et	al.,	2007).	
1.3 Enzymology	of	arginine	methylation	
Methyltransferases	are	a	family	of	enzymes,	which	catalyse	the	methyl	group	transfer	reaction	to	nitrogen,	oxygen,	carbon	and	sulphur	atoms	and	small	
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molecules,	lipids,	proteins	and	nucleic	acids	(Paik	and	Kim,	1970,	Klotz	et	al.,	1990).	It	has	been	shown	that	about	1%	of	the	mammalian	genome	encodes	methyltransferases	(Katz	et	al.,	2003).	Protein	arginine	methyltransferases	(PRMTs)	in	mammals	form	a	subgroup	of	the	methyltransferases	in	eukaryotes.	PRMTs	modulate	arginine	residues	by	adding	a	methyl	group	to	the	δ	or	ω	nitrogen,	reviewed	by	(Krause	et	al.,	2007).	Currently,	there	are	at	least	nine	enzymatically	active forms	of	PRMTs	known	in	mammalian	cells	(Yang	and	Bedford,	2013).	However,	some	studies	suggest	that	F-box	only	proteins	form	another	family	of	methyltransferases	that	include	FBXO10	and	FBXO11	(Cook	et	al.,	2006,	Fielenbach	et	al.,	2007).		
PRMTs	1-8	have	an	identified	enzymatic	activity	in	the	cell	(Krause	et	al.,	2007),	and	the	function	of	PRMT9	has	only	recently	been	described	(Yang	et	al.,	2015).	They	all	catalyse	the	formation	of	MMA,	while	PRMTs	1,	2,	3,	4,	6	and	8,	called	type	I	PRMTs,	catalyse	ADMA	formation	(Yang	and	Bedford,	2013).	On	the	other	hand,	PRMTs	5,	7	and	9	catalyse	the	reaction	resulting	in	SDMA	and	they	are	known	as	type	II	PRMTs	(reviewed	by	Yang	and	Bedford,	2013).	A	type	III	PRMT	was	also	described,	where	the	reaction	stops	at	the	formation	of	MMA	and	no	further	methylation	happens.	PRMT7	was	proposed	to	be	the	only	enzyme	that	exhibits	type	III	activity	in	mammalian	cells	(Zurita-Lopez	et	al.,	2012).	
All	PRMTs	share	a	signature	motif,	which	is	very	similar	to	a	motif	found	in	nucleic	acid	and	small	molecule	methyltransferases	and	PRMT7,	9	and	10	have	two	signature	motifs	(Fackelmayer,	2005).	The	signature	motif	binds	to	S-Adenosyl-L-methionine	(SAM)	which	is	the	only	donor	for	the	methylation	reaction	(Cheng	et	al.,	2004).			
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PRMTs	1-8	have	a	seven-β	strand	methyltransferase	motif,	common	double	E	and	THW	amino	acid	sequences,	which	are	exclusive	to	the	PRMT	subfamily	(Figure	1.2)	(Cheng	et	al.,	2005).	They	also	share	a	less	conserved	C-terminal	domain	that	has	a	potential	role	in	the	enzyme	substrate	interaction	(Cheng	et	al.,	2005).	PRMT9,	similarly	to	PRMT7,	harbours	two	SAM	binding	motifs	(Lee	et	al.,	2005a)	and	differs	from	other	members	of	the	PRMT	family	by	having	three	tetratricopeptide	repeats	(TPR)	in	the	N-terminus	(Lee	et	al.,	2005a).	PRMT10	was	identified	by	homology	to	PRMT7	and	it	possesses	the	main	domains	that	are	unique	to	the	PRMT	subfamily,	yet	no	activity	or	substrate	has	yet	been	identified	(Pal	and	Sif,	2007,	Krause	et	al.,	2007).	PRMT11	or	FBXO10	possess	the	F-Box	domain,	but	no	methyltransferase	activity	has	yet	been	identified	(Fielenbach	et	al.,	2007,	Cook	et	al.,	2006).	Type	IV	of	PRMT	has	only	been	identified	in	the	yeast	Saccharomyces	cerevisiae	and	catalyses	the	addition	of	a	methyl	group	onto	the	internal	guanidine	nitrogen	atom	to	form	δ-MMA	(Niewmierzycka	and	Clarke,	1999).	
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Figure	1.2	The	mammalian	PRMT	family.	All	PRMTs	carry	a	signature	motif	(orange	shaded	area).	PRMT8	carries	the	myristoylation	motif	(Myr)	that	enables	it	to	be	membrane	bound.	Adapted	from	(Yang	and	Bedford,	2013).	
1.4 	The	methionine	cycle	
Methionine	is	produced	from	homocysteine	by	transferring	a	methyl	group	from	folate,	a	reaction	in	which	vitamin	B12	is	required	(Katz	et	al.,	2003).	SAM	also	known	as	AdoMet,	which	is	made	from	ATP	and	methionine	by	the	action	of	adenosyltransferase,	is	the	donor	of	the	methyl	group	(Figure	1.3)	(Katz	et	al.,	2003,	Atkinson,	1977).	S-Adenosyl-methionine	will	be	referred	to	as	SAM	throughout	this	thesis.	SAM	is	the	donor	of	methyl	groups	that	are	required	to	methylate	proteins	by	PRMTs.	SAM	is	transformed	to	S-adenosyl-homocysteine	(SAH)	after	losing	the	methyl	group.	SAH	can	be	recycled	to	form	homocysteine	by	the	action	of	S-adenosyl-homocysteine	hydrolase	(SAHh)	in	a	reversible	reaction	(Katz	et	al.,	2003)	(Figure	1.3).	Homocysteine	is	then	used	to	form	new	molecules	of	methionine	(Figure	1.3).	
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Figure	1.3	The	methionine	cycle.	The	methyl	groups	that	are	required	for	the	methylation	reaction	by	PRMTs	are	generated	by	the	conversion	of	SAM	to	SAH.	
1.5 Arginine	methylation	reversibility	
Free	methylarginine	amino	acids	which	result	from	proteolysis	of	arginine	methylated	proteins	(Dweik,	2007),	are	demethylated	and	converted	to	citrulline	by	an	enzyme	called	di-methylarginine	di-methylaminohydrolase	(DDAH)		(Ogawa	et	al.,	1989).		Another	enzyme,	peptidyl-arginine	deiminase	(PAD4)	was	identified	by	sequence	homology	to	DDAH	and	was	proposed	to	be	responsible	for	demethylating	protein	arginines	that	are	within	intact	proteins	(Wang	et	al.,	2004).	However,	another	study	showed	that	PAD4	can	deiminate	arginine	and	mono-methylated	arginine	residues	(Cuthbert	et	al.,	2004).	Nevertheless,	PAD4	has	later	been	shown	to	be	responsible	for	the	deimination	of	unmodified	arginine	residues	(Raijmakers	et	al.,	2007).	Jumonji	domain-containing	protein	6	(JMJD6),	which	is	a	member	of	the	lysine	demethylases	family,	was	also	thought	to	be	able	to	demethylate	arginine	residues	and	to	directly	generate	free	arginine	residues	from	methylated	histones	(Chang	et	al.,	
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2007).	Nevertheless,	this	enzyme	was	demonstrated	to	catalyse	the	hydroxylation	of	lysyl	of	a	nuclear	protein	called	U2AF65	(Webby	et	al.,	2009).	A	recent	study	has	demonstrated	that	JMJD6	can	demethylate	the	asymmetrically	di-methylated	R260	of	estrogen	receptor	alpha	(ER-α)	and	R3	on	histone	4	(Poulard	et	al.,	2014).	
1.6 Oligomerisation	of	PRMTs	
Several	structural	studies	suggested	that	PRMT1,	as	well	as	its	yeast	homologue	Rmt1p,	functions	only	in	the	form	of	a	homodimer	(Weiss	et	al.,	2000,	Zhang	and	Cheng,	2003).	It	was	recently	suggested	that	the	activity	of	PRMT1	is	increased	when	forming	a	functional	heterodimer	with	PRMT2	(Pak	et	al.,	2011).	In	addition,	solution	behaviour	and	crystal	packing	of	PRMT3	have	indicated	this	enzyme	to	form	dimers	(Zhang	et	al.,	2000).	Dimerisation	of	PRMT4	was	also	shown	by	two	crystallization	studies	in	2007	(Troffer-Charlier	et	al.,	2007,	Yue	et	al.,	2007).	It	has	been	proposed	that	the	phosphorylation	of	PRMT4	at	Ser229	interferes	with	its	dimerisation	and	therefore	it	serves	as	an	inactivation	mechanism	of	PRMT4	(Higashimoto	et	al.,	2007).	However,	it	was	later	reported	that	the	phosphorylation	of	Ser229	has	no	role	in	regulating	the	dimerisation	of	PRMT4	(Feng	et	al.,	2009).	Homo-oligomeric	complexes	were	observed	of	PRMT5	and	shown	to	be	essential	for	its	enzymatic	activity	(Rho	et	al.,	2001,	Sun	et	al.,	2011).	A	later	study	showed	that	PRMT5	and	methylosome	protein	50	(MEP50)	complex	forms	functional	multimers	that	regulate	PRMT5	function	and	substrate	specificity	when	methylating	Sm	proteins	of	the	spliceosome	(Ho	et	al.,	2013).	Sm	proteins	are	a	group	of	seven	proteins	that	form	the	stable	core	of	the	snRNPs	(Schumperli	and	Pillai,	2004).		
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1.6.1 Localisation,	substrates	and	function	of	PRMTs	1-9	Although	all	PRMTs	catalyse	the	production	of	arginine	methylated	proteins,	they	differ	in	their	tissue	and	subcellular	distribution,	substrate	specificity	and	their	effects	on	cellular	pathways.	
1.6.1.1 PRMT1	PRMT1	is	the	most	abundant	PRMT	and	is	responsible	for	most	of	the	type	I	methylation	in	mammalian	cells	(Figure	1.1)	(Bedford	and	Clarke,	2009).	It	is	found	throughout	cells	with	a	highly	conserved	sequence	amongst	eukaryotic	cells	(Yang	and	Bedford,	2013).	PRMT1	was	first	identified	from	rat	by	using	the	early	B-cell	translocation	gene	2	(BTG2)	product	and	the	BTG1	protein	in	a	yeast	two-hybrid	screen	library	in	1996	(Lin	et	al.,	1996).	It	plays	an	important	part	in	the	regulation	of	RNA	binding	proteins	such	as	Src-associated	substrate	during	mitosis	with	a	molecular	weight	of	68kDa	(Sam68)	and	fibrillarin	(Lin	et	al.,	1996,	Lee	and	Bedford,	2002,	Smith	et	al.,	1999).	Also,	the	methylation	by	PRMT1	affects	the	localization	of	some	of	its	substrates	that	are	known	to	shuttle	between	the	cytoplasm	and	the	nucleus	such	as	hnRNPQ	and	Sam68	(Nichols	et	al.,	2000,	Boisvert	et	al.,	2003,	Passos	et	al.,	2006).	There	are	seven	different	isoforms	of	PRMT1	in	the	cell	(Scott	et	al.,	1998)	which	seem	to	only	differ	by	the	location	of	the	start	of	the	N-terminus	(Zhang	and	Cheng,	2003).	PRMT1	isoforms	may	play	a	role	in	cancer	(see	Section	1.7.2).	
1.6.1.2 PRMT2	PRMT2	is	also	known	as	HRMT1L1	and	was	identified	in	1997	as	a	homologue	to	the	rat	PRMT1	(Katsanis	et	al.,	1997).	It	has	a	unique	Src	homology	3	(SH3)	domain	(see	Figure	1.2)	(Scott	et	al.,	1998).	PRMT2	was	earlier	described	as	an	
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ERα	co-activator	(Qi	et	al.,	2002)	and	it	also	binds	to	the	androgen	receptor,	hnRNP	(heterogeneous	nuclear	ribonucleoprotein)	E1B-AP5	and	the	retinoblastoma	gene	product	(Rb)	(Kzhyshkowska	et	al.,	2001,	Meyer	et	al.,	2007,	Yoshimoto	et	al.,	2006).	However,	a	weak	enzymatic	activity	of	PRMT2	as	an	arginine	methyltransferase	was	later	discovered	(Herrmann	et	al.,	2009).	PRMT2	activity	as	a	PRMT	type	I	(see	Figure	1.1)	was	described	with	the	ability	to	methylate	H4	histone	and	the	human	fibrillin	protein	(Lakowski	and	Frankel,	2009).	More	recently,	PRMT2	was	identified	as	a	potential	marker	for	breast	cancer	(Section	1.7.2)	(Zhong	et	al.,	2013).	
1.6.1.3 PRMT3	PRMT3	was	described	for	the	first	time	as	a	type	I	arginine	methyltransferase	after	it	was	identified	as	a	previously	unknown	protein	that	interacted	with	PRMT1	using	the	yeast	two-hybrid	system	(Tang	et	al.,	1998).	It	is	a	cytoplasmic	enzyme	and	its	substrate-binding	domain	is	located	within	its	N-terminal	zinc	finger	domain	(Swiercz	et	al.,	2005).	The	first	reported	substrate	of	PRMT3	was	40S	ribosomal	protein	S2	(rpS2)	(Bachand	and	Silver,	2004,	Swiercz	et	al.,	2005).	PRMT3	also	methylates	the	recombinant	mammalian	nuclear	poly(A)-binding	protein	(PABPN1)	(Smith	et	al.,	1999,	Fronz	et	al.,	2008,	Tavanez	et	al.,	2009).	In	addition,	the	tumour	suppressor	protein	p53	is	methylated	by	PRMT3,	when	the	latter	forms	a	complex	with	the	von	Hippel–Lindau	(VHL)	tumour	suppressor	protein	and	alternative	reading	frame	(ARF)	(Lai	et	al.,	2011).	
1.6.1.4 PRMT4	PRMT4	or	co-activator-associated	arginine	methyltransferase	1	(CARM1)	was	first	discovered	in	1999	using	yeast	two-hybrid	experiments	as	a	protein	that	
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was	bound	to	the	nuclear	hormone	receptor	(NR)	co-activator	GRIP1	(Chen	et	al.,	1999).	PRMT4	is	mainly	localised	in	the	nucleus	(Chen	et	al.,	1999)	and	plays	a	vital	role	in	the	regulation	of	the	transcriptome	in	cells	by	methylating	histone	H3	on	multiple	arginine	residues	(Chen	et	al.,	1999,	Schurter	et	al.,	2006)	and	interacting	with	multiple	transcription	factors	such	as	CBP/p300	(Krause	et	al.,	2007).	PRMT4	was	also	found	to	play	a	role	in	alternative	splicing	by	methylating	some	factors	of	the	splicing	machinery	such	as	SmB,	U1C	and	SAP49	(Cheng	et	al.,	2007,	Ohkura	et	al.,	2005).		PRMT4	is	involved	in	regulation	of	gene	expression	by	activating	nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells	(NF-κB)	(Covic	et	al.,	2005)	and	cell	cycle	progression	regulation	by	promoting	the	expression	of	cyclin	E1	gene	(El	Messaoudi	et	al.,	2006).	Cells	that	lack	PRMT4	methyltransferase	activity	lose	their	ability	to	arrest	the	cell	cycle	in	response	to	DNA	damage	(Lee	et	al.,	2011).	PRMT4	knock-out	mice	show	a	delay	in	endochondral	ossification	and	chondrocyte	proliferation	(Ito	et	al.,	2009).	On	the	other	hand,	PRMT4	deficient	mice	show	an	abnormal	increase	in	their	pulmonary	cell	proliferation	(O'Brien	et	al.,	2010).	PRMT4	is	an	automethylated	enzyme	and	its	automethylation	is	required	for	activating	PRMT4	associated	transcription	and	RNA	splicing	(Kuhn	et	al.,	2011).	
1.6.1.5 PRMT5	PRMT5	was	originally	discovered	in	a	study	to	identify	proteins	that	interact	with	the	Janus	tyrosine	kinase,	Jak2	(Pollack	et	al.,	1999).	PRMT5	mRNA	is	highly	expressed	in	heart,	muscle	and	testis	compared	to	other	tissues	(Pollack	et	al.,	1999).	PRMT5	is	the	major	type	II	PRMT	known	in	eukaryotic	cells	as	it	only	generates	MMA	and	SDMA	(Branscombe	et	al.,	2001).	At	a	cellular	level,	
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PRMT5	is	mainly	a	nuclear	protein	where	it	is	responsible	for	methylating	arginine	residues	on	Histones	H2A,	H3	and	H4	(Pal	et	al.,	2004,	Ancelin	et	al.,	2006).	In	the	cytoplasm,	PRMT5	is	mainly	located	in	the	Golgi	apparatus	and	it	appears	to	maintain	the	structure	of	the	Golgi	apparatus	by	methylating	golgin	GM130	protein	(Zhou	et	al.,	2010).	Similar	to	PRMT4,	PRMT5	is	involved	in	the	transcriptional	machinery	of	the	cell.	However,	PRMT5	plays	more	of	a	transcriptional	suppressor	role	than	PRMT4	(Yue	et	al.,	2007).	PRMT5	was	reported	to	cause	the	suppression	of	cyclin1	E1	gene	expression	when	it	is	present	as	part	of	high	molecular	weight	E2F	complexes	in	the	promoter	region	of	that	gene	(Fabbrizio	et	al.,	2002).	Further,	the	interaction	of	PRMT5	with	co-operator	of	PRMT5	(CORP5)	triggers	PRMT5	function	as	a	transcriptional	co-repressor	(Dacwag	et	al.,	2007).	In	addition,	PRMT5	plays	a	role	in	the	cell	spliceosome	where	it	forms	a	methylation	complex	with	methylosome	protein	50	(MEP50)	and	as	part	of	this	complex	it	methylates	multiple	SnRNPs	(ribonucleoproteins)	(Brahms	et	al.,	2001).	The	symmetrical	methylation	of	these	proteins	by	PRMT5	is	required	for	their	interaction	with	survival	of	motor	neuron	protein	(SMN)	to	form	an	essential	part	of	the	spliceosome	complex	(Friesen	et	al.,	2001,	Brahms	et	al.,	2001).	In	a	recent	study,	PRMT5	was	shown	to	modulate	the	metabolic	response	to	fasting	by	stimulating	the	phosphorylation	of	a	metabolic	protein,	cAMP	response	element	binding	protein	(CREB)	(Tsai	et	al.,	2013).	PRMT5	was	also	recently	reported	to	activate	NF-κB	by	di-methylating	subunit	p65	on	Arg30	(Wei	et	al.,	2013).	
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1.6.1.6 PRMT6	PRMT6	was	discovered	in	an	experiment	to	find	a	new	PRMT	by	sequence	analysis	of	the	human	genome	(Frankel	et	al.,	2002).	It	is	a	nuclear	enzyme,	which	methylates	H3R2,	H4R3	and	H2AR3	(Hyllus	et	al.,	2007,	Iberg	et	al.,	2008).	The	methylation	of	histone	H3	by	PRMT6	antagonises	its	tri-methylation	on	lysine	4	(Hyllus	et	al.,	2007).	This	suggests	an	involvement	of	PRMT6	in	gene	silencing,	as	H3K4	methylation	is	a	gene	activation	marker	(Guccione	et	al.,	2007,	Kirmizis	et	al.,	2007,	Hyllus	et	al.,	2007).	In	a	recent	study	(Harrison	et	al.,	2010),	PRMT6	was	shown	to	be	essential	for	oestrogen-stimulated	transcription	of	progesterone	receptors	in	MCF-7	breast	cancer	cells.	However,	PRMT6	was	also	shown	to	regulate	alternative	splicing	of	vascular	endothelial	growth	factors	in	a	hormone	independent	fashion	(Harrison	et	al.,	2010).	PRMT6	is	also	responsible	for	methylating	the	HIV	Tat,	nucleocapsid	(Nc)	and	Rev	proteins,	which	interferes	with	the	ability	of	these	proteins	to	interact	with	RNA	(Boulanger	et	al.,	2005,	Invernizzi	et	al.,	2007,	Invernizzi	et	al.,	2006).	PRMT6	function	is	regulated	by	automethylation	(Singhroy	et	al.,	2013).	
1.6.1.7 PRMT7	PRMT7	was	identified	as	homologous	to	PRMT1-6	(Miranda	et	al.,	2004,	Lee	et	al.,	2005b).	PRMT7,	however,	has	a	unique	structure	compared	to	the	other	PRMTs	in	that	it	bears	two	SAM	binding	domains	(Figure	1.2)	(Miranda	et	al.,	2004).	PRMT7	is	a	potential	marker	for	kidney	damage	caused	by	antibiotics	(Bleibel	et	al.,	2009,	Gros	et	al.,	2003,	Zheng	et	al.,	2005).		
Alongside	PRMT5,	PRMT7	regulates	the	spliceosome	in	human	cells	where	it	takes	part	in	the	formation	of	snRNPs	(Gonsalvez	et	al.,	2007).	PRMT7	is	also	
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involved	in	gene	expression	regulation	with	many	histone	substrates	such	as	H3R2,	H3R17	and	H3R19	(Gayatri	and	Bedford,	2014).		
1.6.1.8 PRMT8	PRMT8	has	80%	sequence	homology	to	PRMT1	(Lee	et	al.,	2005a).	It	is	a	central	nervous	system	specific	enzyme	(Pelletier,	2011,	Lee	et	al.,	2005a),	and	it	bears	a	myristoylation	motif,	which	allows	it	to	be	membrane	bound	(Figure	1.2)	(Sayegh	et	al.,	2007,	Scaramuzzino	et	al.,	2013).	PRMT8	harbours	two	proline-rich	motifs	at	its	N-terminus	(Sayegh	et	al.,	2007)	and	a	SH3	domain	that	has	the	ability	to	bind	to	the	proline-rich	molecule	Sam68	(Cheung	et	al.,	2007).	Sam68	is	a	splicing	regulator	protein	(Itoh	et	al.,	2002)	and	a	well	characterised	substrate	of	PRMT1	(Bedford	and	Clarke,	2009).		PRMT8’s	N-terminus	also	has	two	automethylation	sites	that	were	shown	to	regulate	PRMT8’s	ability	to	bind	to	SAM	(Dillon	et	al.,	2013).	EWS,	an	Ewing	sarcoma	gene	encoded	pro-oncoprotein,	has	been	shown	to	be	asymmetrically	di-methylated	by	PRMT8	as	well	as	by	PRMT1	(Kim	et	al.,	2008).	
1.6.1.9 PRMT9	PRMT9	is	mainly	found	in	the	cytoplasm	and	its	enzymatic	activity	was	recently	discovered,	where	it	was	reported	to	mono-methylate	and	symmetrically	di-methylate	SAP145,	a	spliceosome	associated	protein	(Yang	et	al.,	2015).	PRMT9’s	biological	function,	therefore,	is	involvement	in	alternative	splicing	and	regulation	of	the	maturation	of	snRNP	(Yang	et	al.,	2015).		
It	is	clear	that	PRMTs	have	a	wide	range	of	function	and	substrates	but	for	the	majority	of	them	substrates	were	identified	by	in	vitro	methylation	of	purified	
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substrates,	purified	enzymes	and	labelled	methyl	groups.	However,	to	determine	the	biological	functions	in	cell	culture,	siRNA	of	specific	PRMTs	and	PRMT	inhibitors	were	used.	
1.6.2 PRMT	inhibitors	
1.6.2.1 Sinefungin		Sinefungin	is	a	SAM	analogue.	It	can	inhibit	all	the	enzymes	that	use	SAM	as	a	methyl	group	donor;	hence	it	lacks	specificity	for	PRMTs	(Williams-Ashman	et	al.,	1982,	Osborne	et	al.,	2007,	Cheng	et	al.,	2004).	
1.6.2.2 AMI-1	and	AMI-408	Arginine	methyltransferase	inhibitors	1	and	408	(AMI-1	and	AMI-408)	are	sulfonated	urea	compounds	that	inhibit	arginine	but	not	lysine	methyltransferases.	AMI,	however,	inhibit	both	type	I	and	type	II	PRMTs	(Cheng	et	al.,	2004,	Bonham	et	al.,	2010).		
1.6.2.3 AdOx	Adenosine	dialdehyde	(AdOx)	inhibits	the	action	of	S-Adenosyl-homocysteine	hydrolase	(SAHh)	(Figure	1.3)	which	is	the	enzyme	responsible	for	producing	homocysteine	from	SAH	(Hoffman	and	Kunz,	1977).	In	the	presence	of	vitamin	B12,	homocysteine	is	converted	to	the	SAM	precursor	methionine	(Figure	1.3)	(Katz	et	al.,	2003).	Inhibition	of	the	formation	of	homocysteine	results	in	an	accumulation	of	SAH	(Figure	1.3),	which	in	turn	prevents	methylation	reactions	in	the	cells	(reviewed	in	Pahlich	et	al.,	2006).	
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1.6.2.4 Trans-2,3-dimethoxy-ß-nitrostyrene	and	trans-α-nitrostilbene	Trans-2,3-dimethoxy-ß-nitrostyrene	and	trans-α-nitrostilbene	are	two	nitroalkenes	discovered	recently	by	high-throughput	screening	to	have	the	ability	to	both	specifically	inhibit	PRMT1	and	PRMT8	(Dillon	et	al.,	2012).	These	two	compounds	are	from	the	Maybridge	Hitfinder	Collection	(Clark	et	al.,	2010)	and	inhibit	the	binding	of	SAM	to	the	catalytic	site	on	PRMT1	and	PRMT8	by	binding	to	the	hyperactive	cysteine	101	which	is	not	present	in	any	other	PRMT	(Dillon	et	al.,	2012).	
1.7 Arginine	methylation	and	disease	
As	mentioned	earlier	in	this	chapter,	arginine	methylated	proteins	are	present	in	both	the	nucleus	and	the	cytoplasm	and	given	the	wide	biological	effects	of	methylated	proteins,	the	disruption	or	alteration	of	methylation	is	likely	to	result	in	disease	(Aletta	and	Hu,	2008).	In	addition,	free	methylated	arginine	amino	acids	are	natural	inhibitors	of	the	enzyme	nitric	oxide	(NO)	synthase	(NOS)	(Figure	1.4)	(Boger	et	al.,	1996)	which	is	an	important	player	in	regulating	the	function	of	the	vascular	system	(Aletta	and	Hu,	2008).	Furthermore,	many	viral	proteins	need	to	be	methylated	for	efficient	virus	replication	and	propagation	to	take	place	(reviewed	by	Mirto	and	Piller,	2010).	The	following	section	will	explore	the	role	of	protein	methylation	in	various	types	of	diseases.	
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Figure	1.4	Nitric	oxide	synthase	(NOS)	inhibition	by	free	methylted	
arginine	amino	acids.	When	arginine	methylated	proteins	are	degraded	in	the	cell,	free	methylated	arginine	amino	acids	are	released	which	are	a	natural	inhibitor	of	NOS.	Free	methylated	arginine	amino	acids	are	converted	to	citrulline	by	DDAH.	Uncoupled	NOS	produces	superoxide	radicals	which	is	the	cause	of	oxidative	stress.	
1.7.1 	Vascular	disease	Free	methylated	arginine	amino	acids	are	the	result	of	proteolytic	processing	of	proteins	containing	methylated	arginine	residues	(Boger	et	al.,	1996).	Mono-methylated	arginines	(MMAs)	and	asymmetrically	di-methylated	arginines	(ADMAs)	but	not	symmetrically	methylated	arginines	(SDMAs)	are	endogenous	inhibitors	of	NOS	(Bode-Boger	et	al.,	1996).	NO	is	involved	in	many	regulatory	mechanisms	of	the	vascular	system,	such	as	vascular	tone	(Aletta	and	Hu,	2008).	NO	also	plays	a	role	in	the	endothelium-mediated	regulation	of	vascular	homeostasis,	as	it	inhibits	platelet	adhesion	and	aggregation,	monocyte	adhesion	and	smooth	muscle	proliferation	(Boger	et	al.,	1996).	Vascular	injury	was	found	to	increase	the	level	of	free	ADMA	in	the	blood	and	therefore	endothelial	NOS	is	inhibited	resulting	in	vascular	impairment	and	relaxation	
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(Cardounel	et	al.,	2007).	In	addition	to	the	inhibition	of	NOS,	it	has	been	suggested	that	the	increase	in	free	ADMA	in	the	blood	can	result	in	uncoupled	endothelial	NOS,	which	produces	superoxide	radicals	instead	of	NO	(Sydow	and	Munzel,	2003).	Therefore,	inhibition	of	the	synthesis	of	NO	by	ADMA	in	the	endothelial	cells	of	the	blood	vessels	results	in	an	imbalance	between	vasodilation	and	vasoconstriction	(Aletta	and	Hu,	2008).	In	a	study	performed	by	Kanazawa	and	colleagues	in	2011,	the	increase	in	serum	ADMA	level	was	found	to	be	associated	with	atherosclerosis	progression	in	patients	with	type	2	diabetes	mellitus	(Kanazawa	et	al.,	2011).	
1.7.2 Cancer	Both	PRMT1	and	PRMT4	function	as	transcriptional	co-activators	and	their	altered	regulation	can	result	in	the	disruption	of	transcriptional	pathways	(Yang	and	Bedford,	2013).	When	hematopoietic	cells	of	the	mouse	were	transduced	with	the	mixed	lineage	leukaemia	(MLL)	fused	with	extra	eleven	nineteen	(EEN),	they	showed	self-renewal	ability	(Cheung	et	al.,	2007).	The	MLL-EEN	fusion	gene	is	found	in	patients	with	acute	myeloid	leukaemia	(Liu	et	al.,	2004).	When	either	PRMT1	or	Sam68	is	fused	directly	to	the	MLL	gene	product,	oncogenesis	is	activated	which	suggests	a	role	of	PRMT1	in	cancer	initiation	(Cheung	et	al.,	2007).	It	was	also	reported	that	the	expression	levels	of	PRMTs	are	altered	in	many	types	of	cancers	(Teyssier	et	al.,	2010).	For	example,	the	expression	of	PRMT1,	2	and	5	is	down	regulated	in	the	oestrogen	dependent	ovarian	carcinomas	(Hendrix	et	al.,	2006,	Ivshina	et	al.,	2006).	Moreover,	Goulet	and	colleagues	(Goulet	et	al.,	2007)	have	reported	that	PRMT1	splice	variants	are	altered	in	breast	cancer	and	the	level	of	arginine-methylated	proteins	was	
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elevated	in	breast	cancer	cell	lines	(Goulet	et	al.,	2007).	Thus,	the	change	in	the	PRMT1	isoform	expression	is	associated	with	changes	in	the	arginine	methylation	in	breast	cancer	cells,	strongly	suggesting	a	relationship	between	dysregulation	of	arginine	methylation	and	breast	cancer	(Teyssier	et	al.,	2010).		
Further,	PRMT2	was	recently	proposed	to	be	a	potential	marker	for	breast	cancer	(Zhong	et	al.,	2013).	PRMT2	protein	levels	drop	in	the	nuclei	of	breast	cancer	cells	and	the	reduced	levels	positively	correlated	with	an	increased	tumour	grade	(Zhong	et	al.,	2013).	The	PRMT4	expression	level	was	shown	to	be	elevated	in	the	nucleus	of	castration-resistant	prostate	cancer	cells	(Majumder	et	al.,	2006).	PRMT5	is	suspected	to	act	as	an	oncoprotein,	as	the	over	expression	of	PRMT5	was	found	to	promote	anchorage-independent	cell	growth	in	an	overexpressing	flag-tagged	PRMT5	cell	line	(Pal	et	al.,	2004).	Expression	levels	of	PRMT1	and	PRMT6	were	found	to	be	increased	in	cancer	cells	of	different	human	tissue	such	as	breast,	pancreas,	cervix,	bladder	and	urethra	(Yoshimatsu	et	al.,	2011)	which	suggests	an	involvement	of	both	PRMT1	and	PRMT6	in	carcinogenesis.	Therefore,	arginine	di-methylation	is	a	possible	therapeutic	target	for	cancer	treatment	in	humans	(Yoshimatsu	et	al.,	2011).	
1.7.3 Viral	disease	Several	viral	proteins	have	been	identified	as	substrates	of	PRMTs	such	as	the	hepatitis	C	virus	protein	NS3	and	the	Epstein-Barr	virus	antigen	2	(reviewed	by	Bedford	and	Richard,	2005,	Mirto	and	Piller,	2010).	In	HIV,	three	proteins,	trans-activator	of	transcription	(Tat)	(Boulanger	et	al.,	2005),	regulator	of	virion	(Rev)	(Invernizzi	et	al.,	2006)	and	nucleocapsid	(NC)	(Invernizzi	et	al.,	2007)	
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were	identified	as	substrates	of	PRMT6.	Inhibition	of	methylation	by	the	general	methylation	inhibitor	AdOx	was	found	to	decrease	HIV	infectivity	and	increase	viral	production	(Willemsen	et	al.,	2006)	suggesting	that	protein	methylation	of	viral	proteins	is	important	for	HIV	replication.	Hence,	protein	methylation	may	provide	a	novel	target	for	antiviral	drug	development.	A	growing	number	of	other	viral	proteins	have	been	identified	to	be	methylated	(reviewed	by	Mirto	and	Piller,	2010).	
1.7.4 Arginine	methylation	in	diseases	affecting	the	nervous	system	Although,	there	has	been	extensive	interest	in	the	connection	between	arginine	methylation,	cell	function	and	disease,	to	date	a	limited	number	of	studies	have	been	performed	on	the	protein	arginine	methylation	in	neurons	or	the	development	of	diseases	affecting	the	nervous	system	in	the	context	of	protein	methylation	(Guo	et	al.,	2014,	Miyata	et	al.,	2008).	Oxidative	stress	is	a	result	of	imbalance	between	the	production	of	oxygen	radicals	and	the	ability	of	the	cell	to	detoxify	the	reactive	intermediates	and	repair	damage	(Berlett	and	Stadtman,	1997).	Arginine	is	used	by	NOS	to	produce	NO	in	a	phenomenon	called	the	arginine	paradox	(Bode-Boger	et	al.,	2007).	The	level	of	NO	depends	on	many	factors	such	as	the	level	of	ADMA,	which	is	a	natural	competitive	inhibitor	of	NOS,	and	the	availability	of	free	arginine	amino	acids	(Beltowski	and	Kedra,	2006).	Production	of	the	dangerous	radical	superoxide	by	NOS	due	to	elevated	levels	of	ADMA	is	one	cause	of	oxidative	stress	(Figure	1.4)	which	is	linked	to	many	diseases	including	neurodegenerative	disease	(Uttara	et	al.,	2009).	Several	studies	have	considered	the	brain	to	be	abnormally	susceptible	to	damage	by	peroxidation	compared	to	other	tissues	due	to	its	high	content	of	
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fatty	acids	which	are	susceptible	to	peroxidation	(Zaleska	and	Floyd,	1985,	Floyd	and	Carney,	1992).	Therefore,	arginine	methylation	might	be	linked	to	neurodegenerative	diseases	such	as	Alzheimer’s	disease	via	the	increased	oxidative	stress	that	is	at	least	partially	caused	by	the	increased	levels	of	ADMA	(Sydow	and	Munzel,	2003).	
In	an	earlier	study,	it	was	reported	that	the	level	of	SAM	in	patients	with	Alzheimer’s	disease	was	markedly	decreased	(Morrison	et	al.,	1996).	However,	the	reason	for	decreased	SAM	was	not	due	to	an	increase	in	methylation	reactions	as	the	level	of	methylated	proteins	was	also	decreased	in	the	brain	of	Alzheimer’s	patients	(Morrison	et	al.,	1996).	In	addition,	lower	levels	of	ADMA	in	the	cerebrospinal	fluid	of	patients	with	Alzheimer’s	disease	were	reported,	suggesting	an	involvement	of	arginine	methylation	in	the	pathogenesis	of	this	disease	(Abe	et	al.,	2001).	
1.8 Arginine	methylation	in	neurons	
To	date,	knowledge	about	the	significance	of	arginine	methylation	in	neurons	is	limited.	However,	a	few	reports	presented	evidence	of	the	involvement	of	PRMTs	in	neuronal	function	and	structure.	Some	early	research	on	PC12	cells	demonstrated	that	neurite	outgrowth	in	response	to	nerve	growth	factor	(NGF)	was	inhibited	completely	in	cells,	when	protein	methylation	was	repressed	by	dihydroxycyclopentenyl	adenine	(DHCA)	(Cimato	et	al.,	1997).	PC12	cells	are	a	cell	line	derived	from	a	pheochromocytoma	of	the	rat	adrenal	medulla	that	stop	growing	and	start	differentiating	once	treated	with	NGF	(Greene	and	Tischler,	1976,	Vaudry	et	al.,	2002).	Furthermore,	details	about	the	relationship	between	the	NGF	pathway	and	protein	arginine	methylation	were	revealed	when	the	
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treatment	of	PC12	cells	with	NGF	resulted	in	down-regulation	of	HuD	(an	RNA	binding	protein)	methylation	by	PRMT4	(Ikenaka	et	al.,	2006).		
Further	evidence	for	the	role	of	arginine	methylation	in	the	neurite	outgrowth	emerged	from	the	fact	that	PRMT1	binds	to	the	BTG2	protein	(Lin	et	al.,	1996)	which	plays	a	role	in	neuronal	differentiation	(el-Ghissassi	et	al.,	2002).	By	employing	transient	PRMT1	depletion,	Miyata	et	al.	(Miyata	et	al.,	2008)	suggested	a	possible	involvement	of	BTG2	in	the	neuritogenesis	via	regulation	of	PRMT1	activity.		
In	2005,	PRMT8	was	described	to	be	a	PRMT	that	is	only	expressed	in	the	CNS	(Lee	et	al.,	2005a).	The	amino	acid	sequence	of	PRMT8	was	found	to	be	very	similar	to	that	of	PRMT1,	however	it	has	a	unique	N-terminus	that	seems	to	be	conserved	only	in	humans	and	mice	(Lee	et	al.,	2005a).	Also,	PRMT8	displays	type	I	methyltransferase	activity	and	seems	to	methylate	a	specific	glycine	and	arginine	rich	(GAR)	motif	from	the	cytoskeletal	glycoprotein	fibrillin	in	neurons	(Lee	et	al.,	2005a,	Cimato	et	al.,	2002).	The	function	of	PRMT8	in	the	brain	is	not	very	well	understood,	yet.	However,	the	mRNA	of	PRMT8	is	highly	expressed	in	the	centromedian	nucleus,	the	caudate	putamen,	the	parafascicular	and	sensorimotor	cortex,	which	suggests	a	possible	function	of	PRMT8	in	regulating	the	motor	pathway	controlled	by	the	ganglia-thalamus-cerebral	cortex	circuits	(Taneda	et	al.,	2007).		
PRMT3,	another	type	I	methyltransferase,	is	highly	expressed	in	the	brain	of	mice	and	was	only	localized	in	neurons	but	not	in	glial	cells	(Cimato	et	al.,	2002).	Although,	PRMT3	was	previously	found	to	have	the	40S	ribosomal	protein	S2	as	a	substrate	in	fission	yeast	(Bachand	and	Silver,	2004),	it	seems	to	
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be	expressed	mostly	in	regions	of	neurons	that	don’t	have	ribosomes,	such	as	the	cell	body	and	dendrites	(Steward	and	Reeves,	1988).	
The	location	of	PRMT3	in	the	neurons	then	suggests	a	possible	role	of	protein	methylation	in	the	dendrite	formation	(Ikenaka	et	al.,	2006).	PRMT3	synthesis	peaks	postnatally,	especially	during	young	adulthood,	which	is	after	the	establishment	of	the	nervous	circuits	(Ikenaka	et	al.,	2006).		This	may	indicate	a	role	in	brain	maturation	rather	than	in	neuronal	differentiation	(Ikenaka	et	al.,	2006).	On	the	contrary,	PRMT1	synthesis	peaks	in	the	embryonic	perinatal	brain	and	could	have	a	function	in	the	formation	of	the	neuronal	circuits	(Wada	et	al.,	2002,	Bedford	and	Richard,	2005).	
In	a	previous	study	(Jwad,	2010),	we	have	discovered	for	the	first	time	that	collapsin	response	mediator	protein-2	(CRMP-2)	is	asymmetrically	di-methylated	using	Western	Blot	analysis,	immunoprecipitation	and	mass	spectrometry.	CRMP-2	was	immunoprecipitated	from	cortical	mouse	primary	neuronal	cell	lysates	using	an	antibody	against	asymmetrically	di-methylated	arginines	and	then	detected	with	an	anti-CRMP-2	antibody	(Jwad,	2010)	in	eluted	fractions	via	Western	blot.	
1.9 Collapsin	response	mediator	protein	(CRMP)	
CRMPs,	Turned	On	After	Division	(TOADs),	UNC33	like	proteins	(Ulips)	or	dihydropyrimidinase	related	proteins	(DRPs)	constitute	a	family	of	five	cytoplasmic	phosphoproteins	that	have	been	identified	independently	in	different	species	by	several	research	groups	(Schmidt	and	Strittmatter,	2007).	They	are	referred	to	as	dihydropyrimidinase	related	proteins	(DRPs)	because	of	
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the	high	sequence	homology	between	them	and	the	liver	enzyme	dihydropyrimidinase	(Hamajima	et	al.,	1996).	They	are	called	UNC33	like	proteins	(Ulip)	also	due	to	the	sequence	homology	with	the	Caenorhabditis	
elegans	protein,	UNC33	(Minturn	et	al.,	1995,	Byk	et	al.,	1996,	Gaetano	et	al.,	1997,	Goshima	et	al.,	1995).	The	name	TOAD,	however,	refers	to	Turned	On	After	Division	proteins	as	described	by	Minturn	and	colleagues	(Minturn	et	al.,	1995).	In	other	publications	the	CRMP	family	was	named	TUC	in	order	to	incorporate	all	the	three	names	(TOAD/Ulip/CRMP)	(Quinn	et	al.,	1999).	
In	mammals,	three	of	the	CRMP	family	members,	CRMP1,	2	and	4	seem	to	result	from	alternative	splicing	(Leung	et	al.,	2002,	Quinn	et	al.,	2003)	and	they	usually	exist	in	hetero-tetrameric	form	(Wang	and	Strittmatter,	1997).	CRMP1-	4	share	75%	of	their	protein	sequence,	while	CRMP-5	carries	approximately	50%	homology	to	the	other	CRMPs	(Inatome	et	al.,	2000,	Fukada	et	al.,	2000).	CRMPs	are	one	of	the	first	expressed	proteins	in	developing	nervous	systems	and	their	expression	peaks	in	the	period	of	axonal	growth	during	brain	neurogenesis	(Wang	and	Strittmatter,	1996,	Doetsch	and	Hen,	2005).	CRMPs	are	mostly	localized	in	the	lamellipodia	and	filopodia	of	the	axonal	growth	cone	which	suggests	an	involvement	in	axonal	guidance	and	elongation	(Minturn	et	al.,	1995).	
1.9.1 Collapsin	Response	Mediator	Protein-2	TUC-2	or	TOAD-64	which	is	now	known	as	CRMP-2	was	the	first	member	of	the	CRMP	family	to	be	discovered	in	rat	cortex	as	a	protein	that	is	regulated	during	corticoneurogenesis	(Geschwind	and	Hockfield,	1989).	In	a	study	to	identify	proteins	which	are	expressed	by	neurons	during	their	development,	CRMP-2	in	
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rat	was	found	to	be	seven-fold	up-regulated	during	corticoneurogenesis	but	not	in	the	progenitor	cells	(Minturn	et	al.,	1995).	Simultaneously,	Goshima	and	colleagues	(Goshima	et	al.,	1995)	have	described	for	the	first	time	that	CRMP-62,	a	chicken	homologue	of	the	mammalian	CRMP-2,	is	a	mediator	in	the	Sema3A	(collapsin-1)	axon	growth	cone	collapse	signalling	pathway	in	the	neurons	of	chick	dorsal	root	ganglia.	CRMP-2	is	highly	expressed	in	developing	rat	cortical	neurons	and	in	hippocampal	pyramidal	cells	(Wang	and	Strittmatter,	1996).	In	mouse	however,	CRMP-2	was	found	to	be	first	expressed	in	the	neuronal	progenitor	cell	as	early	as	the	point	of	the	formation	of	the	neuronal	plate	(Kamata	et	al.,	1998).		
As	mentioned	earlier,	CRMP-2	was	first	described	as	a	mediator	in	the	Sema3A	(collapsin-1)	axon	collapse-signalling	pathway,	yet	the	transmembrane	factor	which	initiates	the	cascade	was	not	identified	(Goshima	et	al.,	1995).	Later	on,	Sema3A	was	found	to	stimulate	the	axon	collapse	through	a	co-receptor	system	of	neuropilin-1	(He	and	Tessier-Lavigne,	1997,	Kolodkin	et	al.,	1997)	and	plexin	A	(Cheng	et	al.,	2001,	Tamagnone	et	al.,	1999,	Takahashi	et	al.,	1999).	Plexin	A,	which	is	the	cytoplasmic	segment	of	the	co-receptor	system	of	Sema3A,	forms	a	complex	with	CRMP-2	in	response	to	Sema3A	and	hence	initiates	the	axon	collapse	cascade	(Schmidt	and	Strittmatter,	2007).	The	neuron	is	a	highly	polarized	cell	and	it	is	composed	of	two	structurally	and	functionally	distinct	parts	which	are	dendrites	and	axon	(Craig	and	Banker,	1994).	In	an	early	study,	UNC-33	knock	out	in	C.	elegans	caused	severe	abnormal	guidance	of	the	growing	axons	in	many	neurons	(Hedgecock	et	al.,	1985).	A	more	recent	study	in	2001	carried	out	by	Inagaki	and	colleagues	(Inagaki	et	al.,	2001)	showed	that	the	
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over-expression	of	CRMP-2	in	growing	hippocampal	neurons	caused	the	formation	of	multiple	axons	(Inagaki	et	al.,	2001).	The	role	of	CRMP-2	in	axonal	differentiation	and	elongation	has	become	more	evident	after	the	discovery	of	the	association	between	tubulin	heterodimers	and	CRMP-2,	which	is	essential	for	microtubule	assembly	and	therefore	axonal	growth	and	elongation	(Fukata	et	al.,	2002).	The	discovery	of	this	function	of	CRMP-2	suggested	that	there	must	be	a	factor	allowing	the	switch	between	the	two	CRMP-2	functions	of	axonal	elongation	and	mediator	in	the	Sema3A	axonal	collapse	pathway.	This	factor	was	suggested	to	be	CRMP-2	phosphorylation	(Yoshimura	et	al.,	2005).	In	response	to	Sema3A,	Fyn,	a	tyrosine	kinase	family	member	becomes	active	and	leads	to	the	activation	of	Cdk5,	another	serine/tyrosine	kinase	which	in	turn	phosphorylates	CRMP-2	at	Ser522	(Sasaki	et	al.,	2002,	Brown	et	al.,	2004).	The	Ser522	phosphorylation	leads	to	further	phosphorylation	of	CRMP-2	by	Glycogen	synthase	kinase	3	beta		(GSK3ß)	at	Ser518,	Thr509,	and	Thr514	(Cole	et	al.,	2004,	Brown	et	al.,	2004,	Uchida	et	al.,	2005,	Yoshimura	et	al.,	2005).	However,	it	appears	that	CRMP-2	with	a	single	mutation	of	any	of	those	phosphorylation	sites	reduces	the	responsiveness	to	Sem3A	but	does	not	stop	the	cone	collapse	completely	as	long	as	the	other	phosphorylation	sites	are	still	intact	(Brown	et	al.,	2004,	Uchida	et	al.,	2005,	Schmidt	and	Strittmatter,	2007).	Furthermore,	Rho	kinase	phosphorylates	CRMP-2	exclusively	at	Thr555	in	response	to	lysophosphatidic	acid	(LPA)	the	axon-collapsing	factor	and	EphrinA5	the	inhibitory	guidance	cue	(Arimura	et	al.,	2005,	Arimura	et	al.,	2000).	At	the	same	time,	binding	of	CRMP-2	to	tubulin	is	remarkably	decreased	when	CRMP-2	is	phosphorylated	by	GSK3ß	at	Thr514.	Therefore	GSK3ß	is	a	major	regulator	of	CRMP-2	function	as	a	crucial	factor	in	neuron	polarity	and	
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axonal	growth	(Figure	1.5)	(Yoshimura	et	al.,	2005).	Furthermore,	Thr514	phosphorylation	at	the	growth	cone	is	significantly	lower	than	in	the	shaft	of	the	axon	(Yoshimura	et	al.,	2005).	This	suggests	that	the	growth	cone	contains	a	pool	of	non-phosphorylated	CRMP-2.		Kinesins	are	a	family	of	motor	proteins	that	transport	microtubules	in	the	cell	using	adenosine	triphosphate		(ATP)	derived	energy	(Kamal	and	Goldstein,	2002).	Kinesin-1	was	demonstrated	to	bind	to	CRMP-2	at	a	region	that	is	independent	from	the	tubulin	binding	region	and	caused	the	binding	between	CRMP-2	and	tubulin	heterodimers	to	occur	(Kimura	et	al.,	2005).	Therefore,	the	actual	role	of	CRMP-2	in	the	tubulin	movement	along	the	axon	is	as	an	escort	along	the	motor	protein,	kinesin-1	(Kimura	et	al.,	2005).	Interestingly,	CRMP-2	was	also	shown	to	have	a	direct	interaction	with	the	retrograde	motor	protein,	dynein	(Arimura	et	al.,	2009).	Dynein	is	a	cytoplasmic	protein	that	is	responsible	for	the	retrograde	movement	of	molecules	in	axons	of	mammalian	neurons	(Vallee	et	al.,	2004).	Arimura	et	al	(2009)	reported	that	cytoplasmic	dynein	directly	binds	to	the	N-terminus	of	CRMP-2	and	this	interaction	interferes	with	the	dynein-driven	microtubule	transport.			
Besides	the	part	CRMP-2	plays	in	initiating	axonal	growth	by	binding	to	tubulin,	CRMP-2	further	contributes	to	the	axonal	growth	but	via	the	endocytosis	of	neuronal	adhesion	molecules	that	are	essential	for	axonogenesis.	Nishimura	and	colleagues	(Nishimura	et	al.,	2003)	demonstrated	that	Numb-mediated	endocytosis	of	L1,	the	neuro-adhesion	molecule	is	promoted	by	the	association	of	CRMP-2	with	Numb.	Numb	is	a	membrane-bound	protein	that	is	involved	in	clathrin-dependent	endocytosis	(Santolini	et	al.,	2000,	Berdnik	et	al.,	2002).	
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Figure	1.5	Schematic	diagram	of	the	currently	known	signalling	cascade	of	
CRMP-2	in	neurons.	GSK3ß,	Rho	and	Cdk5	phosphorylate	CRMP-2	in	response	to	extracellular	signals	such	as	adhesion	molecules.	CRMP-2	phosphorylation	reduces	its	affinity	to	bind	to	tubulin	and	therefore	causes	axonal	cone	collapse	(Yellow	circles	with	a	P	represent	the	phosphate	group	added	by	the	kinases).	In	contrast,	non-phosphorylated	CRMP-2	acts	as	an	escort	of	tubulin	on	the	motor	protein	kinesin-1	and	this	promotes	microtubule	assembly	and	therefore	axonal	elongation.	CRMP-2	also	binds	to	the	cytoplasmic	loop	of	the	presynaptic	voltage	gated	calcium	channels	(CaV2.2)	and	causes	an	increase	in	calcium	current	density	and	thereby	increases	neurotransmitter	release.	CRMP-2	function	extends	to	further	than	axonal	differentiation	and	growth,	as	it	also	has	been	reported	to	have	a	regulatory	role	in	calcium	channel	function	(Brittain	et	al.,	2009).	CRMP-2	interacts	with	the	presynaptic	N-	type	calcium	channel	(CaV2.2)	at	two	regions	of	the	channel	structure;	the	cytoplasmic	loop	and	the	C-terminus	(Brittain	et	al.,	2009).	The	interaction	between	CRMP-2	and	CaV2.2	resulted	in	an	increase	in	the	Ca2+	current	density	due	to	the	rise	in	the	
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number	of	CaV2.2	channels	at	the	cell	surface	of	hippocampal	neurons	(Brittain	et	al.,	2009).	In	developing	central	nervous	system	synapses,	CaV2.2	are	the	major	source	of	Ca2+	influx	that	is	necessary	for	neurotransmitter	release	(Catterall	and	Few,	2008).	The	modulation	of	CaV2.2	by	interacting	proteins	results	in	the	regulation	of	neurotransmitter	release	(Catterall	and	Few,	2008,	Stanley,	1997,	Davies	and	Zamponi,	2008).		CRMP-2,	by	interacting	with	CaV2.2,	was	found	to	cause	an	increase	in	the	release	of	glutamate,	the	excitatory	neurotransmitter	(see	Figure	1.5)	(Brittain	et	al.,	2009).		
Interestingly,	several	studies	have	demonstrated	similarities	between	CRMP-2	and	Tau,	the	protein	in	which	abnormal	phosphorylation	has	been	related	to	the	pathology	of	Alzheimer’s	disease	(Hanger	et	al.,	2007).	Both	CRMP-2	and	Tau	were	found	to	be	hyperphosphorylated	during	the	pathogenesis	of	Alzheimer’s	disease	(Soutar	et	al.,	2009)	and	both	are	mediators	in	the	Sema3A	pathway	(Cole	et	al.,	2004,	Sasaki	et	al.,	2002,	Cole	et	al.,	2007).	In	addition,	CRMP-2	and	Tau	are	both	required	for	microtubule	stability	(Fukata	et	al.,	2002).	
1.10 Tubulin	and	microtubules	
1.10.1 Microtubule	structure	Tubulin	is	a	cytoskeletal	protein	that	forms	the	building	block	of	microtubules	(MT)	in	all	eukaryotic	cells.	MTs	are	non-covalent	polymers	of	tubulin	α	and	β	subunits	that	are	involved	in	cell	shape,	mitosis,	secretion	and	cell	motility	(Stephens,	1970).	Tubulin	subunits	α	and	β	are	arranged	in	long	thin	polymers	called	protofilaments	that	are	assembled	next	to	each	other	forming	the	microtubule	cylinder.		Each	microtubule	is	approximately	24	nm	in	diameter	and	made	of	10-15	protofilaments	(Li	et	al.,	2002).	MTs	are	polarised	structures	
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where	β	subunits	are	arranged	outwards	towards	the	fast-growing	end	of	the	microtubules,	the	plus-end	(Nogales	et	al.,	1997),	while	α	subunits	are	always	towards	the	slow-growing	end,	the	minus	end	(Lowe	et	al.,	2001,	Nogales	et	al.,	1998b).	In	each	protofilament,	the	α	monomers	bind	a	GTP,	which	hydrolyses	to	GDP	and	this	allows	the	binding	of	β	monomers	to	form	the	tubulin	heterodimer	(MacNeal	and	Purich,	1978).	This	GDP	then	becomes	non-exchangeable,	hence	its	binding	site	on	tubulin	α	is	referred	to	as	the	N-site	(non-exchangeable)	(Nogales	et	al.,	1997).	Microtubules	are	dynamic	structures	and	do	not	exist	at	a	stable	length;	they	undergo	rapid	cycles	of	polymerisation	(rescue)	and	depolymerisation	(shrinkage).	During	the	polymerisation	state,	the	GTP	in	the	tubulin	β	nucleotide	exchangeable	site	(E-site)	comes	in	contact	with	the	catalytic	domain	of	the	α	subunit	of	the	next	heterodimer	towards	the	plus-end	and	becomes	ready	for	hydrolysis	(Figure	1.6)	(Nogales,	2001).	At	any	point	of	time,	the	MT	is	stabilized	by	a	minimum	GTP	cap	layer	of	tubulin	(Nogales,	2001).	Once	this	cap	is	lost,	the	protofilaments	detach	and	depolymerisation	starts	(Nogales,	2001).	This	dynamic	instability	of	MTs	enables	them	to	readily	reorganise	their	special	and	temporal	differentiation	according	to	the	cell’s	requirement	(Kirschner	and	Mitchison,	1986).	
1.10.2 Microtubules	in	neurons	Neurons	are	polarised	cells;	usually	with	one	long	process	(axon)	that	serves	as	a	signal	transmitter	and	multiple	shorter	and	thicker	processes	(dendrites)	which	receive	signals	from	other	neurons	or	stimuli	(Craig	and	Banker,	1994).	Axonal	elongation	and	differentiation	from	one	immature	dendrite	requires	recruitment	and	assembly	of	tubulin	(Brown	et	al.,	1992).		
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The	neuronal	MTs	are	mainly	centred	in	the	cell	body	(Yu	et	al.,	1993)	and	readily	released	by	the	action	of	a	MT	severing	protein	Katanin	(Yu	et	al.,	2005,	Ahmad	et	al.,	1999,	Karabay	et	al.,	2004).	MTs	are	then	transported	towards	the	growing	neurite	via	the	action	of	motor	proteins	(Vale,	2003,	Baas	and	Buster,	2004).	Although,	MTs	are	essential	for	the	growth	and	elongation	of	both	dendrites	and	axons,	there	are	two	major	differences	between	the	two	types	of	neurites.	Firstly,	in	axons,	MTs	are	organised	in	tight	parallel	bundles	(Yamada	et	al.,	1971)	with	their	plus	end	always	pointing	towards	the	tip	of	the	axon,	whereas	in	dendrites	MT	plus	ends	could	face	into	either	directions	(Baas	et	al.,	1988).	Secondly,	Microtubule-associated	protein	2	(MAP2)	is	only	found	in	dendrites	while	Tau	prominently	an	axonal	Microtubule-associated	protein	(MAP)	(Dehmelt	and	Halpain,	2005,	Farah	and	Leclerc,	2008).	However,	Tau	has	also	been	reported	in	dendrites	at	low	concentration (Ittner	et	al.,	2010).	Dendritic	Tau	has	been	shown	to	be	involved	in	the	development	of	Alzheimer’s	disease	and	other	associated	disorders	in	mice	by	mediating	early	amyloid	beta	toxicity	(Ittner	et	al.,	2010).	
Actin	filaments,	via	myosin-dependent	contractility	are	involved	in	the	bundling	of	MTs	during	axonal	growth	cone	advance	(Schaefer	et	al.,	2008).		Actin	modulators		such	as	Cdc42,	cofilin	(Garvalov	et	al.,	2007)	and	Rho	(Bito	et	al.,	2000)	are	well-established	regulators	to	the	relationship	between	actin	filaments	and	MT	dynamics.	For	instance,	the	Rho-Rho	kinase	signalling	pathway	is	a	direct	promotor	of		MT	bundling	mediated	by	myosin-dependent	actin	contractility	(Burnette	et	al.,	2008). 
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The	presence	of	more	stable	rather	than	dynamic	MTs	favours	the	formation	of	an	axon	which	suggests	that	axonal	formation	requires	MT	stability	(Witte	and	Bradke,	2008).	Interestingly,	in	a	more	recent	study,	MT	stabilisation	was	used	to	enhance	the	growth	of	axons	after	spinal	cord	injury	(Hellal	et	al.,	2011).	The	stable	MTs	provide	a	track	for	moving	macromolecule	complexes	and	membrane-bound	organelles	along	that	are	required	for	the	growing	axon	(Nakata	and	Hirokawa,	2003).	Furthermore,	motor	proteins	such	as	kinesin-1	seem	to	prefer	binding	to	stabilized	MTs,	which	are	usually	highly	acetylated	(Reed	et	al.,	2006).	MT	stability	is	also	achieved	by	the	accumulation	of	CRMP-2	at	the	tip	of	the	growth	cone	as	it	promotes	the	transport	of	tubulin	heterodimer	for	forming	the	MTs	in	the	growing	axon	(Figure	1.6)	(Fukata	et	al.,	2002).	The	next	section	covers	the	stability	and	dynamics	of	MTs	in	axons	in	more	detail.		
1.10.3 MT	dynamics	in	axons	Neurites	that	are	set	to	be	the	future	axons	go	through	major	morphological	changes	that	are	correlated	with	the	behaviour	of	MTs	in	the	growing	axon	(Dent	et	al.,	1999).	The	accumulation	of	stable	MTs	causes	expansion	in	the	size	of	the	peripheral	lamellipodial	veil	and	an	increase	in	the	size	of	the	growth	cones.	Further,	the	length	of	actin	filaments	decreases	but	their	dynamics	increase	(Bradke	and	Dotti,	1999).	This	is	followed	by	a	move	of	the	assembled	MTs	into	the	centre	of	the	growth	cone	(Dent	and	Gertler,	2003).	These	activities	are	accompanied	by	increased	membrane	traffic	(Bradke	and	Dotti,	1997).		
The	elongation	of	axons	towards	guidance	cues	is	achieved	mainly	by	MT	behaviour	in	the	growth	cone	(Tanaka	and	Kirschner,	1991,	Tanaka	et	al.,	1995).	
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MTs	spread	upon	entering	the	centre	of	the	growth	cone,	loop	and	then	bundle	(Tanaka	and	Kirschner,	1991).		
The	ratio	between	the	number	of	dynamic	and	stable	MTs	in	the	growth	cone	determines	the	rate	at	which	the	axon	is	growing	(Tanaka	and	Kirschner,	1991).	For	example,	when	splaying,	the	number	of	dynamic	tubulin	heterodimers	in	the	growth	cone	appears	constant	at	all	times	(Tanaka	et	al.,	1995).	The	result	is	a	constant	ratio	between	the	number	of	heterodimers	transported	and	the	length	of	the	new	axonal	segment	(Tanaka	and	Kirschner,	1991).		
In	contrast,	paused	axonal	growth	is	achieved	by	MT	looping,	where	the	rate	at	which	the	dimers	polymerise	is	greater	than	that	of	the	growth	cone	advance	(Tanaka	and	Kirschner,	1991).	Finally,	when	MTs	bundle	the	growth	cone	advances	at	a	greater	rate	than	the	rate	of	MT	polymers	transport	across	the	growing	axon	(Tanaka	and	Kirschner,	1991).		
It	is	worth	noting	that	axonal	growth	is	not	only	supported	by	MTs	as	a	cytoskeletal	structure,	but	also	by	the	interaction	of	this	scaffold	with	multiple	cellular	signalling	pathways	and	the	actin	cytoskeleton	(Conde	and	Caceres,	2009).	
1.10.4 The	regulation	of	microtubule	dynamics	in	axons	
1.10.4.1 MT	severing	proteins	MT	severing	proteins	are	responsible	for	dis-assembling	stable	MTs	which	provides	free	tubulin	heterodimers	that	are	required	for	axonal	growth	and	elongation,	in	the	case	of	neurons	(Dent	et	al.,	1999).	Katanin	is	an	ATPase	MT	severing	protein	that	is	highly	expressed	during	axonal	growth,	but	its	
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expression	decreases	when	axons	reach	their	targets	(McNally	and	Vale,	1993).	katanin’s	main	function	seems	to	be	linked	to	axonal	elongation	but	not	axonal	collateral	branching	(Yu	et	al.,	2005).	Spastin	is	another	ATPase	that	functions	at	the	branching	points	of	the	growing	axons	(Errico	et	al.,	2002,	Evans	et	al.,	2005).	
1.10.4.2 MT	destabilising	proteins	Stathmin	is	a	neuronal	MT	destabilizing	protein	that	is	localised	mainly	in	the	cell	body	(Gavet	et	al.,	1998).	Superior	cervical	ganglia	neural-specific	10	protein	(SCG10)	and	SCG10	like	proteins	(SCLIP)	are	mainly	present	in	the	Golgi	complex,	along	young	neurites	and	at	axonal	growth	cones	(Charbaut	et	al.,	2005,	Grenningloh	et	al.,	2004).	These	three	proteins	are	proposed	to	destabilise	MTs	by	antagonising	MAP	and	other	stabilising	agents	to	promote	MT	dynamics	(Morii	et	al.,	2006,	Poulain	and	Sobel,	2007).		
KIF2A	is	another	neuronal	MT	destabilising	protein	and	is	a	member	of	the	kinesin	13-protein	family,	which	depolymerise	MTs	by	using	ATP	hydrolysis	for	energy	(Hirokawa	and	Noda,	2008).	However,	KIF2A	was	also	proposed	to	be	required	for	axonal	elongation	in	murine	hippocampal	cells	(Jimenez-Mateos	et	al.,	2005).	Figure	1.6	illustrates	the	action	and	location	of	stathmin	and	KIF2A	on	the	growing	microtubule.		
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Figure	1.6	Microtubule	dynamics	in	developing	axons.	Proteins	such	as	CRMP-2	promote	microtubule	polymerisation,	while	MAP1B	contributes	to	the	maintenance	of	microtubule	dynamics	and	KIF2	and	Stathmin	induce	microtubule	depolymerisation.	Adapted	from	(Conde	and	Caceres,	2009).	
1.10.4.3 Structural	MAPs	Structural	MAPs	include	MAP1B	and	Tau,	which	are	both	required	in	stabilizing	MTs	(reviewed	by	Dehmelt	and	Halpain,	2005,	Halpain	and	Dehmelt,	2006).	In	addition	to	the	MT	stabilizing	function,	Tau	protects	MTs	from	the	severing	action	of	katanin	(Qiang	et	al.,	2006)	and	interacts	with	the	actin	component	of	the	neuronal	cytoskeleton	(Sharma	et	al.,	2007).	MAP1B	has	been	suggested	to	interact	with	tubulin	tyrosine	ligase	(TTL)	(Utreras	et	al.,	2008)	and	is	one	of	the	regulatory	proteins	of	MTs	in	the	growth	cone	(Gonzalez-Billault	et	al.,	2001,	Gonzalez-Billault	et	al.,	2004).		
In	2011,	Lin	and	co-workers	have	reported	CRMPs	to	be	MAPs	that	have	the	ability	to	stabilise	MTs	through	a	unique	motif	from	their	tubulin-binding	region	(Figure	1.6)	(Lin	et	al.,	2011).	Interestingly,	similar	to	Tau,	the	binding	of	CRMPs	to	MTs	is	down	regulated	by	the	activity	of	GSK3β	(Lin	et	al.,	2011),	which	is	one	of	the	kinases	involved	in	regulation	MTs	dynamic.	
	 35	
1.10.4.4 Kinases	The	main	function	of	the	kinase	family	of	proteins	is	to	regulate	cargo	movement	within	the	cell;	however,	they	also	play	a	role	in	MT	stability	and	MT	movement	during	the	cell	cycle	(Moores	et	al.,	2006).	GSK3	knock-down	in	cell	culture	caused	a	reduction	in	axonal	growth	(Kim	et	al.,	2006).	On	the	other	hand,	when	GSK3	was	inactivated	at	the	distal	growth	cones	of	the	axons,	it	caused	a	reduced	axonal	branching,	but	did	not	affect	axon	elongation	(Kim	et	al.,	2006).	GSK3	affects	MT	dynamics	by	its	ability	to	phosphorylate	CRMP-2,	APC	as	well	as	MTP1B	(Yoshimura	et	al.,	2005,	Kim	et	al.,	2006).	At	the	growth	cone,	when	GSK3	is	inactive	(phosphorylated	by	PI3K)	(Shi	et	al.,	2003),	it	cannot	phosphorylate	CRMP-2,	which	promotes	binding	to	tubulin	subunits	and	therefore	MT	assembly	(Yoshimura	et	al.,	2005).	When	GSK3	is	inactive	along	the	shaft	of	the	axon,	it	inhibits	the	action	of	MAP1B	and	that	favours	the	MT	dynamics	(Kim	et	al.,	2006).	
Mitogen	activated	protein	kinases	(MAPKs)	are	a	family	of	kinases	that	are	highly	expressed	in	the	brain	and	are	implicated	in	brain	development	(Pearson	et	al.,	2001).	Some	evidence	suggests	that	MAPK8	is	responsible	for	the	phosphorylation	of	MAP2	and	MAP1B	and	therefore	can	regulate	their	ability	to	bind	to	MTs	(Chang	et	al.,	2003).		
Other	kinases	that	are	involved	in	MT	dynamics	are	the	serine	and	threonine	kinase	LKB1	and	its	partner	STE20-related	kinase	adaptor	(STRAD)	(Shelly	et	al.,	2007),	which	can	phosphorylate	several	other	kinases	that	in	turn	phosphorylate	MAPs	such	as	Tau	(Biernat	et	al.,	2002).	
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1.10.4.5 Plus	end	tracking	proteins	Plus	end	tracking	proteins	are	found	at	the	plus	end	of	the	MT	polymer	and	are	mainly	involved	in	control	of	the	growth	directionality	and	dynamic	as	well	as	the	interaction	with	other	proteins	in	the	cell	body	(Akhmanova	and	Steinmetz,	2008,	Jaworski	et	al.,	2008).	The	tumour	suppressor	adenomatous	polyposis	coli	(APC)	was	found	to	function	in	the	hippocampal	neurons	as	a	plus	end	tracking	protein	(Votin	et	al.,	2005)	
Other	proteins	that	are	considered	as	plus	end	tracking	proteins	include	LIS1,	which	is	involved	in	neuronal	migration	and	axonal	elongation	via	interaction	with	dynein	and	doublecortin	(DCX)	a	MAP	involved	in	MT	bundling	(reviewed	by	Conde	and	Caceres,	2009).	
1.10.4.6 Minus	end	tracking	proteins	Dynein	is	a	cytoplasmic	protein	that	carries	out	a	multitude	of	functions	inside	the	cell	(Friocourt	et	al.,	2003).	In	neurons,	mutations	in	Dynein	1,	which	is	the	major	form	of	Dynein	(Rodriguez-Crespo,	2011)	was	linked	to	neuronal	disease	such	as	pachygyria	(smooth	cortex)	and	polymicrogyria	(smaller	gyri)	(Vallee	et	al.,	2012).	Other	Dynein	mutations	also	cause	peripheral	neuropathies	and	an	axonal	form	of	Charcot-Marie-Tooth	disease	(Poirier	et	al.,	2013a).	It	has	been	hypothesised	that	the	effect	of	Dynein	mutations	on	cortical	development	is	due	to	the	impairment	of	MT	transport	in	migrating	neurons	of	the	developing	cortex	(reviewed	by	Weedon	et	al.,	2011).	
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1.10.4.7 Interaction	of	MTs	with	actin	and	Rho	GTPase	The	actin	arc-shaped	filaments	are	found	between	the	central	and	the	peripheral	regions	of	the	growth	cone	and	they	go	through	contractions	mediated	by	myosin	II	protein	(Breuss	and	Keays,	2014).	These	contractions	are	vital	to	bundle	MTs	and	bring	them	towards	the	central	part	of	the	growth	cone	(Burnette	et	al.,	2008).	
Some	members	of	the	Rho	family	of	small	GTPases	were	found	to	play	a	vital	role	in	regulating	the	interaction	between	MTs	and	actin	filaments	(Schaefer	et	al.,	2008).	For	example,	actin-arc	contraction	and	MT	bundling	driven	by	myosin	seem	to	be	promoted	by	the	Rho-Rho	kinase	signalling	pathway	(Ishizaki	et	al.,	2001).	When	this	pathway	was	inhibited	in	hippocampal	neurons,	the	formation	of	new	axons	was	induced	which	was	suggested	to	be	due	to	the	inhibition	of	the	actin	barrier	of	MTs	at	the	growth	cone	(Burnette	et	al.,	2008).	
1.10.5 Tubulin	isotypes	and	the	“microtubule	code”	The	human	tubulin	isotypes	result	from	the	expression	of	eight	genes	for	tubulin	α	and	seven	genes	for	tubulin	β	(Hammond	et	al.,	2010).	Tubulin	β	isotypes	show	tissue	specific	distribution	in	humans	and	the	expression	of	β2,	β3	and	β4	is	increased	in	the	brain	(Khodiyar	et	al.,	2007,	Ludueña,	1997).	These	isotypes	differ	from	each	other	only	in	the	last	20	amino	acids	of	their	acidic	C-terminus	(Leandro-Garcia	et	al.,	2010).	The	presence	of	tubulin	isotypes	and	their	extensive	post-translational	modifications	give	rise	to	numerous	versions	of	tubulin	heterodimers	(Lewis	et	al.,	1985,	Villasante	et	al.,	1986,	Wang	et	al.,	1986,	Burgoyne	et	al.,	1988).	Many	studies	agree	that	post-translational	modifications	of	tubulin	seem	to	be	associated	with	MT	stability	as	
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highly	modified	tubulin	heterodimers	are	found	in	established	organelles	or	parts	of	the	cells	such	as	axons	(Verdier-Pinard	et	al.,	2009).	Furthermore,	tubulin	modifications	are	found	on	the	C-terminus,	which	is	the	binding	region	for	MAPs	and	motor	proteins	(Westermann	and	Weber,	2003,	Gundersen	et	al.,	1989,	Gundersen	et	al.,	1987).	The	diversity	of	tubulin	isotypes	and	the	potential	impact	this	diversity	has	on	regulating	their	post-translational	modifications	appears	to	serve	as	a	code	for	interacting	proteins	to	translate	and	act	upon	which	is	referred	to	as	the	“microtubule	code”	(Verhey	and	Gaertig,	2007).	
1.10.6 Tubulin	post-translational	modifications	Tubulin	and	MTs	are	subject	to	a	wide	range	of	PTMs.	It	has	become	evident	that	understanding	the	role	of	these	modifications	is	vital	in	determining	the	function	and	the	dynamics	of	MTs.	In	this	section,	all	known	PTMs	of	tubulin	are	discussed	in	detail.	
Tubulin	was	found	to	be	reversibly	retyrosinated/detyrosinated	in	1973	(Barra	et	al.,	1973).	In	the	detyrosination	process,	the	genetically	encoded	tyrosine	at	the	C-terminus	of	tubulin	α,	is	removed	by	an	unknown	enzyme.	However,	the	retyrosination	is	performed	by	tubulin	tyrosine	ligase	TTL	(Hallak	et	al.,	1977).	Furthermore,	when	α	tubulin	is	detyrosinated,	it	can	be	irreversibly	converted	into	∆2-tubulin	α		by	removal	of	the	second	last	glutamate	residue	(Ersfeld	et	al.,	1993).	The	detyrosinated-tubulin	rich	domains	of	MTs	are	found	to	resist	depolymerisation	by	motor	proteins	and	are	more	stable,	hence	are	located	in	the	proximal	axon	(Paturle-Lafanechere	et	al.,	1991).			
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Both	α	and	β	tubulin	are	glutamylated	on	the	C-terminus	but	within	the	MT	polymer	as	a	short	or	a	long	side	chain	(Peris	et	al.,	2009).	An	enzyme	complex	named	tubulin	tyrosine	ligase	like	protein	(TTLL)	is	responsible	for	tubulin	glutamylation	(Edde	et	al.,	1990,	Alexander	et	al.,	1991,	Rudiger	et	al.,	1992).	A	family	of	TTLLs	has	been	identified	which	vary	in	their	preference	to	glutamylate	α	or	β	subunits	and	in	initiating	or	elongating	the	glutamate	side	chain	(Janke	et	al.,	2005).	In	neurons,	the	functional	significance	of	glutamylation	has	not	been	determined,	however	some	studies	suggest	that	it	might	play	a	very	selective	regulatory	role	in	controlling	neuronal	traffic	(Ikegami	et	al.,	2006,	van	Dijk	et	al.,	2007,	Ikegami	et	al.,	2008,	Ikegami	and	Setou,	2009,	Rogowski	et	al.,	2009).		
Tubulin	acetylation	has	been	shown	to	function	as	guidance	for	specific	motor	proteins	(Janke	and	Kneussel,	2010).	Although	acetylation	is	only	found	on	stable	MTs,	it	shows	no	effect	on	stabilizing	the	MT	structure	(Setou	et	al.,	2002).	
Phosphorylation	has	also	been	observed	on	tubulin	β	subunits,	which	are	phosphorylated	on	Ser172	by	Cdk1	(Palazzo	et	al.,	2003).	In	contrast	to	most	known	tubulin	post-translational	modifications,	tubulin	β	phosphorylation	prevents	the	interaction	of	tubulin	heterodimers	and	therefore	stops	MT	polymerisation	(Fourest-Lieuvin	et	al.,	2006).		
Polyamination	of	MTs	is	the	crosslinking	of	polyaminated	glutamines	by	the	activity	of	transglutaminase	(TG),	mainly	TG2,	in	mature	axons	and	polymerised	MTs	(Fourest-Lieuvin	et	al.,	2006).	MT	stability	is	remarkably	reduced	when	
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TG2	is	inhibited	chemically	or	by	gene	knock	out	(Song	et	al.,	2013).	In	vitro,	polyamination	of	tubulin	increases	MT	polymerisation	(Song	et	al.,	2013).		
Enzymatic	glycosylation	of	tubulin	is	thought	to	regulate	protein-protein	interaction	(Song,	2010).	Glycosylation	of	tubulin	βIII	has	been	linked	to	anti-cancer	drug	resistance	(Hino	et	al.,	2003).		
Non-enzymatic	glycation	of	MTs	is	observed	on	diabetic	patients’	axons	due	to	hyperglycaemia	and	is	thought	to	be	the	cause	of	diabetic	neuropathy	(Cicchillitti	et	al.,	2008).		
Ubiquitylation	of	tubulin	is	the	covalent	addition	of	a	small	protein	(ubiquitin)	to	tubulin	by	the	activity	of	the	ligase	enzyme	Parkin	(McLean,	1997).	In	some	familial	cases	of	Parkinson’s	disease	(Varshavsky,	2012),	Parkin	is	mutated	and	it	ubiquitylates	tubulin	dimers	causing	an	increase	in	their	dissociation	and	recycling	(Cookson	and	Bandmann,	2010).	Mutated	Parkin	and	ubiquitylated	tubulin	subunits	aggregate	in	Parkinson’s	disease	affected	neurons	(Ren	et	al.,	2003).	In	most	cases,	the	addition	of	single	ubiquitin	to	a	protein	is	linked	to	protein-protein	interactions	and	localisation	(Ardley	et	al.,	2003,	Muqit	et	al.,	2004).	
SUMOylation	in	neurons	is	the	covalent	linkage	of	SUMO	proteins	to	other	proteins	such	as	tubulin	(Varshavsky,	2012).	The	addition	of	a	single	SUMO	protein	is	thought	to	play	a	role	in	the	protein-protein	interaction	or	intracellular	trafficking	of	MTs	(reviewed	by	Komander	and	Rape,	2012).	
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Recently,	the	methylation	of	three	arginines	was	reported	in	tubulin	β	in	mouse	brain,	however,	no	functional	significance	has	been	reported	yet	(Guo	et	al.,	2014).	
Despite	the	fact	that	each	tubulin	PTM	serves	a	distinctive	molecular	function,	cross-talk	can	happen	between	one	or	more	of	these	PTMs	(Song	and	Brady,	2015).	It	is	possible	that	one	signal	in	the	cell	can	be	achieved	by	the	physiological	effect	of	multiple	tubulin	PTMs.	For	example	in	neurons,	detyrosination	(Flotho	and	Melchior,	2013),	acetylation	(Konishi	and	Setou,	2009)	and	polyglutamylation	(Reed	et	al.,	2006,	Cai	et	al.,	2009)	act	together	as	a	cue	to	redirect	KIF5	into	the	axonal	compartment	during	neuronal	differentiation	(Maas	et	al.,	2009).	All	currently	known	tubulin	post-translational	modifications	are	summarised	in	Table	1.1.		
While	PTMs	are	important	in	regulating	MT	function,	mutations	in	tubulin	subunits	can	occur	and	some	of	them	have	devastating	effects,	which	can	lead	to	neuronal	disease	development.		
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Table	1.1	Post-translational	modifications	of	tubulin	
Modification Location Enzyme Function 
Acetylation 
 
Tubulin α Lys40. Inside 
the lumen. Other 
locations on tubulin α 
and β 
ARD1–NAT1 
complex and 
Elongator complex 
Guidance cue for 
motors. 
Not involved in the 
stabilization of MT 
Detyrosination of 
tubulin α 
C-terminus outer 
surface of the polymer 
Unknown 
Carboxypeptidase 
Contribution to MT 
stabilization, 
inversely regulates 
motor proteins 
binding 
Glutamylation/ 
glycylation 
Last 15 residues of C-
terminus of tubulin α 
and β outer surface of 
polymer 
Multiple 
Glutamylases and 
glycylases 
Regulation of MT 
and the interactions 
with MAPs and 
motor proteins 
Glycosylation Multiple sites on tubulin α and β Unknown 
Regulation of 
protein-protein 
interactions 
Phosphorylation Ser172 on tubulin β Cdk1 
Prevention 
heterodimers 
polymerisation 
Polyamination Q15 on tubulin β and other sites Transglutaminase 
Stabilisation of MT 
in mature axons 
SUMOylation Multiple site on tubulin α and β Unknown 
Intracellular 
trafficking? 
Ubiquitylation Multiple site on tubulin α and β Parkin 
Protein-protein 
interactions? 
Methylation R162, R318 and R320 on β-TUB Unknown Unknown For	references	see	Section	1.10.6		 	
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1.10.7 Tubulin	mutations	and	neuronal	disease	
1.10.7.1 Tubulin	α	mutations	Tubulin	α	1A	isotype	(TUBA1A)	mutations	were	studied	in	Jenna	mice	models	(Keays	et	al.,	2007).	The	Jenna	(Jna/+)	mouse,	generated	from	an	N-ethyl-N-nitrosourea	mutagenesis	screen,	has	a	dominantly	inherited	mutation	in	exon	four	of	the	tubulin	α	gene,	which	caused	a	S140G	substitution	in	the	tubulin	α1A	chain.	This	mutation	was	observed	to	cause	abnormalities	in	brain	structure	due	to	retardation	in	neuronal	migration	during	brain	development	(Keays	et	al.,	2007).	As	a	result,	mutant	animals	have	a	fractured	pyramidal	cell	layer	in	the	hippocampus,	and	laminar	abnormalities	in	the	cerebral	cortex,	predominantly	in	layers	III	and	IV	(Keays	et	al.,	2007).	In	humans,	lissencephaly	is	identified	by	smooth	brain	due	to	abnormal	migration	of	neurons	during		weeks	12-24	of	gestation	(Dobyns,	1987).	Lissencephaly	patients	were	identified	with	de	novo	mutations	of	TUBA1A	with	abnormalities	related	to	their	gyri	such	as	reduction	(pachygyria),	increase	in	number	(polygyria)	or	absence	of	gyri	(agyria)	(Keays	et	al.,	2007).	These	patients	also	have	abnormal	corpus	callosum	growth	patterns,	hypoplasia	of	basal	ganglia,	large	ventricles	and	hypoplasia	of	the	cerebellum	(Kumar	et	al.,	2010,	Poirier	et	al.,	2007,	Poirier	et	al.,	2013b).	Some	of	these	TUBA1A	mutations	are	thought	to	cause	impairment	in	the	heterodimer	folding	similar	to	that	caused	in	the	Jenna	mouse	model	(Sohal	et	al.,	2012).	However,	other	mutations	are	speculated	to	affect	the	binding	of	motor	proteins	and	MAPs	to	the	MTs	when	the	mutated	α	tubulin	is	part	of	the	tubulin	dimer	structure	(Sohal	et	al.,	2012,	Kumar	et	al.,	2010).		
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Mutation	of	tubulin	α	8	isotype	(TUBA8)	has	also	been	implicated	in	neurodevelopmental	disease.	A	14	base	pair	deletion	in	intron	1	of	TUBA8	identified	by	genetic	mapping	was	linked	to	polymicrogyria	and	optic	nerve	impairment	in	two	families	(Tian	et	al.,	2010,	Amos	and	Schlieper,	2005).	
1.10.7.2 Tubulin	β	mutations	
The	first	mutations	in	tubulin	β	II	B	chain	(TUBB2B)	were	identified	in	2009	in	patients	with	asymmetric	polymicrogyria	who	also	have	a	range	of	neurodevelopmental	diseases	that	are	very	similar	to	those	caused	by	TUBA1A	mutations	(Abdollahi	et	al.,	2009).	Other	TUBB2B	mutations	induce	lissencephaly	(Cederquist	et	al.,	2012),	pachygyria	and	polygyria	(Cushion	et	al.,	2013)	and	schizencephaly	with	polymicrogyria	(Guerrini	et	al.,	2012).	Several	other	TUBB2B	mutations	have	been	found	to	affect	the	folding	of	tubulin	heterodimers	and	therefore	negatively	impact	the	binding	of	MTs	to	other	proteins	(reviewed	by	Romaniello	et	al.,	2012).	
Tubulin	β	III	(TUBB3)	has	two	types	of	mutations	identified	in	patients	so	far.	Firstly,	six	mutations	were	identified	in	patients	with	congenital	fibrosis	in	the	extraocular	muscle	(type	3),	however	they	expressed	no	cortical	or	gyral	abnormalities	(Breuss	and	Keays,	2014).	Other	mutations	in	TUBB3,	however,	were	linked	to	patients	with	impairment	of	cortical	development	due	to	defects	in	neuronal	migration	(Tischfield	et	al.,	2010).	Interestingly,	the	alanine	in	position	302	causes	congenital	fibrosis	in	the	extraocular	muscle	(type	3)	if	it	is	mutated	to	threonine	(Poirier	et	al.,	2010),	while	it	is	the	cause	of	gyral	developmental	impairment	if	it	is	replaced	with	valine	(Poirier	et	al.,	2010).	
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There	are	an	expanding	number	of	neurological	developmental	disorders	associated	with	mutations	in	TUBB3	such	as	photophobia,	defective	olfactory	function	and	peripheral	neuropathy	(Tischfield	et	al.,	2010).	
Mutations	in	tubulin	β	V	isotype	(TUBB5)	were	reported	to	cause	microcephaly,	distinctive	from	other	neuronal	disease	causing	tubulin	mutations	(Chew	et	al.,	2013).	The	patients	with	TUBB5	mutations	presented	abnormal	corpus	callosum	and	basal	ganglia,	similar	to	those	with	mutations	of	other	tubulin	mutations	(Breuss	et	al.,	2012)	which	further	supports	that	tubulin	function	is	vital	for	correct	brain	development.	
1.11 Preliminary	results	
Arginine	methylation	in	primary	cortical	neurons	was	investigated	during	a	previous	Honours	study	(Jwad,	2010).	In	that	study,	the	asymmetric	di-methylation	of	several	neuronal	proteins	was	observed	to	be	changing	during	the	14-day	culture	period	(Figure	1.7).		 	
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Figure	1.7	Western	blot	of	whole	cell	lysates	from	mouse	embryonic	
cortical	neuronal	cultures	from	various	days	in	culture	(Day	3	–Day	14)	
probed	with	a	primary	antibody	specific	for	asymmetrically	di-methylated	
arginines.		Molecular	weight	is	indicated	on	the	right	in	kDa	and	the	boxed	region	highlights	a	protein	of	~85	kDa	which	was	only	detected	in	significant	amounts	from	day	10	onwards.	Further,	the	general	inhibition	of	methylation	using	AdOx	caused	a	visual	decrease	in	the	length	of	axons	of	live	cultured	primary	cortical	neurons	(Figure	1.8).	However	statistical	analysis	was	not	applied	to	determine	whether	the	decrease	in	axonal	length	was	significant.	
	 47	
	
Figure	1.8	Phase-contrast	photographic	images	of	primary	mouse	
embryonic	cortical	neurons	at	day	14	in	culture.		Control	(A).	Treated	with	25	µM	AdOx	since	day	10	(B).		Original	magnification	x	200.	Scale	bar=100µm	Preliminary	mass	spectrometry	analysis	of	the	proteins	in	the	region	60-85	kDa	from	a	single	experiment	(Figure	1.7)	revealed	arginine	methylation	on	CRMP-2	(Jwad,	2010).	Immunoprecipitation	and	Western	blotting	then	confirmed	the	asymmetric	di-methylation	of	arginine	residues	of	CRMP-2	(Figure	1.9).	
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Figure	1.9	CRMP-2	is	asymmetrically	di-methylated.		Western	Blot	with	CRMP-2	antibody	(A).	The	sample	before	immunoprecipitation,	the	flow	through	and	the	first	eluted	fraction	off	the	asymmetrically	di-methylated	antibody	IP	column	are	shown.	The	box	shows	an	asymmetrically	di-methylated	protein	detected	in	the	first	elution	fraction	by	the	CRMP-2	antibody.	Western	Blot	with	asymmetrically	di-methylated	antibody	(B).	The	sample	before	immunoprecipitation,	the	flow	through	and	the	first	eluted	fraction	off	the	CRMP-2	antibody	column	are	shown.	The	box	shows	a	protein	eluted	in	the	first	fraction	from	the	CRMP-2	antibody	column,	which	was	detected	by	the	asymmetric	di-methyl	arginine	specific	antibody	at	the	size	of	65	kDa.	Based	on	these	preliminary	data,	we	speculated	that	the	methylation	of	CRMP-2	has	a	regulatory	effect	on	the	growth	and	development	of	axons	in	cortical	neurons	via	regulating	CRMP-2	binding	to	other	proteins,	possibly	to	tubulin.	The	other	hypothesis	was	that	tubulin	itself	was	methylated	on	arginine	
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residues	and	therefore	when	arginine	methylation	is	inhibited,	this	caused	a	decrease	in	axonal	length	due	to	interruption	to	tubulin	function	or	structure.	
1.12 Aims	of	the	study	
Arginine	methylation	is	a	ubiquitous	post-translational	modification	that	plays	an	essential	role	in	many	cellular	functions	in	both	the	cytoplasm	and	the	nucleus.	Numerous	studies	have	been	performed	to	investigate	the	cellular	pathways	in	which	methylated	proteins	are	involved.	However,	few	studies	have	been	performed	to	clarify	the	involvement	of	arginine	methylation	of	neuronal	proteins	and	neuronal	disease	development,	prognosis	and	therapy.	Following	on	from	the	preliminary	data	obtained	during	Honours	(see	section	1.11),	the	major	aims	of	this	thesis	were	to	investigate	the	arginine	methylation	of	two	major	neuronal	proteins	in	mouse	cortical	neurons;	CRMP-2	and	its	binding	partner	tubulin.		
In	addition	to	mouse	cortical	neurons,	the	Neuro2a	cell	line,	immortalised	neuroblasts	derived	from	the	brain	of	Mus	musculus	affected	with	neuroblastoma	(Olmsted	et	al.,	1970,	Tsuji	et	al.,	1988,	Spero	and	Roisen,	1985)	was	also	utilised	as	a	model	for	dividing	neurons	affected	by	cancer	and	also	to	minimize	the	use	of	mice	for	primary	cortical	neuronal	cell	culture.		
The	specific	aims	of	this	project	were	to:	
1) Confirm	the	methylation	status	of	the	previously	identified	CRMP-2	in	mouse	primary	neurons	and	identify	methylated	arginine	residues	of	CRMP-2	and	its	binding	partner	tubulin.	
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2) Investigate	the	effect	of	the	identified	arginine	methylation	on	neurites	growth	of	cortical	neurons	and	on	the	cell	cycle.		
3) Identify	the	PRMTs	involved	in	arginine	methylation	of	the	neuronal	proteins	identified	in	aim	1.		 	
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Chapter	2 Materials	and	Methods		
Chemicals	and	reagents	used	in	this	study	are	listed	in	Table	2.1	while	all	the	buffers	used	are	listed	in	Table	2.2.	Table	2.3	lists	all	the	equipment	used	in	this	study,	Table	2.4	lists	the	antibodies	and	Table	2.5	lists	the	esiRNAs	used.		 	
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Table	2.1	List	of	chemicals,	reagents	and	consumables	
Materials Abbreviation Supplier 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid HEPES GIBCO
® Invitrogen Australia 
25 mm thick pre-filter paper  Life Technologies, Australia 
25% Trypsin in EDTA 
(Ethylenediaminetetraacetic acid)  GIBCO
® Invitrogen Australia 
96-well plates (flat bottom)  Sigma-Aldrich Australia 
Acetonitrile ACN Sigma-Aldrich Australia 
Adenosine periodate  AdOx Sigma-Aldrich Australia 
Ammonium bicarbonate  NH4HCO3 Sigma-Aldrich Australia 
BCIP/NBT liquid substrate   Sigma-Aldrich Australia 
Bicinchoninic acid BCA Sigma-Aldrich Australia 
Borosilicate glass pipette   Coring - Sigma Aldrich Australia 
Bovine serum albumin powder BSA Sigma-Aldrich Australia 
Cell strainer 70 µM  Corning, Australia 
Chymotrypsin   Promega 
Colloidal brilliant blue stain  Sigma-Aldrich Australia 
Copper (II) Sulfate Cu2SO4 Sigma-Aldrich Australia 
Dimethyl sulfoxide DMSO Sigma-Aldrich Australia 
Dithiothreitol  DTT Sigma-Aldrich Australia 
Dulbecco's modified Eagle's 
medium DMEM GIBCO
® Invitrogen Australia 
Ethanol (absolute)   Sigma-Aldrich Australia 
Extravidin-alkaline phosphatase  ExAP Sigma-Aldrich Australia 
Fetal calf serum  FCS GIBCO® Invitrogen Australia 
Flow cytometer Setup and Tracking 
Beads  CST BD Bioscience 
Formic acid   Sigma-Aldrich Australia 
GenMute transfection Kit for 
Neuro2a   SignaGen Laboratories 
Glutamax   GIBCO® Invitrogen Australia 
Glycerol  Sigma-Aldrich Australia 
HALT Protease Inhibitor (100x) HALT PI Thermo Scientific 
Hank’s balanced salt solution  HBSS GIBCO® Invitrogen Australia 
Iodoacetamide  IAA Sigma-Aldrich Australia 
Methanol  MeOH Sigma-Aldrich Australia 
Mini-protean precast gels 4-20%   Bio-Rad 
Mission esiRNA targeting mouse 
KIF11   Sigma-Aldrich Australia 
Mission esiRNA targeting mouse 
PRMT1   Sigma-Aldrich Australia 
Mission esiRNA targeting mouse 
PRMT8   Sigma-Aldrich Australia 
Neurobasal medium   GIBCO® Invitrogen Australia 
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Materials Abbreviation Supplier 
Nonidet P-40 NP-40  
Page Ruler Plus Prestained Protein 
Ladder   Thermoscientific 
Penicillin-Streptomycin (antibiotic) Pen/Strep GIBCO®  Invitrogen Australia 
Phosphate buffered saline tablets PBS Sigma-Aldrich Australia 
Pierce crosslink IP kit   Thermo Scientific 
Placlitaxal from Taxus brevifolia  Taxol Sigma-Aldrich Australia 
Poly-D-lysine coated 6 and 24 well 
plates  BD biocoat Australia 
Polyvinylidene difluoride membrane PVDF Millipore-Australia 
Propidium iodide PI Sigma-Aldrich Australia 
RNase   Sigma-Aldrich Australia 
Round Bottom Polystyrene Test 
Tube, with Cell Strainer Snap Cap 
(Falcon) 
 Corning, Australia 
Skim milk powder   Coles 
Sodium azide   Sigma-Aldrich Australia 
Trans-2,3-dimethoxy-ß-nitrostyrene PRMT1/8 inhibitor Sigma-Aldrich Australia 
Trifluoroacetic acid TFA Sigma-Aldrich Australia 
Trypan blue   Sigma-Aldrich Australia 
Trypsin-EDTA buffer   GIBCO® Invitrogen Australia 
Trypsin Gold   Promega 
Tubulin, GST tagged (human)  Sigma, NSW, Ausralia 
Tween 20  Sigma, NSW, Australia 			 	
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Table	2.2	List	of	buffers	and	solutions	
Buffer Name Use Composition 
10x Phosphate buffered 
saline 
Cell culture and Western 
Blot 
1.8 mM KH2PO4, 138 mM 
NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4.2H2O in dH2O. 
Adjusted pH to 7.4 
5x Laemmli loading dye SDS-PAGE 
0.5 M Tris base, Glycerol (10% 
v/v), 0.028 M SDS, β-
mercaptoethanol (4% v/v) and 
0.15 mM Bromophenol blue in 
dH2O 
BCA colour solution BCA Protein Assay 1:50  CuSO4 : Bicinchoninic acid 
Chymotrypsin working 
solution  
mass spectrometry peptide 
digestion  
10 ng chymotrypsin in 10 mM 
ammonium bicarbonate pH 7.4 
Conditioning buffer Immunoprecipitation 
Propriety solution from Pierce 
Crosslink IP Kit (Product 
#26147)  
DMEM complete Cell Culture and Transient Transfection 
Heat inactivated FCS (10% 
v/v), Penicillin (1000 U/mL), 
Streptomycin (0.1 mg/mL), 
2mM L-Glutamine 
Elution buffer Immunoprecipitation 
Propriety solution from Pierce 
Crosslink IP Kit (Product 
#26147) 
ExtrAvidin - Alkaline 
phosphatase Western Blot 
PBST (10 mL), ExAP (0.02% 
v/v) 
GenMute transfection buffer Neuro2a siRNA transfection 
Propriety solution from 
SignaGen Laboratories, 
transfection kit  
Neurobasal media complete Mouse embryonic neuronal primary cell culture 
1x B27, 0.5 mM L-glutamine, 
25 μM glutamate, 100 IU/mL 
penicillin and 100 μg/mL 
streptomycin  
Phosphate buffered saline + 
Tween 20 (PBST) Western Blot 1x PBS, Tween 20 (0.01% v/v) 
PI staining solution staining cells for flow cytometry analysis 
0.02 mg/mL PI, 0.5 mg/mL 
RNAse A, 5% FCS in PBS 
solution 
Pierce IP wash/lysis buffer Cell lysis, IP columns wash 
25mM Tris-HCl pH 7.4, 150mM 
NaCl, 1mM EDTA, 1% NP-40 
and 5% glycerol, 1x HALT PI 
Primary antibody solution Western Blot PBST (10 mL), Primary Antibody (1% v/v) 
SDS/tris/glycine Running 
Buffer 10x SDS-PAGE 
1.9 M Glycine, 0.25 M Tris 
base, 0.035 M SDS  
Secondary antibody 
solution Western Blot 
PBST (10 mL), Secondary 
Antibody (0.4% v/v) 
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Buffer Name Use Composition 
Skim milk blocking solution Western Blot 5% w/v skim milk powder in PBS 
Transfer buffer (1x) Western Blot 
1:10 of 10x Transfer buffer, 
2:10 MeOH and 7:10 dH2O. 
(Example 10 mL 10x transfer 
buffer, 20 mL MeOH, 70 mL 
dH2O) 
Transfer buffer 10x Western Blot 1.9 M Glycine, 0.25 M Tris base  
Trypsin gold working 
solution 
Mass spectrometry peptide 
digestion  
10 ng trypsin in 10 mM 
ammonium bicarbonate pH 7.4 	
Table	2.3	List	of	equipment	
Equipment Supplier 
Centrifuge 5425-Eppendorf Eppendorf South Pacific, NSW, Australia  
Centrifuge 5810 R-Eppendorf Eppendorf South Pacific, NSW, Australia  
CO2 Water-Jacketed Incubator-NUAIRE In Vitro Technologies, VIC, Australia 
Dissection microscope-Motic  Optic Central, VIC, Australia 
Fitted camera-Leica Leica Microsystems, NSW, Australia 
Haemocytometer Hausser Scientific, PA, USA 
Image station gel scanner 4000nm-Kodak Millennium Science, VIC, Australia 
Light microscope-Leica Leica Microsystems, NSW, Australia 
Mass spectrometer/QToF-Waters Waters, NSW, Australia 
Microplate incubator-Thermostar BMG Labtech, VIC, Australia 
Mini-Protean tetra System Bio-Rad, VIC, Australia 
Nano Aquity C18 BEH130 column  Waters, NSW, Australia 
Nano Aquity UPLC Waters, NSW, Australia 
OWL HEP series semi-dry blotter Thermo Scientific, VIC, Australia 
Pellet pestle Sigma-Aldrich, Australia 
PowerPac HC Bio-Rad, VIC, Australia 
Sonicator-Branson 2510 Consonic, NSW, Australia 
Spectrophotometer-FLUOstar OPTIMA  BMG Labtech, VIC, Australia 
Speed vac concentrator- Savant DNA 120 Thermo Scientific, VIC, Australia 
Vortex mixer Ratek Instruments, VIC, Australia 		 	
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Table	2.4	List	of	antibodies	
Antibody Primary/ 
Secondary 
Working 
Concentration 
Catalogue 
Number 
Supplier 
Alpha tubulin A1 
chain Primary 1:5000 ab18251 Abcam 
Asym24 Primary 1:500 07-414 Millipore 
Beta tubulin III Primary 1:800 ab18207 Abcam 
CRMP-2 Primary 1:10,000 ab62661 Abcam 
KIF11 Primary 1:500 K36382 Sigma-Aldrich Australia 
PRMT1 Primary 1:500 07-404 Millipore 
PRMT5 Primary 1:500 07-405  
PRMT8 Primary 1μg/mL ab168134 Abcam 
Biotinylated anti-
rabbit whole 
molecule goat IgG  
Secondary 1:2500  B7389 
Sigma-Aldrich 
Australia 
Sym10  Primary 1:500 07-412 Millipore 	
Table	2.5	List	of	esiRNAs	
esiRNA Catalogue Number NCBI accession No. 
Mouse PRMT1 EMU016791 NM_019830 
Mouse PRMT8  EMU055401 NM_201371 
Mouse Kif11 EMU017691 NM_010615 		 	
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2.1 Cell	culture	
2.1.1 Mouse	primary	embryonic	cortical	neuronal	cell	culture	16-day	pregnant	Balb/c	mice	were	purchased	from	the	Animal	Resource	Centre	(ARC),	Perth,	WA.	The	mice	were	sacrificed	by	passing	CO2	gas	into	a	sealed	plastic	cage	in	compliance	with	the	Western	Sydney	University	animal	ethics	protocol	(ARP#	A6750).	The	abdominal	surface	of	the	mice	was	rinsed	with	75%	ethanol	and	cut	along	the	midline.	After	removing	the	foetuses	from	the	uterus	they	were	placed	in	a	Petri	dish	containing	ice-cold	Hank’s	Balanced	Salt	Solution	(HBSS)	without	magnesium	and	calcium	supplemented	with	10	mM	HEPES	(7.4	pH).	The	foetuses	were	then	decapitated.	Embryonic	cortices	were	collected	after	removing	the	skull	and	the	meninges	under	a	dissection	microscope.	The	cortices	were	transferred	into	a	50	mL	centrifuge	tube	containing	10	mL	of	ice-cold	HBSS	without	magnesium	and	calcium	and	were	washed	twice	with	10	mL	of	the	same	buffer.	Following	a	digestion	with	10	mL	of	25%	trypsin	in	EDTA	buffer	for	10	minutes	at	37°C,	cortical	tissue	was	then	washed	as	mentioned	before.	With	a	10	mL	borosilicate	glass	pipette	the	tissue	was	dissociated	in	10	mL	of	HBSS	without	magnesium	and	calcium	by	20	strokes.	The	suspension	was	then	passed	through	a	70	µm	cell	strainer	into	a	50	mL	centrifuge	tube	that	contained	20	mL	of	HBSS	with	magnesium	and	calcium	and	centrifuged	at	960	x	g	for	10	minutes	at	4°C.	After	removing	the	supernatant,	the	cortical	cell	pellet	was	re-suspended	in	complete	neurobasal	media	(see	Table	2.2).	The	cortical	neurons	were	counted	using	a	Bright-Line	Neubauer	Hemocytometer	(Section	2.2).	The	cells	were	seeded	at	a	concentration	of	106	cells/mL	in	each	well	of	poly-D-lysine	coated	24-well	
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plates.	Cells	were	incubated	at	37°C,	5%	CO2	and	cultured	for	14	days.	Half	of	the	complete	neurobasal	media	was	replaced	every	three	to	four	days.	
2.1.2 Neuro2a	cell	line	culture	Neuro2a	cells,	kindly	provided	by	Prof	Gerald	Muench	from	the	Western	Sydney	University,	are	immortalised	neuroblasts	derived	from	the	brain	of	Mus	
musculus	affected	with	neuroblastoma	(Klebe	and	Ruddle,	1969).	Cells	were	cultured	at	37°C	and	5%	CO2	in	complete	DMEM	(Table	2.2)	and	propagated	at	approximately	80%	confluence.	
2.2 Cell	counting	
Before	seeding	the	cells	into	the	wells	of	poly-D-lysine	coated	culture	plates	the	extracted	mouse	embryonic	primary	neurons	were	counted	using	a	Bright-Line	Neubauer	Hemocytometer.	A	small	volume,	usually	10	µL	of	the	neurobasal	media	cell	suspension	was	diluted	10	times	with	fresh	complete	neurobasal	media	(Table	2.2)	then	the	latter	was	further	mixed	with	trypan	blue	at	a	1:1	ratio.	10	µL	was	pipetted	onto	the	Hemocytometer	and	then	cells	were	counted	under	an	inverted	light	microscope.	The	Neuro2a	cells	were	counted	using	the	same	steps	described	above	except	that	they	were	only	diluted	at	1:1	ratio	with	trypan	blue.	Based	on	the	cell	count	cells	were	seeded	at	the	desired	density.		
2.3 Methylation	inhibition	experiments	
2.3.1 Treatment	with	AdOx	At	day	10	of	culture,	25	µM	AdOx	was	added	to	the	primary	mouse	cortical	cell	culture	after	replacing	half	of	the	culture	media	with	fresh	media.	The	same	treatment	was	repeated	at	day	12	and	the	cells	were	then	imaged	or	harvested	
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and	lysed	at	day	14.	The	concentration	of	25	µM	was	determined	by	examining	the	level	of	protein	arginine	inhibition	using	Western	blot	analysis	with	Asym	24	antibody	against	asymmetrically	di-methylated	proteins	(Table	2.4	and	Section	2.8).	The	effect	of	treatment	with	AdOx	at	5,	25	and	50	µM	was	investigated.	The	effect	of	5	µM	on	the	cells’	morphology	and	protein	methylation	is	shown	in	Figure	2.1.	As	5	µM	did	not	show	any	significant	inhibition	and	50	µM	AdOx	was	toxic	to	the	cells,	25	µM	was	used	throughout	this	study.	For	original	Western	blot	including	irrelevant	lanes	which	were	removed	for	clarity	in	Figure	2.1	and	a	Western	blot	with	GAPDH	as	a	loading	control	are	shown	in	the	Appendix	see	Figure	A.1.		
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Figure	2.1	The	effect	of	AdOx	treatment	on	primary	cortical	neurons.	Microscopic	images	of	primary	cortical	neurons	after	4	days	treatment	with	various	concentrations	of	AdOx	(A-D).	Scale	bar	=	100	μm.	Control	(A),	5	μM	AdOx	(B),	25	μM	AdOx	(C),	50	μM	AdOx	(D).	Western	blot	of	whole	cell	lysates	using	Asym24	primary	antibody	specific	for	proteins	with	asymmetrically	di-methylated	arginines	(E).	
2.3.2 Neuro2a	cell	treatment	with	PRMT1/8	inhibitor	Trans-2,	3-dimethoxy-ß-nitrostyrene,	referred	to	in	this	thesis	as	PRMT1/8	inhibitor,	is	a	nitroalkene	discovered	recently	by	high-throughput	screening	to	have	the	ability	to	specifically	inhibit	both	PRMT1	and	PRMT8.	(Dillon	et	al.,	
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2012).	PRMT1/8	inhibitor	works	by	inhibiting	the	binding	of	SAM	to	the	catalytic	site	on	PRMT1	and	PRMT8	by	binding	to	the	hyperactive	cysteine	101	which	is	not	present	in	any	other	PRMT	(Dillon	et	al.,	2012)	(see	Section	1.6.2.4).	PRMT1/8	inhibitor	was	reconstituted	in	100%	DMSO	and	then	added	to	complete	DMEM	at	a	final	concentration	of	10	µM,	2	µM,	1.5	µM	or	1	µM.	Neuro2a	cells	were	seeded	at	3	x	105	cells	per	well	in	24-well	plates.	After	24	hours,	the	culture	media	was	replaced	with	complete	DMEM	containing	the	PRMT1/8	inhibitor.	The	cells	were	incubated	at	37°C	and	5%	CO2	and	they	were	then	harvested	and	lysed	as	described	in	Section	2.6	for	further	analysis	by	SDS-PAGE	and	Western	blot	(Section	2.8)	either	directly	or	after	immunoprecipitation	(IP)	(Section	2.10).	
2.4 Imaging	neuronal	cells	
Cells	at	day	14	in	culture	were	imaged	using	an	inverted	light	microscope	with	a	digital	camera	fitted	(Table	2.3).	The	images	were	taken	at	200	times	magnification.	
2.5 Measuring	neurite	length	and	area	of	the	cell	body	using	
ImageJ	
Before	measuring	the	length	of	the	neurites	of	both	control	and	AdOx	treated	primary	neurons,	the	images	were	randomised	to	avoid	bias	while	performing	the	measurements.	ImageJ	(Fiji	version)	plug	in,	Simple	Neurite	tracer	was	used	to	measure	the	length	of	the	neurites.		Only	neurites	which	had	a	visually	identifiable	growth	cone	and	hence	were	deemed	to	be	“axons”	were	included	in	the	measurements.	Neurites	which	were	intertwined	with	other	cells	and	did	not	have	very	definite	paths	were	excluded	from	the	measurements.	Figure	2.2	
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A	shows	an	example	image	to	demonstrate	the	analysis	of	neurite	length	in	ImageJ.	The	area	of	the	cell	body	of	each	neuron	used	for	neurite	length	measurement	was	also	determined	using	ImageJ	Area	analysis	tool.		
 
Figure	2.2	Mouse	primary	cortical	neurons	with	a	trace	of	simple	Neurite	
Tracer	plugin	of	the	ImageJ	software	to	measure	neurite	length	and	cell	
body	area.		Screenshots	of	ImageJ	with	traced	axon	using	Simple	Neurite	Tracer	(A)	and	cell	body	traced	prior	to	area	measurement	(B).	The	pink	line	is	a	traced	axon	and	the	yellow	line	is	a	traced	cell	body.	The	software	automatically	traces	the	axon	after	the	start	and	the	end	of	the	axonal	path	indicated	by	the	user. 	
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Each	measurement	was	automatically	recorded	as	an	independent	path	by	the	software	and	data	were	exported	as	.CSV	files.		
The	data	from	the	CSV	files	were	then	combined	in	one	Excel	sheet	for	each	treatment	condition	and	the	t	test	and	box	plot	statistical	analysis	was	performed	using	IBM	SPSS	Statistical	Package	22.	
2.6 Cell	harvest	and	lysis	
For	this	thesis,	all	cell	lysis	was	performed	using	Pierce	IP	wash/lysis	buffer.	Primary	cortical	neurons	cultured	in	24-well	plates	at	106	cells	per	well	were	lysed	with	200	µL	Pierce	IP	wash/lysis	buffer	containing	1x	HALT	PI	(Table	2.2).	First,	the	cells	were	washed	with	500	µL	ice-chilled	PBS,	and	then	they	were	incubated	with	the	lysis	buffer	on	ice	for	10	minutes.	The	cells	were	then	collected	and	lysates	from	two	wells	were	combined	in	one	1.5	mL	Eppendorf	tube.	To	ensure	the	lysing	of	most	cells	in	the	suspension,	a	micro	pellet	pestle	homogenizer	was	used	for	approximately	5	seconds.	The	cells	were	then	centrifuged	at	15,000	x	g	for	10	minutes	after	which	the	supernatants	were	collected	into	fresh	tubes	and	frozen	at	-20°C.	Neuro2a	cells	were	collected	from	6-well	plates	for	lysis	when	they	reached	a	cell	confluency	of	80-100%.	The	Pierce	IP	wash/lysis	buffer	volume	used	for	each	6-well	was	400	µL	per	well	and	the	same	harvest	and	lysis	steps	were	followed	as	described	above	for	the	primary	cortical	neurons.	
2.7 Protein	concentration	measurement	
The	concentration	of	total	protein	in	the	prepared	cytoplasmic	cell	lysate	was	determined	using	the	BCA	assay.	Duplicates	of	20	µL	of	BSA	solution	of	
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concentrations	of	2,	1.5,	1,	0.75,	0.5,	0.25,	0.125	mg/mL	in	96-well	plates	were	used	as	standards	to	generate	a	standard	curve	(see	Figure	2.3).	20	µL	of	each	cell	lysate	sample	was	used	in	the	assay.	Cu2SO4	solution	was	diluted	in	BCA	at	a	1:50	ratio,	then	200	µL	of	the	BCA	diluted	solution	was	added	to	each	of	the	standards	and	samples	and	the	plate	was	then	covered	with	parafilm	and	incubated	at	37°C	for	10	minutes.	The	absorbance	at	a	wavelength	of	595	nm	for	each	well	was	measured	on	a	FLUOstar	OPTIMA	spectrophotometer	(Table	2.3).		
Using	the	FLUOstar	OPTIMA	software,	the	protein	concentration	of	each	cell	lysate	sample	was	calculated	based	on	the	generated	standard	curve	from	the	values	of	the	standards	absorbance.	Using	the	absorbance	data,	a	standard	curve	was	generated	using	the	BSA	standards,	as	shown	in	Figure	2.3.	The	plotted	line	to	generate	the	curve	is	a	linear	regression	line	of	best	fit	assuming	that	the	relationship	between	all	the	concentrations	and	the	absorbance	is	linear	and	therefore	the	R2	cut	off	value	being	no	less	than	0.97.	The	absorbance	of	the	cell	lysate	samples	were	then	corrected	for	the	background	absorbance	of	the	lysis	buffer	by	subtracting	the	absorbance	value	of	the	buffer	from	the	absorbance	value	of	each	of	the	cell	lysate	samples.	The	corrected	absorbance	values	of	the	cell	lysate	samples	were	then	plotted	on	the	standard	curve	to	obtain	the	concentration	of	the	samples.	If	a	sample	lysate	was	outside	the	linear	range	of	the	BSA	standard	curve,	the	BCA	assay	was	repeated	and	the	outlying	sample	was	diluted	until	it	fell	within	the	linear	range	of	the	BSA	standard	curve.	It	is	important	to	note	however,	if	less	than	20	µL	of	the	cell	lysate	sample	was	used	in	the	assay,	the	dilution	factor	was	taken	into	account	when	calculating	the	final	total	concentration	of	the	sample.	The	data	obtained	
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from	the	BCA	assay	were	used	to	normalize	the	cell	lysate	sample	loading	in	SDS-PAGE	and	all	cell	lysates	were	diluted	to	the	protein	concentration	of	the	lowest	sample	for	each	SDS-PAGE	performed.	This	ensured	that	for	all	samples,	the	same	total	protein	concentration	was	loaded	in	each	lane.	The	total	amount	of	proteins	loaded	onto	each	gel	lane	ranged	between	10-25	µg	for	all	experiments	performed.	
	
Figure	2.3	Example	of	a	BSA	Standard	Curve	of	the	BCA	Assay.	A	representative	example	of	a	standard	curve	of	the	BCA	assay	with	an	R2	value	of	0.99,	a	linear	regression	line	was	fitted	and	the	linear	equation	was	used	to	calculate	the	concentration	of	each	cell	lysate	sample.	
2.8 SDS-PAGE	and	Western	blotting	
Sodium	dodecyl	sulfate	(SDS)	polyacrylamide	gel	electrophoresis	(PAGE)	was	used	to	separate	the	proteins	of	the	cell	lysates	on	a	mini	protean	precast	gel.	The	proteins	were	separated	using	a	Bio-Rad	mini	ProteanTetra	cell	with	1x	Tris/glycine/SDS	running	buffer	for	50	minutes	at	150	Volts.	The	semi-dry	blot	system	(Owl	HEP-1;	Thermo	Scientific,	Table	2.3)	was	used	to	transfer	the	proteins	from	the	gel	onto	PVDF	membranes.	The	SDS	polyacrylamide	gel	was	placed	onto	filter	paper	(Table	2.1)	soaked	with	1x	transfer	buffer	(see	Table	2.2)	placed	on	the	cathode	of	the	blotter.	Then	the	membrane	was	soaked	
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in	100%	methanol	for	30	sec	and	carefully	placed	over	the	gel.	The	membrane	was	then	covered	with	another	filter	paper	soaked	with	1x	transfer	buffer	(see	Table	2.2).	The	formed	sandwich	was	pressed	gently	with	a	small	roller	to	remove	the	excess	of	transfer	buffer	before	fitting	the	anode	part	of	the	blotter	on	top.	The	proteins	were	transferred	for	a	minimum	of	an	hour	at	a	constant	current	of	0.2	Ampere	per	gel.	The	blotted	membranes	were	blocked	with	5%	skim	milk	in	PBS	overnight	rocking	at	room	temperature.	Before	incubating	the	membranes	with	primary	antibody	solutions,	the	membranes	were	washed	2	times	with	excess	of	PBST	for	5	minutes	each	time.		
The	concentration	of	primary	antibody	(Table	2.4)	working	solutions	was	prepared	according	to	manufacturers’	instructions	and	they	were	diluted	in	PBST	with	0.02%	sodium	azide.	The	membranes	were	exposed	to	the	primary	antibody	for	a	minimum	of	1	hour	rocking	at	room	temperature	or	overnight	at	4°C.	
The	membranes	were	then	washed	with	PBST	twice	and	incubated	with	the	secondary,	biotinylated	antibody	(1:2500)	(Table	2.4)	in	PBST	for	a	minimum	of	30	minutes.	After	a	further	2	washes	with	PBST,	extravidin-alkaline	phosphatase	(1:5000)	in	PBST	was	added	for	30	minutes.	After	4	washes	with	PBST,	proteins	were	visualised	using	the	BCIP®/NBT	liquid	substrate	(Table	2.1).	After	bands	appeared,	the	membranes	were	washed	in	deionised	water	and	dried	overnight.	The	membranes	were	scanned	and	if	necessary,	contrast	of	the	entire	membrane	was	adjusted	using	Adobe	Photoshop.	
	 67	
2.9 Densitometry	analysis	of	Western	blot	bands	
The	NIH	ImageJ	analysis	tool	was	used	to	determine	the	optical	density	of	the	selected	Western	blot	bands.	The	images	were	imported	into	ImageJ	with	the	background	subtracted	with	a	rolling	ball	radius	of	50.0	pixels.	The	mean	optical	density	was	obtained	by	placing	an	elliptical	selection	around	the	bands,	and	calculated	automatically	by	the	program.	The	mean	optical	densities	from	three	independent	blots	were	then	placed	into	Microsoft	Excel	(2010)	and	the	average	of	the	mean	was	calculated.	The	resulting	data	were	used	to	create	a	bar	diagram	with	standard	error	of	the	mean	shown	as	error	bars.	For	statistical	analysis	t-test	was	performed	and	the	level	of	significance	was	indicated	as	*p<0.05,	**p<0.005,	***p<0.0005.	
2.10 Immunopreciptation		
For	all	immunoprecipitation	(IP)	experiments	in	this	project,	the	Pierce	Cross-linking	IP	kit	was	used.	
Two	controls	were	used	in	this	experiments,	esiRNA	for	KIF11	as	a	protein	control	and	negative	control	that	contained	the	transfection	reagents	without	any	esiRNA.	
2.10.1 Binding	of	antibody	to	protein	A/G	Plus	Agarose	20	μL	of	Pierce	Protein	A/G	Plus	Agarose	(resin	slurry)	was	added	to	two	spin	columns	and	centrifuged	at	1000	x	g	for	one	minute.	10	μg	of	the	primary	antibody	of	interest	(Table	2.4)	was	adjusted	to	100	μL	with	sufficient	milli-Q	water	and	20x	Pierce	coupling	buffer	was	then	added	to	each	column	separately	after	washing	the	column	with	Pierce	coupling	buffer.	
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The	columns	were	then	incubated	at	room	temperature	for	1	hour	on	an	orbital	rocker.	After	this	incubation,	the	columns	were	washed	three	times	with	coupling	buffer.	
2.10.2 Crosslinking	the	bound	antibody	To	each	column,	9	μL	of	2.5	mM	of	Disuccinimidyl	suberate	in	DMSO,	2.5	μL	20x	coupling	buffer	and	38.5	μL	of	milli-Q	water	was	added	to	obtain	a	final	working	concentration	of	450	μM	of	Disuccinimidyl	suberate	(DSS).	The	columns	were	then	incubated	rocking	at	room	temperature.	After	the	incubation,	the	columns	were	washed	with	50	μL	Pierce	elution	buffer	and	the	flow-through	was	collected	to	verify	that	the	crosslinking	was	successful.	After	that,	the	columns	were	washed	twice	with	the	elution	buffer	to	get	rid	of	any	non-cross-linked	antibody.	The	cross-linked	IP	columns	were	stored	in	1x	coupling	buffer	at	4°C	until	used.	
2.10.3 Pre-clearing	the	cell	lysate	
Cell	lysates	were	pre-cleared	by	incubating	with	80	µL	of	Pierce	Agarose	control	beads	for	30	minutes	at	room	temperature	while	rocking	in	a	fresh	spin	column.	The	preclearing	was	performed	prior	to	every	IP	experiment	to	minimize	non-specific	interactions;	therefore,	isotype	negative	control	was	not	used	in	this	experiment.	The	lysates	were	then	centrifuged	at	1000	x	g	for	1	minute	ready	to	be	immunoprecipitated	in	a	cross-linked	IP	column.	
2.10.4 Antigen	immunoprecipitation	Pre-cleared	cell	lysates	were	diluted	in	Pierce	IP	wash/lysis	buffer	to	400	μL	added	to	the	spin	columns	and	incubated	rocking	for	2	hours	at	room	
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temperature	or	at	4°C	overnight.	The	spin	columns	were	then	centrifuged	at	1000	x	g	for	1	minute	and	the	flow-through	was	collected.	Next,	the	columns	were	washed	with	IP	lysis/wash	buffer	twice,	followed	by	one	more	wash	with	the	Pierce	conditioning	buffer.	IP	columns	were	washed	twice	with	Pierce	IP	wash/lysis	buffer	and	then	stored	at	4°C	in	PBS	buffer	with	0.2%	sodium	azide	until	used	again.	
2.10.5 Antigen/protein	elution	For	each	antibody	column,	three	fresh	microfuge	tubes	were	prepared	by	adding	5	μL	of	Tris	solution	at	pH	of	9.5	to	neutralise	the	acidic	elution	buffer	(pH	2.5).	Three	elution	fractions	were	collected	using	the	Pierce	elution	buffer.	Each	fraction	was	collected	in	one	of	the	microfuge	tubes.	For	each	fraction,	10	μL	of	Pierce	elution	buffer	was	added	and	the	column	was	centrifuged	at	1000	x	g	for	1	minute.	Then	50	μL	of	the	elution	buffer	was	added	to	the	column	and	incubated	at	room	temperature	for	5	minutes	while	kept	in	the	same	collection	tube.	The	column	was	centrifuged	again	at	1000	x	g	for	1	minute	to	yield	the	first	elution	fraction.	Repeating	the	same	steps	as	described	for	fraction	1,	the	2nd	and	the	3rd	fractions	were	collected.		
The	immunoprecipitated	fractions	were	then	analysed	by	SDS-PAGE	and	Western	blotting	(see	Section	2.8).	
2.11 Mass	spectrometry	analysis	
2.11.1 Preparing	peptides	for	mass	spectrometry	The	cell	lysates	that	were	used	for	mass	spectrometry	analysis	were	first	separated	on	an	SDS-PAGE	using	Bio-Rad	4-20%	gradient	precast,	10-well	50	μL	
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mini	gels.	Samples	containing	10-25	µg	of	protein	as	estimated	by	BCA	assay	(Section	2.7)	were	loaded	on	each	lane	and	electrophoresed	at	200	Volts	for	40	minutes.	The	gels	were	then	either	stained	using	colloidal	brilliant	blue	stain	for	a	minimum	of	2	hours	at	room	temperature	or	the	bands	at	the	size	of	interest	were	excised	without	staining.		The	stained	gels	were	destained	with	distilled	water	overnight.	The	protein	bands	of	interest	were	then	excised	with	a	sterile	scalpel	and	placed	in	an	Eppendorf	tube.	The	unstained	gel	slices	were	directly	dehydrated	with	100%	ACN	for	20	minutes.	The	stained	gel	slices	were	further	destained	with	100%	ACN	and	25	μM	ammonium	bicarbonate	(1:1)	solution	overnight	at	room	temperature.	Next,	the	destaining	solution	was	removed	and	the	gel	slices	were	dehydrated	with	100%	ACN	for	20	minutes.	After	the	ACN	was	removed	from	the	tubes,	the	gel	slices	were	incubated	with	100	μL	of	10	μM	DTT	for	60	minutes	at	37°C	in	order	to	reduce	cysteine	residues	to	assist	in	the	digestion	of	the	proteins.	100	μL	of	25	μM	freshly	prepared	IAA	was	added	to	the	gel	slices	for	60	minutes	at	37°C	to	alkylate	the	proteins.	After	alkylation,	the	gel	slices	were	washed	3	times	with	milli-Q	water,	followed	by	3	washes	with	25	mM	of	ammonium	bicarbonate.	The	gel	slices	were	then	reduced	with	100%	ACN	for	at	least	20	minutes	or	until	they	became	white	and	brittle.	The	excess	ACN	was	evaporated	for	5	minutes	in	a	speed-vacuum.	
2.11.2 Trypsin	and	chymotrypsin	digestion	Trypsin	solution	10	ng/µL,	pH	7.4	or	chymotrypsin	solution	10	ng/µL,	at	pH	7	were	added	to	the	dehydrated	gel	slices	at	37°C	and	25°C	respectively	for	16	hours.	After	incubation	with	each	enzyme,	the	liquid	off	the	gel	slice	was	collected	into	new	tubes.	To	extract	the	maximum	amount	of	peptides	from	the	
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gels,	each	gel	slices	was	sonicated	for	10-15	minutes	with	0.1%	TFA.	The	liquid	was	also	collected	and	added	to	the	fresh	tubes.	Then	the	previous	step	was	repeated	with	TFA:	ACN	(1:1).	
2.11.3 LC-MS/MS	analysis	LC-MS/MS	analysis	was	performed	on	a	nanoAquity	UPLC	(Waters	Corp.,	Milford,	MA,	USA)	linked	to	a	Xevo	QToF	mass	spectrometer	from	Waters.	1	µl	of	digested	peptides	was	loaded	onto	a	nanoAquity	C18	BEH130	column	(1.7	µm,	75	µm×250	mm)	and	then	separated	and	eluted	from	the	column	using	a	binary	gradient	program	at	a	flow	rate	of	0.3	µL/min:	mobile	phase	A	was	0.1%	formic	acid	in	water;	and	mobile	phase	B	was	0.1%	formic	acid	in	ACN.	The	nano-UPLC	gradient	was	used	as	follows:	0	min,	97:3	A/B;	5	min,	97:3	A/B;	75	min,	40:60	A/B;	85	min,	10:90	A/B;	97	min,	97:3	A/B;	110	min,	97:3	A/B.	The	mass	spectrometer	was	operated	in	positive	ESI	mode	with	capillary	voltage	of	3.5	kV,	cone	voltage	of	40	Volts,	source	temperature	of	80	°C.	Targeted	MS/MS	data	or	DDA	(data	dependent	acquisition)	data	was	acquired	with	collision	energy	ramping	from	30	to	40	eV	on	the	eight	most	intense	peaks	of	MS	mode	with	mass	ranges	of	250	–	3000	Da.	The	data	were	acquired	by	the	software	Masslynx	(Version	4.1,	Micromass	UK).	
The	acquired	DDA	data	from	Masslynx	with	raw	extension	were	then	converted	to	.pkl	files	by	Proteinlynx	Global	Server	(PLGS),	before	interpretation	by	the	Mascot	database.			
The	MS/MS	data	files	were	searched	against	the	SwissProt	database	only	and	with	trypsin	or	chymotrypsin	as	the	enzyme.	The	following	parameters	were	set	in	the	Mascot	Editor	tab	for	identification	of	the	peptides:		maximum	missed	
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cleavage	of	3,	positive	peptide	charge	of	2	and	3,	peptide	mass	tolerance	of	0.2	Da	in	MS	and	MS/MS	data	base,	ion	score	threshold	was	set	to	10	and	fixed	modification:	carbamidomethyl	(C)	and	variable	modifications:	oxidation	(M),	methylation	(K),	di-methylation	(K),	methylation	(R)	and	di-methylation	(R).	
The	MS/MS	spectra	of	the	identified	peptides	are	generated	by	Mascot	and	are	represented	by	b	ions	that	extend	from	the	amino	end	of	the	peptide	and	y	ions	that	extend	from	the	carboxyl	end	of	that	peptide.		
2.12 Sequence	alignment	
FASTA	sequences	of	the	detected	proteins	were	aligned	using	the	Cobalt	Constraint-based	Multiple	Protein	Alignment	Tool.	
http://www.ncbi.nlm.nih.gov/tools/cobalt.	
2.13 Flow	cytometry	
Flow	cytometry	was	used	to	determine	the	cell	cycle	profile	of	Neuro2a	cells	after	treatment	with	AdOx,	Taxol,	AdOx	and	Taxol	combined	or	PRMT1/8	inhibitor.	
2.13.1 Treatment	and	fixing	Neuro2a	cells	were	seeded	onto	a	10	cm	culture	dish	at	a	density	of	2	x105	cells	with	5	mL	of	complete	DMEM.	After	48hr	incubation	at	37°C,	5%	CO2,	the	culture	media	was	aspirated	and	replaced	with	5mL	of	fresh	complete	DMEM	containing	the	treatments.	
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Neuro2a	cells	were	treated	with	50	nM	Taxol	in	DMSO,	10	µM	AdOx	in	DMSO,	both	50	nM	Taxol	and	10	µM	AdOx	combined,	PRMT1/8	inhibitor	or	DMSO	(0.2%)	as	control.		
After	24	hours,	the	media	containing	the	treatment	was	collected	in	fresh	tubes	and	centrifuged	at	400	x	g	for	5	minutes	to	collect	any	non-adherent	cells	and	the	media	was	discarded.	The	adherent	cells	in	the	culture	dishes	were	then	washed	twice	with	3	mL	PBS	and	the	wash	was	pooled	in	the	tubes	used	previously	and	centrifuged	again	at	400	x	g	for	5	minutes	and	the	supernatant	was	discarded.	The	cells	in	the	culture	dishes	were	then	incubated	with	3	mL	of	trypsin-EDTA	at	37°C,	5%	CO2	for	5	minutes.	The	cells	were	then	collected	in	the	previous	tubes	followed	by	one	last	wash	with	3	mL	of	PBS	to	remove	the	complete	DMEM.	The	tubes	were	centrifuged	once	again	at	the	same	conditions	and	the	supernatant	was	discarded.	The	cells	were	then	fixed	with	1-3	mL	of	70%	ethanol	depending	on	the	size	of	the	cell	pellet.	Ethanol	(70%)	was	added	drop	wise	while	pulse	vortexing.	The	cells	were	kept	at	4°C	for	1-4	days	before	staining	with	propidium	iodide	(PI)	and	analyses	of	cell	cycle.	
2.13.2 Staining	with	propidium	iodide	(PI)	Propidium	iodide	(PI)	is	an	intercalating	agent	that	binds	to	double	stranded	DNA	of	dead	cells	and	does	not	permeate	the	membrane	of	live	cells	(Sasaki	et	al.,	1987).	
Ethanol	was	removed	from	the	cells	by	centrifuging	at	800	x	g	for	5	minutes.	The	cells	were	then	rehydrated	twice	with	3	mL	of	PBS	with	5%	FCS	and	centrifuged	at	400	x	g	for	5	minutes	each	time.	The	PI	staining	solution	was	
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freshly	prepared	in	the	dark,	then	500	µL	of	the	staining	solution	was	added	to	each	tube	in	the	dark	and	then	incubated	at	37°C,	5%	CO2	for	30	minutes.	After	incubation,	the	PI	staining	solution	was	removed	by	centrifuging	at	400	x	g	for	5	minutes.	The	cells	were	washed	once	with	3	mL	of	PBS	with	5%	FCS	and	centrifuged	at	400	x	g	for	5	minutes.	The	stained	cells	were	then	re-suspended	with	0.5-2	mL	of	PBS	with	5%	FCS	depending	on	the	size	of	the	cell	pellets.	Before	flow	cytometry	analysis,	the	cells	were	passed	through	a	70	µm	cell	strainer	followed	by	a	30	µm	one.	
2.13.3 Flow	cytometry	and	cell	cycle	analysis	Before	the	start	of	the	analysis	the	flow	cytometer	(BD	FACSCanto	II	using	FACSDiva	6.0	software),	BD™	Cytometer	Setup	and	Tracking	(CST)	beads	(Table	2.1),	which	are	designed	to	work	with	FACSDiva	software,	were	used	as	a	control	to	set	up	the	software	parameters	for	accurate	gating	and	analysis.	200-500	µL	of	cell	suspension	was	transferred	into	flow	cytometry	tubes	and	was	then	analysed	using	the	low	speed	setting	for	better	cell	resolution.	100-200	events	per	second	was	used	for	the	analysis,	when	the	cell	density	was	higher,	the	cell	suspension	was	diluted	with	PBS	with	5%	FCS.	The	blue	laser	was	used	to	excite	the	PI	stained	cells	at	488nm	and	the	fluorescence	was	detected	at	585±42	nm.		
Once	cell	fluorescence	was	detected,	the	laser	voltage	settings	were	adjusted	to	move	cells	into	the	gated	area.	Voltage	was	adjusted	per	run	dependent	upon	cell	type	and	moved	cells	on	the	side	scatter	(SSC-A)	(area)	(Y-axis)	versus	Forward	scatter	(FSC-A)	(area)	(X-axis)	graph	towards	a	45	degree.	Once	the	voltage	was	set,	the	cells	were	gated	using	a	B-585/42-A	(area)	(Y-axis)	and	
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B_585/42-W	(width)	(X-axis)	graph	to	exclude	cell	debris,	doublets	and	triplets	(see	Figure	2.4).	The	doublets	and	triplets	are	clumps	and	clusters	of	2	cells	or	more	that	appear	with	DNA	content	of	4N,	6N	or	more	while	the	cell	debris	are	dead	cells	that	have	been	fragmented	(Wersto	et	al.,	2001).	Following	successful	setup,	cells	were	processed	through	the	FACS	Canto	II	until	at	least	10,000	events	for	each	sample	lay	within	the	singlets	population	gate.	
	
Figure	2.4	Screenshot	of	the	set-up	used	for	cell	cycle	data	collection.	Dotplots	of	Area	vs.	Height	and	Area	vs.	Width	can	be	used	to	identify	doublets	so	that	they	can	be	excluded	by	gating	for	a	more	precise	cell	cycle	analysis.	Dotplots	of	SSC-A	vs.	FSC-A	(A)	and	B_585/42-A	vs.	B_585/42-W	(B)	were	used	to	gate	out	doublets	and	cellular	debris.	The	B-585/42-A	vs.	B_585/42-H	(C)	dotplot	can	also	be	used	to	gate	and	exclude	doublets	and	debris	from	analysis.	A	histogram	of	Count	vs.	B_585/42-A	(D)	shows	the	basic	cell	cycle	distribution	of	cells	from	the	P1	gate	(B).	P	refers	to	the	gate	generated	and	numbered	in	order	of	creating	the	gates	during	analysis.		 	
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2.13.4 FlowJo	cell	cycle	analysis	Analysis	of	cell	cycle	results	collected	on	the	BD	FACS	Canto	II	(Table	2.3)	was	performed	using	FlowJo	software	version	X	10.0.7r2.	Cells	were	entered	into	a	new	workspace	per	experiment	and	each	sample	was	gated	first	with	SSC-A	(Y-axis)	and	FSC-A	(X-axis)	to	exclude	cell	debris	(P1).	Then	cells	were	gated	with	FSC-H	(height)	(Y-axis)	and	FSC-A	(X-axis)	to	remove	the	doublets	(P2).	Live	population	of	cells	was	determined	using	a	histogram	with	cell	count	on	the	Y-axis	and	B_585/42-A	(area)	on	the	X-axis,	between	50K	to	150K	of	PI	intensity	(P3)(Figure	2.5).	The	cell	cycle	analysis	was	then	performed	on	the	live	sub-gated	population	using	the	univariate	model	of	FlowJo	with	the	coefficient	of	variation	(CV)	constrained	and	the	ratio	between	G0/G1	and	G2/M	peaks	set	to	be	1.95.		The	univariate	model	fits	the	2N	(G0/G1)	population	with	a	red	Gaussian	distribution,	the	4N	(G2/M)	population	with	a	green	Gaussian	distribution	and	the	S	population	with	a	blue	polynomial	(Figure	2.5).	This	univariate	analysis	uses	the	Watson	pragmatic	model	(Watson	et	al.,	1987).	In	this	model,	either	the	G0/G1	or	the	G2/M	peak	is	identifiable	as	the	model	assumes	that	the	data	within	these	two	peaks	are	normally	distributed.	
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Figure	2.5	Cell	cycle	analysis	using	FlowJo	software.		SSC-A	vs.	FSC-A	was	gated	to	exclude	cell	debris	(P1)	(A).	FSC-H	vs	FSC-A	was	gated	to	exclude	doublets	(P2)	(B).	Cell	count	vs	PI	intensity	was	used	to	gate	on	the	live	cell	population	(P3)	(C).	Cell	cycle	analysis	was	performed	on	the	live	singlet	populations	(D).		
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The	G0/G1	peak	is	approximated	by	the	model	as	a	Gaussian	distribution	with	the	initial	mean	guessed	by	finding	the	channel	with	the	most	cells	in	the	left	portion	of	the	data.	Then	the	standard	deviation	(SD)	is	found	by	finding	the	width	at	60%	of	the	height	of	the	peak.	To	improve	the	fit	of	the	curve	over	the	cell	population,	the	process	of	least	square	fitting	is	executed	over	a	-3	to	1	range	of	SD.	The	G2/M	mean	is	then	placed	at	1.75	times	the	intensity	of	the	G0/G1	mean.	The	SD	is	then	estimated	in	the	same	way	as	the	G0/G1	peak	(Watson	et	al.,	1987).	The	created	Gaussian	distribution	is	then	subtracted	from	the	data	to	leave	the	cells	that	are	considered	to	be	in	the	S	phase	(Figure	2.6).	The	S	curve	is	fitted	by	an	integrating	function,	which	modifies	the	edges	to	reflect	the	G0/G1	and	G2/M	edges,	and	then	multiplying	the	curves	value	channel	by	the	frequency	of	cells	in	the	channel.		
	
Figure	2.6	Cell	cycle	analysis	using	FlowJo.	The	univariate	model	generated	by	FlowJo	using	Watson	pragmatic	model	assumes	that	the	G0/G1	or	the	G2/M	peak	are	normally	distributed	(2N	(G0/G1)	population	with	a	red	Gaussian	distribution	and	the	4N	(G2/M)	population	with	a	blue	Gaussian	distribution)	(A)	The	created	Gaussian	distribution	is	then	subtracted	from	the	data	to	leave	the	cells	that	are	considered	to	be	in	the	S	phase	and	the	S	population	with	a	green	polynomial	(B).			
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2.14 esiRNA	transfection	of	Neuro2a	cells		
Neuro2a	cells	were	transfected	with	esiRNA	for	PRMT1,	PRMT8	or	KIF11	(see	Table	2.5)	as	a	positive	control	to	show	that	transfection	was	working	and	no	effect	on	methylation	was	seen	in	KIF	siRNA	treated	cells	showing	that	the	effects	were	specific	to	siRNA	treatment	with	PRMT1	or	8	.	The	transfection	was	performed	using	the	GenMute	transfection	kit	for	Neuro2a	and	the	manufacturer’s	protocol	was	followed.	Briefly,	Neuro2a	cells	were	seeded	onto	a	6-well	plate	approximately	24	hours	prior	to	transfection	at	a	density	of	2x105	cells/well.		
Before	transfecting,	the	culture	media,	complete	DMEM,	was	aspirated	and	replaced	with	1	mL	of	fresh	complete	media	(see	Table	2.2)	and	the	cells	were	incubated	at	37°C,	5%	CO2	for	30-60	minutes.	In	the	meantime,	for	each	well,	3	
µL	of	10	µM	stock	of	esiRNA	was	added	to	97	µL	of	the	GenMute	transfection	buffer,	mixed	well	by	pipetting	up	and	down,	then	3	µL	of	GenMute	transfection	reagent	was	added.	The	transfection	solution	was	then	incubated	at	room	temperature	for	no	more	than	30	minutes	and	then	added	to	the	cells	drop-wise	while	rocking	the	plate	back	and	forth.	The	transfection	media	was	only	left	on	the	cells	at	37°C,	5%	CO2	for	exactly	5	hours	and	was	then	replaced	with	3	mL	of	fresh	complete	DMEM.	KIF11	esiRNA	was	used	as	a	positive	control	for	the	transfection.	The	negative	control	consisted	of	the	transfection	reagent	containing	no	esiRNA.		 	
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Chapter	3 Protein	Arginine	Methylation	of	CRMPs	and	
Tubulin	
Based	on	the	previous	preliminary	Honours	results	(see	Section	1.11)	(Jwad,	2010),	where	CRMP-2	was	identified	to	be	asymmetrically	di-methylated	in	mouse	primary	cortical	neurons	(n=1).	The	first	aim	of	this	thesis	was	to	confirm	the	methylation	status	of	CRMP-2	(see	Section	1.12)	
3.1 CRMP-2	is	asymmetrically	di-methylated	on	arginine	
residues	
Anti-CRMP-2	antibody	(Table	2.4)	covalently	cross-linked	to	an	immunoprecipitation	(IP)	column	(see	Section	2.10)	was	used	to	immunoprecipitate	CRMP-2	from	mouse	primary	cortical	whole	cell	lysates.	Then	the	fractions	eluted	from	the	CRMP-2	column	were	immunoblotted	using	Asym24	antibody	(Table	2.4).	Also,	an	Asym24	IP	column	was	used,	and	the	eluted	fractions	were	then	immunoblotted	with	CRMP-2	antibody	(Figure	3.1).		A	single	band	at	an	approximate	molecular	weight	of	62	kDa	was	observed	in	both	eluted	fractions	from	immunoprecipitation	with	CRMP-2	and	Asym24,	confirming	the	preliminary	results	obtained	previously	during	Honours	(Jwad,	2010).	These	experiments	were	performed	only	once	during	Honours	and	therefore	both	IPs	and	Western	blots	were	performed	two	more	independent	times	with	representative	results	shown	in	Figure	3.1	A	and	B	and	the	repeat	displayed	in	the	Appendix	Figure	A.2	
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Figure	3.1	CRMP-2	is	asymmetrically	di-methylated.		Western	blot	with	Asym24	primary	antibody	of	mouse	primary	cortical	whole	cell	lysate	used	as	an	IP	input	and	the	elution	fraction	off	the	CRMP-2	IP	column	(A).	Western	blot	with	CRMP-2	primary	antibody	of	mouse	primary	cortical	whole	cell	lysate	(IP	input)	and	the	elution	fraction	off	the	Asym24	IP	column	(B).	Both	elution	fractions	in	A	and	B	show	a	single	band	at	approximately	62	kDa	(see	arrow).	
3.2 Mass	spectrometry	confirms	the	arginine	methylation	of	
CRMPs	and	tubulin	α	and	β 
To	detect	the	location	of	the	methylated	arginines	on	CRMP-2,	whole	cell	lysates	of	mouse	primary	cortical	neurons	as	well	as	from	Neuro2a	cells	were	separated	on	SDS-PAGE	and	stained	with	Brilliant	Blue	Colloidal	stain.	The	protein	bands	at	the	approximate	size	of	50-70	kDa	were	excised	and	digested	using	either	trypsin	or	chymotrypsin	(see	Section	2.11.2).	The	digested	peptides	were	then	analysed	using	QToF	mass	spectrometry	(see	Section	2.11).		
Figure	3.2	shows	an	example	of	the	cut	out	areas	from	an	SDS-PAGE	that	were	used	for	mass	spectrometry.	
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Figure	3.2	Excised	bands	on	an	SDS	polyacrylamide	gel	stained	with	
Brilliant	Blue	Colloidal	stain.	Mouse	primary	cortical	neuron	whole	cell	lysates	were	separated	on	a	4-20%	gradient	SDS-PAGE,	which	was	stained	with	Brilliant	Blue	Colloidal	stain	overnight.	The	bands	between	50-70	kDa	were	excised	and	processed	for	mass	spectrometry	analysis.	Interestingly,	the	mass	spectrometry	analysis	not	only	revealed	CRMP-2	with	methylated	arginines,	but	also	CRMP-1	and	CRMP-3,	as	well	as	both	tubulin	α	and	β	subunits.	Detected	methylated	peptides	are	listed	in	Table	3.1.	ATPase	synthase	α	and	beta	subunits	and	pyruvate	kinase	isoenzyme	M1/M2	β	are	the	only	three	other	proteins	with	methylated	arginines	consistently	identified	by	mass	spectrometry,	see	Appendix	Table	A.1.			
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Table	3.1	Summary	of	the	mass	spectrometry	analysis	of	CRMP	and	
tubulin	proteins	 	
Cell 
type Protein Peptide 
Methylation 
position 
Digestive 
enzyme 
% of 
methylated 
peptide 
detection * 
Cortex CRMP-1 
ILEMGITGPE
GHALSRPEEL
EAEAVFR 
267 Trypsin 50% 
Cortex CRMP-2 NIPRITSDR 11 Trypsin 50% 
Cortex CRMP-2 TIEAHSRMVIPGGIDVHTR 63 Trypsin 75% 
Cortex CRMP-2 
DRFQLSDSQI
YEVLSVIR 173 Trypsin 50% 
Cortex CRMP-3 
RAVTIAKQAN
CPLYITKVM 
SKGAADMVAQ
AKRRGVVVF 
238, 270 Chymotrypsin 50% 
Cortex Tubulin α 
AVFVDLEPTV
IDEVR 79 Trypsin 100% 
Cortex Tubulin α 
AVCMLSNTTA
IAEAWAR 390 Trypsin 50% 
Neuro2a Tubulin β 
VPRAVLVDLE
PGTMDSVRSG
PF 
62 Chymotrypsin 75% 
Cortex Tubulin β VREEYPDR 156 Trypsin 100% 
Cortex Tubulin β 
LTTPTYGDLN
HLVSATMSGV
TTCLR  
241 Trypsin 50% 
Cortex Tubulin β TSRGSQQY 276 Chymotrypsin 50% 
Cortex/
Neuro2a Tubulin β 
RALTVPELTQ
QMF 282 Chymotrypsin 100% 
Cortex Tubulin β ISEQFSAMFR 390 Trypsin 100% 	*		Trypsin	digestion	n=8,	chymotrypsin	digestion	n=4.	The	percentage	of	peptide	detection	is	calculated	as	the	number	of	times	the	peptide	was	detected	as	methylated	divided	by	the	total	number	of	independent	experiments	conducted	x100.	Mono-methylated	arginines	are	shown	as	bold	R	and	di-methylated	as	bold	and	underlined	R.	
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MS/MS	spectra	of	the	detected	methylated	peptides	were	generated	by	Mascot	Daemon	and	shown	in	Figure	3.3	to	Figure	3.13.	The	spectra	for	CRMP-1	and	CRMP-3	are	shown	in	the	Appendix	Figure	A.4	and	Figure	A.5	due	to	the	long	peptide.	In	the	MS/MS	spectrum	of	some	of	the	methylated	arginine	residues	such	as	R11	(Figure	3.3),	the	methylated	arginine	was	one	of	the	ions	generated	by	fragmenting	the	peptide	by	QToF	and	that	was	used	to	identify	the	peptide	by	Mascot	and	therefore	is	labelled	on	the	spectrum.	Other	peptides	are	predicted	to	be	methylated	by	Mascot	when	the	total	mass	of	the	peptide	had	a	shift	of	28	kDa	(di-methylated)	or	14	kDa	(mono-methylated)	although	the	ion	of	the	methylated	residue	was	not	one	of	the	ions	recovered	by	QToF.	The	ion	score	in	Mascot	for	an	MS/MS	match	is	based	on	the	calculated	probability,	P,	that	the	observed	match	between	the	experimental	data	and	the	database	sequence	is	a	random	event.	To	reduce	the	detection	of	random	peptides	by	Mascot,	the	ion	score	cut-off	was	increased	from	0	to	10	and	all	detected	peptides	with	ion	score	less	than	10	were	excluded.		 	
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Figure	3.3	Mass	spectrum	of	di-methylated	R11	in	CRMP-2.	MS/MS	spectrum	of	di-methylated	R11	identified	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	70	kDa	was	digested	with	trypsin.	Site-determining	ions	b*(4)	define	the	methylated	residue.	The	monoisotopic	mass	of	the	neutral	peptide	was	1098.6145	kDa	and	the	ion	score	was	10.		
		
Figure	3.4	Mass	spectrum	of	di-methylated	R63	in	CRMP-2.	MS/MS	spectrum	of	di-methylated	R63	identified	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	70	kDa	was	digested	with	trypsin.	The	monoisotopic	mass	of	the	neutral	peptide	was	2196.0875	kDa	and	ion	score	was	11.		
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Figure	3.5	Mass	spectrum	of	mono-methylated	R173	in	CRMP-2.	MS/MS	spectrum	of	mono-methylated	R173	identified	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	70	kDa	digested	with	trypsin.	The	monoisotopic	mass	of	the	neutral	peptide	was	2181.1430	kDa	and	the	ion	score	was	46.		
	
Figure	3.6	Mass	spectrum	of	di-methylated	R79	in	tubulin	α.		MS/MS	spectrum	of	di-methylated	R79	identified	in	tubulin	α	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~55	kDa	was	digested	with	trypsin.	Site-determining	ions	y1	define	the	methylated	residue.	The	monoisotopic	mass	of	the	neutral	peptide	was	1700.8985	kDa	and	ion	score	was	53.		
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Figure	3.7	Mass	spectrum	of	mono-methylated	R390	in	tubulin	α.	MS/MS	spectrum	of	mono-methylated	R390	identified	in	tubulin	α	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~55	kDa	was	digested	with	trypsin.	The	monoisotopic	mass	of	the	neutral	peptide	was	1893.9077	kDa	and	the	ion	score	was	35.		
	
Figure	3.8	Mass	spectrum	of	di-methylated	R62	in	tubulin	β.	MS/MS	spectrum	of	di-methylated	R62	identified	in	tubulin	β	from	Neuro2a	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~55	kDa	digested	with	chymotrypsin.	The	monoisotopic	mass	of	the	neutral	peptide	was	2355.2257	kDa	and	the	ion	score	was	46.		
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Figure	3.9	Mass	spectrum	of	di-methylated	R156	in	tubulin	β.	MS/MS	spectrum	of	di-methylated	R156	identified	in	tubulin	β	III	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~55	kDa	was	digested	with	trypsin.	Site-determining	ions	b2	and	b*	define	the	methylated	residue.	Monoisotopic	mass	of	neutral	peptide	is	1076.5251	kDa	and	ion	score	is	32.		
	
Figure	3.10	Mass	spectrum	of	mono-methylated	R241	in	tubulin	β.		MS/MS	spectrum	of	mono-methylated	R241	identified	in	tubulin	β	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~50kDa	was	digested	with	trypsin.	Site-determining	ions	y*(1)++	define	the	methylated	residue.	The	monoisotopic	mass	of	the	neutral	peptide	was	2707.3310	kDa	and	the	ion	score	was	56.		
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Figure	3.11	Mass	spectrum	of	di-methylated	R276	in	tubulin	β.	MS/MS	spectrum	of	di-methylated	R276	identified	in	tubulin	β	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~55	kDa	was	digested	with	chymotrypsin.	Site-determining	ions	b3	define	the	methylated	residue.	The	monoisotopic	mass	of	the	neutral	peptide	was	953.46	kDa	and	the	ion	score	was	22.		
	
Figure	3.12	Mass	spectrum	of	di-methylated	R282	in	tubulin	β.	MS/MS	spectrum	of	di-methylated	R282	identified	in	tubulin	β	from	Neuro2a	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~50	kDa	digested	with	chymotrypsin.	Site-determining	ions	b1++	define	the	di-methylated	residue.	The	monoisotopic	mass	of	the	neutral	peptide	was	1546.8177	kDa	and	the	ion	score	was	20.			
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Figure	3.13	Mass	spectrum	of	mono-methylated	R390	in	tubulin	β.	MS/MS	spectrum	of	mono-methylated	R390	identified	in	tubulin	β	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	~55	kDa	was	digested	with	trypsin.	Site-determining	ions	y*(1)++	define	the	methylated	residue.	The	monoisotopic	mass	of	the	neutral	peptide	was	1244.5860	kDa	and	the	ion	score	was	26.	
3.3 Confirming	tubulin	asymmetric	di-methylation	by	
immunoprecipitation	and	Western	blot	
Tubulin	was	not	the	target	protein	in	the	initial	mass	spectrometry	analysis.	However,	it	was	not	surprising	that	it	was	detected	due	to	the	similar	molecular	weight	to	CRMP-2.	The	excised	SDS-PAGE	slices	covered	a	molecular	weight	range	between	50-70	kDa	(Figure	3.2)	which	makes	tubulin	detection	highly	likely	given	that	it	is	an	abundantly	expressed	protein.		
After	detecting	the	methylated	arginine	residues	in	tubulin	subunits	α	and	β	using	mass	spectrometry,	immunoprecipitation	and	Western	blotting	with	Asym24	was	performed	to	determine	whether	tubulin	is	asymmetrically	di-methylated.	
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Mouse	primary	cortical	neuronal	whole	cell	lysates	were	used	for	IP	using	cross-linked	IP	column	with	anti-tubulin	α1A	chain	or	Asym24	separately.	To	visualise	tubulin	α	asymmetric	di-methylation	by	Western	blot,	the	elutions	from	both	columns	were	separated	using	SDS-PAGE	and	then	transferred	onto	PVDF	membranes.	The	membranes	containing	elutions	from	the	Asym24	IP	column	were	incubated	with	anti-tubulin	α	antibody	while	the	ones	containing	elution	from	the	tubulin	α	IP	column	were	incubated	with	Asym24	antibody.	Figure	3.14	shows	representative	Western	blots	with	a	single	band	in	the	eluted	fractions	of	a	molecular	weight	of	approximately	55	kDa,	which	corresponds	to	the	molecular	weight	of	the	tubulin	α	subunit.	Repeat	Western	blots	are	shown	in	Appendix	(Figure	A.3	A).	
	
Figure	3.14	Tubulin	α	is	asymmetrically	di-methylated.	Western	blot	of	mouse	primary	cortical	neuronal	whole	cell	lysates	input	and	eluted	fractions	from	tubulin	α	antibody	IP	column	probed	with	Asym24	antibody	(A).	Western	blot	of	Asym24	IP	column	eluted	fraction	probed	with	tubulin	α	antibody	(B).	Tubulin	α	is	detected	at	55	kDa	(see	arrow).		
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The	same	procedure	was	followed	to	confirm	asymmetric	arginine	methylation	in	tubulin	β	using	a	cross-linked	IP	column	with	tubulin	βIII	antibody	to	immunoprecipitated	tubulin	β	proteins.	The	same	antibody	was	then	used	to	detect	the	presence	of	tubulin	in	the	IP	elutions	from	the	Asym24	IP	column.	In	both	immunoblots,	a	band	of	~55	kDa	was	visible	corresponding	to	the	molecular	weight	of	tubulin	β	(Figure	3.15).	Repeats	Western	blots	from	independent	repeats	are	shown	in	the	Appendix	(Figure	A.3	B).	
	
Figure	3.15	Tubulin	β	is	asymmetrically	di-methylated.	Western	blot	of	mouse	primary	cortical	neuronal	whole	cell	lysates	input	and	eluted	fractions	from	tubulin	β	antibody	IP	column	probed	with	Asym24	antibody	(A).	Western	blot	of	Asym24	IP	column	eluted	fraction	probed	with	tubulin	β	antibody	(B).	Tubulin	β	is	detected	at	55	kDa	(see	arrows).	
3.4 Discussion 
3.4.1 Confidence	of	arginine	methylation	detection	The	combined	results	from	Western	blot	,	IP	and	mass	spectrometry	indicate	that	CRMP-2	and	both	tubulin	α	and	β	are	methylated	on	multiple	arginine	
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residues.	Although	only	CRMP-2	was	targeted	initially	in	this	study	based	on	preliminary	results	from	the	Honours	work	(Jwad,	2010),	the	mass	spectrometry	analysis	also	detected	novel	methylated	arginine	residues	on	CRMP-1,	CRMP-3	as	well	as	on	both	tubulin	α	and	β	(see	Table	3.1).	Arginine	methylation	of	CRMPs	and	tubulin	has	been	recently	reported	(Guo	et	al.,	2014).	In	the	study	by	Guo	et	al.	2014,	the	identification	of	arginine	methylation	was	achieved	as	part	of	a	large	scale	experiment	where	entire	mouse	brains	from	adult	mice	or	embryos	were	homogenised	and	then	immunoprecipitated	with	antibodies	specific	to	methylated	arginines	and	lysine	that	are	not	commercially	available.	The	immunoprecipitated	fractions	were	digested	with	trypsin	and	used	to	identify	the	methylated	residues	by	mass	spectrometry		using	Orbitrap	Elite	or	a	Q	Exactive	mass	spectrometer	(Guo	et	al.,	2014).	Interestingly,	CRMP-2	was	only	detected	to	be	methylated	on	two	residues	(R552	and	R565)	and	with	a	low	frequency.		R552	was	detected	to	be	mono-methylated	once,	while	they	show	R565	to	be	once	mono-methylated	and	once	di-methylated	out	of	8	experiments	in	adult	mouse	brain	only	(Guo	et	al.,	2014).	Other	members	of	the	CRMP	family	of	proteins	were	not	detected	to	contain	methylated	arginine	residues	in	the	study	by	Guo	et	al	2014.	Three	different	arginines	in	tubulin	β	were	detected	to	be	di-methylated	(R162,	R318	and	R320)	with	each	of	them	again	only	detected	once	out	of	8	experiments	in	adult	mouse	brain	(Guo	et	al.,	2014).	In	this	thesis,	the	methylation	R565	and	R552	in	CRMP-2	was	not	detected,	however,	in	tubulin	β	R318	was	confirmed	to	be	di-methylated	and	was	detected	3	times	out	of	8	independent	experiments	(see	Table	3.1).	The	proteins	that	were	detected	to	be	methylated	on	arginine	residues,	in	this	thesis	were	obtained	from	primary	mouse	embryonic	cortical	neurons	(not	whole	
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brain)	as	well	as	from	the	mouse	neuroblastoma	cell	line,	Neuro2a.	Adult	brains	were	not	tested	in	this	thesis	and	therefore	the	residues	that	were	only	identified	in	adult	mouse	brain	by	Guo	et	al	(2014)	are	possibly	subjected	to	methylation	postnatally,	or	during	mouse	adulthood.	On	the	other	hand,	Guo	and	colleagues	(2014)	did	not	detect	any	of	the	methylated	residues	that	were	identified	in	this	thesis.	This	could	be	due	to	multiple	factors	including	variable	peptide	recovery	percentage	by	the	mass	spectrometer	or	that	those	proteins	were	not	immunoprecipitated	successfully	by	the	antibodies	used	in	their	study	which	are	different	to	those	used	in	this	thesis.	Based	on	a	study	that	questioned	the	validity	of	large	scale	mass	spectrometry	identification	of	methylation	(Hart-Smith	et	al.,	2016),	it	is	possible	that	some	of	the	methylated	arginine	residues	reported	by	Guo	et	al	(2014)	were	indeed	false	positives.	However,	the	arginine	residues	identified	in	this	thesis	are	not	false	positives	as	several	steps	were	taken	to	confirm	the	results.	Firstly,	in	this	thesis,	the	identification	was	not	on	a	large	scale	basis	but	rather	the	proteins	from	mouse	embryonic	cortical	neurons	or	Neuro2a	whole	cell	lysates	were	separated	on	SDS-PAGE	and	only	a	small	area	between	70-50	kDa	was	excised	and	used	for	mass	spectrometry	analysis.	Secondly,	the	trypsin	digestion	was	repeated	eight	independent	times	while	chymotrypsin	digestion	was	repeated	four	times.	Each	methylated	peptide	was	detected	by	mass	spectrometry	at	least	twice	(see	Table	3.1).	Furthermore,	the	spectrometer	used	here	(Xevo	QToF,	Waters)	is	different	from	the	ones	used	in	the	study	that	suggested	the	possibility	of	false	positives	(Hart-Smith	et	al.,	2016).	
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Lastly,	it	was	suggested	by	Hart-Smith	et	al.	(2016)	that	the	method	of	peptide	preparation	could	result	in	identifying	false	positive	arginine	methylation	due	to	the	use	of	alcohol	such	as	methanol	and	isopropanol	which	could	lead	to	ethylation	and/or	isopropylation	of	glutamic	acid	and	aspartic	acid.	These	modifications	of	aspartic	acid	and	glutamic	acid	could	result	in	a	mass	similar	to	that	of	methylated	arginines	and	lysine	residues.	The	use	of	these	solvents	was	eliminated	in	the	preparation	of	peptides	in	this	thesis	and	all	of	the	reported	arginines	were	still	detected	to	be	methylated.	As	a	final	confirmation,	that	the	method	used	to	prepare	the	peptides	for	mass	spectrometry	analysis	in	this	thesis	was	not	producing	false	positives,	a	bacterially	expressed	(hence	non-methylated)	bovine	tubulin	was	purchased	(Sigma)	(see	Table	2.1)	and	prepared	with	colloidal	staining	as	well	as	without	staining	and	analysed	by	mass	spectrometry.	None	of	the	previously	identified	arginines	were	detected	to	be	methylated	in	these	preparations.	Interestingly,	R162	was	identified	as	potentially	methylated	as	part	of	a	large	peptide.	However,	R162	was	not	ever	identified	in	this	thesis	as	methylated	in	mouse	embryonic	neurons	nor	in	Neuro2a	cells	to	be	methylated	and	most	likely	represent	a	false	positive.	Interestingly,	R162	was	one	of	the	residues	identified	by	Guo	et	al.	(2014).	Furthermore,	when	performing	the	peptide	search	on	Mascot	Daemon,	the	ion	score	was	increased	from	0	to	10	which	increases	the	probability	of	the	detected	peptides	and	further	reduces	the	likelihood	of	the	false	detection	of	a	methylated	arginine	residue.	Taken	together	the	method	used	in	this	thesis	to	prepare	peptides	for	mass	spectrometry	and	the	mass	spectrometry	analysis	performed	allow	the	identification	of	the	reported	methylated	arginine	residues	with	high	confidence.				
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3.4.2 The	efficiency	of	the	digestion	of	methylated	peptides			For	this	thesis,	trypsin	or	chymotrypsin	were	used	for	digestion	of	the	proteins	for	mass	spectrometry	see	Table	3.1	Earlier	studies	have	indicated	that	methylation	of	arginine	residues	prevents	cleavage	by	trypsin	(Martin	et	al.,	2010).	This	is	not	however,	supported	by	our	observations.	Our	results	are	in	agreement	with	reports	by	others	(Boisvert	et	al.,	2003,	Singhroy	et	al.,	2013)	where	trypsin	cleavage	was	detected	on	methylated	arginine	residues	albeit	with	lower	kinetics.	Similarly,	methylated	arginine	residues	have	successfully	been	identified	in	PRMT6	automethylation	after	in-gel	trypsin	cleavage	(Singhroy	et	al.,	2013)	and	recently	from	mouse	brain,	embryonic	brain	and	in	HCT116	cells	after	trypsin	cleavage	(Guo	et	al.,	2014).	Nevertheless,	it	is	possible	that	due	to	inefficient	cleavage,	some	arginine	methylation	sites	were	not	identified	and	hence	most	likely	the	total	number	of	methylated	arginines	in	proteins	is	underestimated	when	using	trypsin	as	the	only	digestive	enzyme.	In	support	of	this,	some	arginine	residues	were	only	detected	after	chymotrypsin	digestion	in	this	thesis	but	not	after	trypsin	digestion	(see	Table	3.1).	
3.4.3 The	significance	of	the	methylated	arginine	residues	in	relation	to	
the	protein	structure	and	function	
3.4.3.1 CRMP	Methylated	arginine	residues	were	detected	in	three	members	of	the	CRMP	family;	CRMP-1,	2	and	3	(Table	3.1).	
CRMP1,	2	and	3	are	members	of	the	CRMP	family	of	5	proteins	that	are	expressed	mainly	in	the	nervous	system	(Wang	and	Strittmatter,	1996).	CRMPs	are	one	of	the	first	group	of	proteins	expressed	in	developing	nervous	systems	
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(Wang	and	Strittmatter,	1996,	Doetsch	and	Hen,	2005).	CRMPs	are	mostly	localized	in	the	lamellipodia	and	filopodia	of	the	axonal	growth	cone	which	suggests	an	involvement	in	axonal	guidance	and	elongation	(Minturn	et	al.,	1995).	
CRMP1-3	share	approximately	75%	sequence	homology	and	they	are	reported	to	form	functional	hetero-tetramers	(Wang	and	Strittmatter,	1997).		
Sequence	alignments	of	CRMP1,2	and	3	with	mass	spectrometry	coverage	of	the	peptides	containing	methylated	arginine	residues	is	shown	Figure	3.16.		 	
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CRMP-1    1MSHQGKKSIP HITSDRLLIR GGRIINDDQS FYADVYLEDG LIKQIGENLI50  
CRMP-2     MSYQGKKNIP RITSDRLLIK GGKIVNDDQS FYADIYMEDG LIKQIGENLI  
CRMP-3     MSFQGKKSIP RITSDRLLIK GGKIVNDDQS FHADLYVEDG LIKQIGENLI  
 
CRMP-1   51VPGGVKTIEA NGRMVIPGGI DVNTYLQKPS QGMTSADDFF QGTKAALAGG100  
CRMP-2     VPGGVKTIEA HSRMVIPGGI DVHTRFQMPD QGMTSADDFF QGTKAALAGG  
CRMP-3     VPGGIKTIDA HGLMVLPGGV DVHTRLQMPV MGMTPADDFC QGTKAALAGG  
 
CRMP-1  101TTMIIDHVVP EPGSSLLTSF EKWHEAADTK SCCDYSLHVD ITSWYDGVRE150  
CRMP-2     TTMIIDHVVP EPGTSLLAAF DQWREWADSK SCCDYSLHVD ITEWHKGIQE  
CRMP-3     TTMILDHVFP DAGVSLLAAY EQWRERADSA ACCDYSLHVD IPRWHESTKE  
 
CRMP-1  151ELEVLVQDKG VNSFQVYMAY KDLYQMSDSQ LYEAFTFLKG LGAVILVHAE200  
CRMP-2     EMEALVKDHG VNSFLVYMAF KDRFQLTDSQ IYEVLSVIRD IGAIAQVHAE  
CRMP-3     ELEALVRDKG VNSFLVFMAY KDRCQCTDGQ IYEIFSLIRD LGAVAQVHAE  
 
CRMP-1  200NGDLIAQEQK RILEMGITGP EGHALSRPEE LEAEAVFRAI AIAGRINCPV250  
CRMP-2     NGDIIAEEQQ RILDLGITGP EGHVLSRPEE VEAEAVNRSI TIANQTNCPL  
CRMP-3     NGDIVEEEQK RLLEQGITGP EGHVLSHPEE VEAEAVYRAV TIAKQANCPL  
 
CRMP-1  251YITKVMSKSA ADIIALARKK GPLVFGEPIA ASLGTDGTHY WSKNWAKAAA300  
CRMP-2     YVTKVMSKSA AEVIAQARKK GTVVYGEPIT ASLGTDGSHY WSKNWAKAAA  
CRMP-3     YVTKVMSKGA ADMVAQAKRR GVVVFGEPIT ASLGTDGSHY WSKNWAKAAA  
 
CRMP-1  301FVTSPPLSPD PTTPDYLTSL LACGDLQVTG SGHCPYSTAQ KAVGKDNFTL350  
CRMP-2     FVTSPPLSPD PTTPDFLNSL LSCGDLQVTG SAHCTFNTAQ KAVGKDNFTL  
CRMP-3     FVTSPPINPD PTTADHLTSL LSSGDLQVTG SAHCTFTTAQ KAVGKDNFTL  
 
CRMP-1  351IPEGVNGIEE RMTVVWDKAV ATGKMDENQF VAVTSTNAAK IFNLYPRKGR400  
CRMP-2     IPEGTNGTEE RMSVIWDKAV VTGKMDENQF VAVTSTNAAK VFNLYPRKGR  
CRMP-3     IPEGVNGIEE RMSVVWEKCV ASGKMDENEF VAVTSTNAAK IFNFYPRKGR  
 
CRMP-1  401IAVGSDADVV IWDPDKMKTI TAKSHKSTVE YNIFEGMECH GSPLVVISQG450  
CRMP-2     ISVGSDADLV IWDPDSVKTI SAKTHNSALE YNIFEGMECR GSPLVVISQG  
CRMP-3     VAVGSDADLV IWNPRATKVF SAKSHNLNVE YNIFEGVECR GVPTVVISQG  
 
CRMP-1  451KIVFEDGNIS VSKGMGRFIP RKPFPEHLYQ RVRIRSKVFG LHSVSRGMYD500  
CRMP-2     KIVLEDGTLH VTEGSGRYIP RKPFPDFVYK RIKARSRLAE LRGVPRGLYD  
CRMP-3     RVVLEDGNLL VTPGAGRFIP RKTFPDFVYK RIKARNRLAE IHGVPRGLYD  
 
CRMP-1  501GPVYEVPATP KHAAPAPSAK SSPSKHQPPP IRNLHQSNFS LSGAQIDDNN550  
CRMP-2     GPVCEVSVTP KTVTPASSAK TSPAKQQAPP VRNLHQSGFS LSGAQIDDNI  
CRMP-3     GPVHEVMLPA KPGSGTQARA SCSGKISVPP VRNLHQSGFS LSGSQADDHI  
 
CRMP-1  551PRRTGHRIVA PPGGRSNITS LG 
CRMP-2     PRRTTQRIVA PPGGRANITS LG 
CRMP-3     ARRTAQKIMA PPGGRSNITS LS 	
Figure	3.16	Sequence	alignment	of	mouse	CRMP1,	2	and	3	that	are	
detected	to	carry	methylated	arginines	by	mass	spectrometry.	The	grey	highlighted	is	the	covered	sequence	of	the	protein	by	mass	spectrometry.	Methylated	arginines	are	shown	in	bold	font	and	underlined	R	are	the	di-methylated	arginines.	The	protein	accession	numbers	are	CRMP-1:	P97427,	CRMP-2:	NP_034085,	CRMP-3:	035098.	In	CRMP-3,	R238,	which	was	detected	to	be	di-methylated,	is	situated	within	helix	H7	of	the	predicted	structure	of	CRMP-3,	while	R270	is	within	helix	H8	(Deo	et	al.,	2004).		Helix	H7	and	helix	H8	are	part	of	the	interfaces	of	CRMP-3	
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molecules	when	forming	a	homotetramer	or	a	heterotetramer	with	other	members	of	the	CRMP	family	(Deo	et	al.,	2004,	Wang	and	Strittmatter,	1997).	The	location	of	both	arginines	suggests	that	their	methylation	could	be	playing	a	role	in	regulating	the	formation	of	CRMP-3	functional	tetramers.	
The	mono-methylated	R226	of	CRMP-1	is	located	in	helix	H6	of	the	tertiary	structure	that	is	between	helix	H5	and	helix	H7.	H5	and	H7	are	part	of	the	sequence	of	interface	2	of	two	CRMP-1	monomers	within	a	tetramer	(Deo	et	al.,	2004).	Even	though	H6	is	not	a	direct	part	of	interface	2,	the	position	of	R226	implies	that	its	methylation	could	cause	a	conformational	change	that	may	affect	the	monomer/monomer	interaction.	The	location	of	CRMP-1	R226	in	relation	to	H6,	H7	and	the	monomer/monomer	interface	is	shown	in	Figure	3.17.	
	
Figure	3.17	3D	structure	of	CRMP-1	in	a	dimer.	Highlighted	in	yellow	is	the	interface	to	form	CRMP-1	tetramers	with	the	next	dimer.	R226	is	located	in	the	centre	of	the	interface	cavity.	Helix	6,	7	(H6,	H7)	as	well	as	R266	(detected	to	be	mono-methylated)	are	identified	by	black	arrows.	Structure	obtained	from	MMDB	ID	number:	112379.		
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R173	of	CRMP-2,	on	the	other	hand	is	part	of	the	C-terminus	of	the	protein.	R173	has	been	identified	previously	to	be	one	of	the	residues	that	line	the	TIM	barrel	structure	of	CRMP-2	(Wang	and	Strittmatter,	1997).	The	TIM	(triosephosphate	isomerase)	barrel	makes	up	the	largest	part	of	the	CRMP-2	structure	and	it	corresponds	to	the	active	site	of	dihydropyrimidinase	(DHP)	in	the	liver	(Wang	and	Strittmatter,	1997).	However,	the	residues	that	are	responsible	for	the	enzymatic	activity	in	DHP	are	not	conserved	(Wang	and	Strittmatter,	1997).	Even	though	CRMP-2	has	been	shown	to	have	no	DHP	enzymatic	activity,	the	pocket	represented	by	the	TIM	barrel	is	thought	to	play	a	role	in	binding	to	smaller	molecules	(Stenmark	et	al.,	2007).	When	highlighting	the	position	of	the	methylated	R173	in	the	3D	structure	of	a	CRMP-2	tetramer	(Figure	3.18),	it	shows	that	this	residue	is	facing	the	outside	of	the	tetramer,	which	further	suggests	its	possible	role	in	binding	to	other	molecules.	
	
Figure	3.18	3D	structure	of	CRMP-2.		Side	view	of	a	CRMP-2	dimer	(A).	Full	structure	of	a	CRMP-2	functional	tetramer	(B).	R173	is	highlighted	in	cyan	and	indicated	by	the	black	arrows.	R173	is	located	towards	the	outside	of	the	CRMP-2	dimer	and	tetramer.	Structure	obtained	from	MMDB	ID	number:	66269.		
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Arginine	11	and	63	in	CRMP-2,	which	both	were	identified	as	di-methylated,	are	located	within	the	small	N-terminal	domain.	This	position	has	not	yet	been	shown	to	have	any	significant	functional	role	in	CRMP-2	tetramer	formation	or	binding	to	other	proteins.	However,	given	that	methylation	is	an	energy	costly	biological	modification	(Atkinson,	1977),	it	remains	to	be	determined	what	role	the	methylation	of	R11	and	R63	plays	in	CRMP-2	function.		
3.4.3.2 	Tubulin	α	and	β	
Tubulin	subunits	α	and	β	are	both	reported	to	be	heavily	post-translationally	modified	(Song	and	Brady,	2015).		
In	this	thesis,	novel	methylated	arginine	residues	were	detected	on	both	tubulin	α	and	β.	In	tubulin	α,	R79	and	R390	were	observed	in	all	the	detected	tubulin	α	isotypes	which	suggests	that	this	modification	is	not	isotype	specific	and	may	be	required	as	part	of	the	tubulin	heterodimer	structure.	In	tubulin	β,	six	novel	arginine	residues	were	identified	to	be	methylated	for	the	first	time	(R62,	R156,	R241,	R276,	R282	and	R390).	R62	was	only	observed	in	the	tubulin	β4	chain,	but	not	in	any	other	isotypes.	Similarly,	R156	was	only	observed	in	the	tubulin	
β3	chain	even	though	the	same	peptide	was	covered	in	other	detected	tubulin	β	proteins.	In	contrary,	R276	was	seen	on	tubulin	β6	and	that	was	the	only	tubulin	β	isotype	to	have	that	region	of	the	sequence	covered	by	mass	spectrometry	in	all	the	experiments	which	makes	it	possible	that	it	is	methylated	in	other	tubulin	β	chains.	Further,	R241	was	shown	to	be	methylated	in	the	tubulin	β2	and	4	chains	however,	the	peptide	which	contains	R241		was	not	covered	in	the	other	detected	tubulin	β	isotypes.	R282	and	R390,	
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however,	were	found	to	be	methylated	in	every	tubulin	β	isotype	with	that	region	of	the	sequence	covered	in	all	detected	tubulin	β	isotypes.	This	selectiveness	of	methylation	site	to	specific	tubulin	isotypes	is	not	surprising	as	it	has	been	previously	reported	that	selective	PTMs	contribute	to	what	is	referred	to	as	the	microtubule	code	(Verhey	and	Gaertig,	2007).	The	microtubule	code	explains	the	specificity	of		PTMs	to	subgroups	of	microtubules	which	forms	a	code	that	can	be	detected	by	MAPs	in	the	cells	(Verhey	and	Gaertig,	2007).		
Figure	3.19	shows	the	sequence	alignment	of	all	the	detected	tubulin	isotypes	with	their	methylated	residues	and	the	coverage	of	the	detected	peptides	for	the	mass	spectrometry	experiments.	 	
	 103	
Tub β4A    1 MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DL—-QLERIN50  
Tub β2B     MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPTGSYHGDS DL—-QLERIN  
Tub β3      MREIVHIQAG QCGNQIGAKF WEVISDEHGI DPSGNYVGDS DL--QLERIS  
Tub β6      MREIVHIQAG QCGNQIGTKF WEVISDEHGI DQAGGYVGDS AL--QLERIS 
Tub α1A     MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK TIGGGDDSFN  
Tub α1B     MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK TIGGGDDSFN  
Tub α1c     MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK TIGGGDDSFN   
Tub α3      MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK TIGGGDDSFN  
Tub α8      MRECISVHVG QAGVQIGNAC WELFCLEHGI QADGTFGTQA SKINDDDSFT 
 
Tub β4A    51VYYNEATGGN YVPRAVLVDL EPGTMDSVRS GPFGQIFRPD NFVFGQSGAG100  
Tub β2B     VYYNEATGNK YVPRAILVDL EPGTMDSVRS GPFGQIFRPD NFVFGQSGAG  
Tub β3      VYYNEASSHK YVPRAILVDL EPGTMDSVRS GAFGHLFRPD NFIFGQSGAG 
Tub β6      VYYNESSSKK YVPRAALVDL EPGTMDSVRS GPFGQLFRPD NFIFGQTGAG 
Tub α1A     TFFSETGAGK HVPRAVFVDL EPTVIDEVRT GTYRQLFHPE QLITGKEDAA  
Tub α1B     TFFSETGAGK HVPRAVFVDL EPTVIDEVRT GTYRQLFHPE QLITGKEDAA  
Tub α1c     TFFSETGAGK HVPRAVFVDL EPTVIDEVRT GTYRQLFHPE QLITGKEDAA   
Tub α3      TFFSETGAGK HVPRAVFVDL EPTVVDEVRT GTYRQLFHPE QLITGKEDAA  
Tub α8      TFFSETGNGK HVPRAVMVDL EPTVVDEVRA GTYRQLFHPE QLITGKEDAA 
 
Tub β4A   101NNWAKGHYTE GAELVDAVLD VVRKEAESCD CLQGFQLTHS LGGGTGSGMG150  
Tub β2B       NNWAKGHYTE GAELVDSVLD VVRKESESCD CLQGFQLTHS LGGGTGSGMG  
Tub β3      NNWAKGHYTE GAELVDSVLD VVRKECENCD CLQGFQLTHS LGGGTGSGMG 
Tub β6      NNWAKGHYTE GAELVDSVLD VVRKECENCD CLQGFQLTHS LGGGTGSGMG 
Tub α1A     NNYARGHYTI GKEIIDLVLD RIRKLADQCT GLQGFLVFHS FGGGTGSGFT  
Tub α1B     NNYARGHYTI GKEIIDLVLD RIRKLADQCT GLQGFLVFHS FGGGTGSGFT  
Tub α1c     NNYARGHYTI GKEIIDLVLD RIRKLADQCT GLQGFLVFHS FGGGTGSGFT  
Tub α3      NNYARGHYTI GKEIVDLVLD RIRKLADLCT GLQGFLIFHS FGGGTGSGFA  
Tub α8      NNYARGHYTV GKESIDLVLD RIRKLTDACS GLQGFLIFHS FGGGTGSGFT  
 
Tub β4A   151TLLISKIREE FPDRIMNTFS VVPSPKVSDT VVEPYNATLS VHQLVENTDE200  
Tub β2B      TLLISKIREE YPDRIMNTFS VMPSPKVSDT VVEPYNATLS VHQLVENTDE  
Tub β3      TLLISKVREE FPDRIMNTFS VVPSPKVSDT VVEPYNATLS IHQLVENTDE 
Tub β6      TLLISKIREE FPDRIMNTFS VMPSPKVSDT VVEPYNATLS VHQLVENTDE 
Tub α1A     SLLMERLSVD YGKKSKLEFS IYPAPQVSTA VVEPYNSILT THTTLEHSDC  
Tub α1B     SLLMERLSVD YGKKSKLEFS IYPAPQVSTA VVEPYNSILT THTTLEHSDC 
Tub α1c     SLLMERLSVD YGKKSKLEFS IYPAPQVSTA VVEPYNSILT THTTLEHSDC 
Tub α3      SLLMERLSVD YGKKSKLEFA IYPAPQVSTA VVEPYNSILT THTTLEHSDC 
Tub α8      SLLMERLSLD YGKKSKLEFA IYPAPQVSTA VVEPYNSILT THTTLEHSDC 
 
Tub β4A   201TYCIDNEALY DICFRTLKLT TPTYGDLNHL VSATMSGVTT CLRFPGQLNA250  
Tub β2B      TYCIDNEALY DICFRTLKLT TPTYGDLNHL VSATMSGVTT CLRFPGQLNA  
Tub β3      TYCIDNEALY DICFRTLKLT APTYGDLNHL VSATMSGVTT SLRFPGQLNA 
Tub β6      TYCIDNEALY DICFRTLKLT TPTYGDLNHL VSATMSGVTT SLRFPGQLNA 
Tub α1A     AFMVDNEAIY DICRRNLDIE RPTYTNLNRL IGQIVSSITA SLRFDGALNV  
Tub α1B     AFMVDNEAIY DICRRNLDIE RPTYTNLNRL ISQIVSSITA SLRFDGALNV  
Tub α1c     AFMVDNEAIY DICRRNLDIE RPTYTNLNRL ISQIVSSITA SLRFDGALNV  
Tub α3      AFMVDNEAIY DICRRNLDIE RPTYTNLNRL IGQIVSSITA SLRFDGALNV  
Tub α8      AFMVDNEAIY DICRRNLDIE RPTYTNLNRL ISQIVSSITA SLRFDGALNV 
 
Tub β4A   251DLRKLAVNMV PFPRLHFFMP GFAPLTSRGS QQYRALTVPE LTQQMFDAKN300  
Tub β2B     DLRKLAVNMV PFPRLHFFMP GFAPLTSRGS QQYRALTVPE LTQQMFDSKN  
Tub β3      DLRKLAVNMV PFPRLHFFMP GFAPLTSRGS QQYRALTVPE LTQQMFDAKN 
Tub β6      DLRKLAVNMV PFPRLHFFMP GFAPLTSRGS QQYRALTVPE LTQQMFDAKN 
Tub α1A     DLTEFQTNLV PYPRIHFPLA TYAPVISAEK AYHEQLSVAE ITNACFEPAN  
Tub α1B     DLTEFQTNLV PYPRIHFPLA TYAPVISAEK AYHEQLSVAE ITNACFEPAN  
Tub α1c     DLTEFQTNLV PYPRIHFPLA TYAPVISAEK AYHEQLTVAE ITNACFEPAN  
Tub α3      DLTEFQTNLV PYPRIHFPLA TYAPVISAEK AYHEQLSVAE ITNACFEPAN  
Tub α8      DLTEFQTNLV PYPRIHFPLV TYAPIISAEK AYHEQLSVAE ITSSCFEPNS  
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Tub β4A   301MMAACDPRHG RYLTVAAVFR GRMSMKEVDE QMLSVQSKNS SYFVEWIPNN350  
Tub β2B     MMAACDPRHG RYLTVAAIFR GRMSMKEVDE QMLNVQNKNS SYFVEWIPNN  
Tub β3      MMAACDPRHG RYLTVAAVFR GRMSMKEVDE QMLAIQSKNS SYFVEWIPNN 
Tub β6      MMAACDPRHG RYLTVAAVFR GRMSMKEVDE QMLAIQNKNS SYFVEWIPNN 
Tub α1A     QMVKCDPRHG KYMACCLLYR GDVVPKDVNA AIATIKTKRT IQFVDWCPTG  
Tub α1B     QMVKCDPRHG KYMACCLLYR GDVVPKDVNA AIATIKTKRS IQFVDWCPTG  
Tub α1c     QMVKCDPRHG KYMACCLLYR GDVVPKDVNA AIATIKTKRT IQFVDWCPTG  
Tub α3      QMVKCDPRHG KYMACCMLYR GDVVPKDVNA AIATIKTKRT IQFVDWCPTG   
Tub α8      QMVKCDPRHG KYMACCMLYR GDVVPKDVNV AIAAIKTKRT IQFVDWCPTG  
 
Tub β4A   351VKTAVCDIPP RGL------- -KMAATFIGN STAIQELFKR ISEQFTAMFR400  
Tub β2B       VKTAVCDIPP RGL------- -KMSATFIGN STAIQELFKR ISEQFTAMFR  
Tub β3      VKVAVCDIPP RGL------- -KMSSTFIGN STAIQELFKR ISEQFTAMFR 
Tub β6      VKVAVCDIPP RGL------- -KMASTFIGN STAIQELFKR ISEQFSAMFR 
Tub α1A     FKVGINYQPP TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA  
Tub α1B     FKVGINYQPP TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA   
Tub α1c     FKVGINYQPP TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA  
Tub α3      FKVGINYQPP TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA  
Tub α8      FKVGINYQPP TVVPGGDLAK VQRAVCMLSN TTAIAEAWAR LDHKFDLMYA  
 
Tub β4A   401RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQGATA –EEGE-FEEE450  
Tub β2B     RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQDATA DEQGE-FEEE  
Tub β3      RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEMYEDD 
Tub β6      RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQDATV NDGEEAFEDE 
Tub α1A     KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGVDSV --EGEGEEEG  
Tub α1B       KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGVDSV --EGEGEEEG  
Tub α1c     KRAFVHWYVG EGMEEGEFSE AREDMAALEK DYEEVGADSA --EG--DDEG  
Tub α3      KRAFVHWYVG EGMEEGEFSE AREDLAALEK DYEEVGVDSV --EAE-AEEG  
Tub α8      KRAFVHWYVG EGMEEGEFSE AREDLAALEK DYEEVGTDSF --EEE--NEG  
 
Tub β4A   451AEEEVA---- 
Tub β2B      EGEDEA----  
Tub β3      DEESEAQGPK  
Tub β6      DEEINE---- 
Tub α1A     EEY------- 
Tub α1B     EEY------- 
Tub α1c     EEY------- 
Tub α3      EEY—------ 
Tub α8      EEF—------ 
 
Figure	3.19	Sequence	alignment	of	all	the	mouse	tubulin	ispotypes		that	
were	detected	to	contain	methylated	arginines		by	mass	spectrometry.		Highlighted	in	grey	is	the	covered	sequence	of	the	protein	by	mass	spectrometry.	Methylated	arginines	are	shown	in	bold	font	and	the	underlined	
R	represents	the	di-methylated	arginines.	The	protein	accession	numbers	are	Tub	β4A:	AAH19959,	Tub	β2B:	AAI38937, Tub	β3:	EDL11742,	Tub	β6:	EDL09648, Tub	α1A:	AAH85256, Tub	α1B:	AAH85256, Tub	α1C:	AAH94022, TUB	α3A:		NP_033475,	TUB	α8:	ADD82895	 Arginine	79	is	located	in	the	N	terminus	of	tubulin	α	(Figure	3.20)	which,	like	the	acetylated	K40,	is	located	in	the	lumen	of	the	MT	molecule	(LeDizet	and	Piperno,	1987).	The	function	of	the	acetylation	of	K40	remained	unexplained	until	the	discovery	of	the	enzyme	that	is	responsible	for	this	acetylation	(Creppe	
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et	al.,	2009).	Histone	acetylase	complex	ARD1	(ADP-ribosylation	factor	domain	protein	1)	and	NAT1	(N-terminal	acetyltransferase)	(Park	and	Szostak,	1992)	form	a	complex	that	is	able	to	acetylate	K40	as	well	as	lysine	residues	on	histone	proteins.	Creppe	and	colleagues	(2009)	have	shown	that	acetylation	of	K40	on	tubulin	α	is	required	for	cortical	neurons	to	migrate	and	differentiate	(Creppe	et	al.,	2009).	When	a	subunit	of	the	acetylase	complex	was	silenced	or	a	tubulin	α	mutant	with	lysine	40	mutated	to	alanine	(K40A)	was	overexpressed,	cortical	neurons	showed	significant	impairment	in	the	migration	and	dendrite	arborisation	(Creppe	et	al.,	2009).	Therefore,	it	is	possible	that	R79	methylation	is	another	regulator	of	neuronal	differentiation	due	to	its	location	inside	the	MT	polymer.		
Conversely,	R390	is	located	within	the	C-terminus	of	tubulin	α	(Figure	3.20)	where	most	interactions	with	MAPs	and	motor	proteins	occur	(Chau	et	al.,	1998,	Nogales,	2001).	As	glutamylation	of	tubulin	which	occurs	on	the	C-terminus	has	been	suggested	to	regulate	the	interaction	between	tubulin	and	specific	MAPs	(Bonnet	et	al.,	2001,	Boucher	et	al.,	1994,	Larcher	et	al.,	1996),	other	PTMs	such	as	methylation	are	highly	likely	to	also	be	a	regulator	of	some	MAPs	and	motor	proteins.		
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Figure	3.20	3D	structure	of	a	tubulin	heterodimer	α/β	showing	the	
location	of	methylated	arginines	on	tubulin	α	.	Arginine	390	location	on	tubulin	α	subunit	is	shown	in	cyan	(A).	Highlighted	in	yellow	are	the	areas	of	protein-protein	interaction	within	the	tubulin	heterodimer	(C-	terminus).	Arginine	79	location	on	tubulin	α	is	shown	in	cyan	(B).	Highlighted	in	yellow	are	the	areas	of	protofilament’s	lateral	contact	of	the	heterodimer.	Structure	obtained	from	MMDB	ID	number:	8900.	The	structure	of	tubulin,	both	α	and	β,	consists	of	three	regions;	the	N-terminal	region,	the	intermediate	region,	and	the	C-terminus	(Nogales	et	al.,	1997).	The	intermediate	region	is	involved	in	the	binding	of	tubulin	β	to	the	stabilising	anticancer	drug	Taxol	(Nogales,	2001).	The	binding	pocket	of	Taxol	is	located	on	
	 107	
the	M-loop	of	tubulin	β	which	is	part	of	the	lateral	contact	of	protofilaments	in	microtubules	(Nogales	et	al.,	1998b)	along	with	the	H1-S2	loop	and	helix	H3	of	both	α	and	β	subunits	(Nogales,	2001).		
Arginine	62	is	positioned	in	the	N-terminus	of	tubulin	β	and	is	part	of	the	H1-S2	loop	(Figure	3.21).	The	bumpy	inside	of	the	MT	polymer	is	formed	by	several	loops	of	both	tubulin	subunits,	which	are;	H1-S2,	H2-S3	and	S9-S10	(Nogales,	2001).	Also,	H1-S2	is	part	of	the	protofilaments	lateral	contact	during	MT	polymer	formation.	Therefore,	R62	methylation	could	be	a	possible	regulatory	mechanism	of	MT	assembly.	Similar	to	R79	and	K40	in	tubulin	α,	as	previously	discussed	in	Section	3.4.3.2,	the	location	of	R62	inside	the	MT	polymer	makes	it	a	possible	candidate	as	a	regulator	of	neuronal	differentiation	and	migration.	
Lateral	contact	between	the	protofilaments	also	involves	Helices	H6,	H9	and	H4	where	R156	is	positioned	in	both	tubulin	subunits	(Nogales,	2001).	
R241	is	located	within	a	conserved	region	between	tubulin	α	and	β	subunits	referred	to	as	the	T7-loop	(Nogales	et	al.,	1998a).	Residues	in	this	loop	are	in	contact	with	the	nucleotide	of	the	next	subunit	in	the	protofilament	structure	and	therefore	important	for	tubulin	heterodimer	stability	(Nogales	et	al.,	1998a).		
R390	is	the	only	methylated	arginine	identified	in	this	study	that	is	located	within	the	C-terminus	of	tubulin	and	is	possibly	involved	in	tubulin	interaction	with	other	proteins	such	as	kinesins	and	MAPs	(Nogales,	2001). 
R276	and	R282	of	tubulin	β	are	located	in	the	M-loop	and	it	has	been	shown	that	R282	mutated	to	glutamine	(R282Q)	causes	resistance	to	the	anticancer	
	 108	
drug	epothilone	B	in	a	human	cancer	cell	lines	(Giannakakou	et	al.,	2000).	R276	has	been	shown	to	be	one	of	five	residues	in	the	M-loop	that	are	essential	for	Taxol	binding	and	together	they	are	in	direct	contact	with	the	oxetane	ring	that	serves	as	the	hydrogen	bond	acceptor	in	the	tubulin-Taxol	complex		(Wang	et	al.,	2000).	Therefore,	the	detection	of	arginine	di-methylation	on	R276	and	R282	by	mass	spectrometry	raised	the	question	of	whether	this	modification	plays	a	role	in	the	binding	of	tubulin	to	anticancer	drugs	such	as	epothilones	and	Taxol	(see	Chapter	4).		
	
Figure	3.21	3D	structure	of	a	tubulin	heterodimer	showing	the	location	of	
methylated	arginines	on	tubulin	β.	Highlighted	in	yellow	are	the	areas	of	protofilament’s	lateral	contact	of	the	heterodimer.	R62,	R276	and	R282	are	pointed	out.	Structure	obtained	from	MMDB	ID:8900.		 	
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Chapter	4 The	Effect	of	Methylation	Inhibition	in	Mouse	
Cortical	Primary	Neurons	and	in	the	Neuro2a	Cell	Line	
4.1 The	effect	of	methylation	inhibition	on	the	cell	cycle	of	
Neuro2a	cells	
In	the	previous	chapter,	mass	spectrometry	analysis	revealed	the	methylation	of	R276	and	R282	in	tubulin	β	(Section	3.2),	which	are	both	residues	of	the	M	loop	and	part	of	the	binding	region	to	the	anticancer	drug	Taxol	(Nogales,	2001).	Therefore,	the	methylation	inhibition	by	AdOx	in	Neuro2a	cells	was	utilised	to	investigate	whether	it	could	alter	the	effect	of	Taxol	in	arresting	Neuro2a	cells	in	the	G2	phase	of	the	cell	cycle.	Neuro2a	cells	were	treated	for	24	hrs	with	10	
µM	AdOx	(this	was	based	on	higher	sensitivity	of	Neuro2a	cells	to	AdOx	than	primary	neurons	(Shir-Ali,	2011).	50	nM	Taxol	or	0.02%	DMSO	(solvent	for	both	AdOx	and	Taxol)	was	used	as	vehicle	control.	
After	fixing	the	cells	with	ethanol,	the	cells	were	stained	using	propidium	iodide.	The		cell	cycle	analysis	was	performed	using	flow	cytometry	and	the	data	were	analysed	by	FlowJo	software	(Version	10),	as	described	in	Sections		2.13.3	and	2.13.4.	
The	addition	of	Taxol	caused	a	4-fold	increase	in	the	number	of	cells	that	were	arrested	in	the	G2/M	phase	(Figure	4.1).	Interestingly,	the	addition	of	AdOx	to	the	culture	at	the	same	time	as	Taxol,	caused	a	6-fold	increase	in	the	number	of	cells	compared	to	DMSO	control	that	were	arrested	in	the	G2/M	phase	across	all	experiments.	The	percentage	of	cells	in	the	G2/M	phase	after	combined	Taxol	and	AdOx	treatment,	was	significantly	higher	than	Taxol	treatment	alone	
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(Figure	4.1	E).	The	percentage	of	cells	in	the	S	phase	did	not	significantly	change	after	the	addition	of	Taxol.	AdOx	by	itself	however,	showed	a	different	effect	on	the	cell	cycle	of	Neuro2a	cells.	The	24	hr	treatment	with	10	µM	AdOx	induced	a	cell	cycle	arrest	where	the	number	of	cells	in	the	S	phase	of	the	cell	cycle	was	2	fold	higher	than	that	of	vehicle	control	treated	Neuro2a	cells	(Figure	4.1	E).	The	flow	cytometry	experiment	was	performed	six	independent	times.	A	representative	experiment	is	shown	in	Figure	4.1	A-D	and	the	raw	data	obtained	from	all	six	experiments	are	shown	in	Table	B.1.		 	
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Figure	4.1	 Flow	cytometry	and	cell	cycle	analysis	of	Neuro2a	cells.		SSC-A	vs.	FSC-A	was	gated	to	exclude	cell	debris	(P1)	(A).	(B)	FSC-H	vs.	FSC-A	was	gated	to	exclude	doublets	(P2)	(B).		Cell	count	vs.	PI	fluorescence	was	used	to	gate	for	live	cells	(C).	Cell	cycle	analysis	was	performed	on	Live	population	(D).	Statistical	analysis	of	six	independent	flow	cytometry	experiments	was	performed	with	IMB	SPSS	22.		*p<	0.05	(E).		
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4.2 The	effect	of	AdOx	on	the	methylation	of	tubulin	α	and	β	in	
mouse	primary	neurons	
To	confirm	that	AdOx	reduced	the	methylation	of	tubulin	α	and	β,	primary	cortical	neurons	were	treated	with	25	µM	AdOx	for	4	days.		The	cells	were	then	harvested	and	lysed	and	tubulin	α	and	β	proteins	were	immunoprecipitated	from	cortical	cell	lysates	using	anti-tubulin	α1A	and	anti-tubulin	βIII	antibody.	Then	the	immunoprecipitated	elutions	containing	tubulin	α	and	β	were	immunoblotted	with	Asym24.	The	amount	of	asymmetrically	di-methylated	tubulin	α	and	β	immunoprecipitated	from	AdOx	treated	lysates	was	significantly	lower	than	that	immunoprecipitated	from	control	as	revealed	by	the	densitometry	analysis	of	two	independent	experiments	(Figure	4.2,	Appendix	Table	B.2	and	Table	B.3).	For	tubulin	α,	AdOx	treatment	resulted	in	a	2/3	reduction	of	methylation,	while	a	50%	reduction	in	methylation	of	tubulin	β	was	observed.	The	total	amount	of	immunoprecipitated	tubulin,	however	was	not	affected	(Figure	4.2).	The	independent	repeats	of	these	experiments	are	shown	in	the	Appendix		(Figure	B.1	and	Figure	B.2).	
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Figure	4.2	Tubulin	α	and	β		methylation	is	reduced	by	AdOx	treatment.	Western	blots	with	Asym24	antibody	of	tubulin	α1A	(A)	and	β	III	(B)	IP	columns	immunoprecipitates.	Control		and	25	µM	AdOx	treated	primary	cortical	neuron	whole	cell	lysate	were	used	for	the	immunoprecipitation.	The	densitometry	analysis	of	the	bands	of	two	independent	experiments	is	shown	as	a	ratio	of	the	methylated	tubulin	from	the	total	immunoprecipitated	tubulin	α	(C)	and	β	(D).			
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4.3 The	effect	of	methylation	inhibition	by	AdOx	on	neurite	
growth	in	cultured	primary	neurons	
In	the	preliminary	Honours	study	(Jwad,	2010),	treatment	of	primary	neurons	with	AdOx	visually	reduced	the	amount	of	neurites	(see	Section	1.11).	Based	on	the	results	obtained	from	mass	spectrometry	that	both	CRMP-2	and	tubulin	are	methylated	(see	chapter	3),	it	was	hypothesized	that	one	of	the	effects	of	methylation	inhibition	would	be	a	reduction	of	neurite	outgrowth	for	which	both	CRMP-2	and	tubulin	are	required.	Therefore,	the	second	aim	of	this	thesis	was	to	investigate	the	effect	of	arginine	methylation	of	CRMP-2	and	tubulin	on	neurite	outgrowth.	
To	examine	the	effect	of	methylation	inhibition	by	AdOx	on	the	neurite	growth	of	cortical	neurons,	mouse	primary	cortical	neurons	were	cultured	at	a	density	of	1	X	105	cells	per	well	in	6-well	plates	as	explained	in	the	methods	section	(see	Section	2.3).	The	cells	were	treated	with	AdOx	at	a	concentration	of	25	µM	10	days	after	seeding	based	on	initial	dose	experiments	(see	Section	2.3).	The	treatment	was	repeated	at	day	12	after	changing	the	media.	At	Day	14,	phase	contrast	images	were	taken	of	both	control	and	treated	cells.	It	was	observed	that	addition	of	AdOx	to	the	primary	neurons	caused	a	retraction	of	their	neurites	in	comparison	to	the	untreated	cells	(Figure	4.3).	The	decrease	in	neurite	length	caused	by	the	inhibition	of	methylation	by	AdOx	was	measured	using	the	ImageJ2	Simple	Neurite	Tracer	plugin.	The	images	used	for	measurement	were	blindly	randomised	and	a	total	of	105	neurons	were	used	for	the	measurement	from	either	treatment	or	control	group.	Statistical	analysis	of	the	neurite	lengths	revealed	a	significant	decrease	in	the	length	after	4	days	
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of	treatment	with	AdOx	(Figure	4.4	A).		Measurements	of	the	neurons	cell	body	area	using	ImageJ	showed	that	AdOx	treatment	did	not	cause	a	significant	decrease	in	the	cell	body	area	of	treated	neurons	(Figure	4.4	B).	The	raw	measurements	of	neurite	length	and	neurons	cell	body	area	are	shown	in	the	Appeddix	(Table	B.4).		
	
Figure	4.3	Methylation	inhibition	with	AdOx	caused	a	decrease	in	the	
neurite	lengths	of	primary	mouse	cortical	neurons	in	vitro.		Phase-contrast	images	of	primary	mouse	cortical	neurons	(E16)	at	day	14	in	culture.	Untreated	cells	(control)	(A).	Cells	treated	with	25	µM	AdOx	for	4	days	(B).	Original	magnification	x200.	Scale	bar	100µm.		
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Figure	4.4	AdOx	treatment	reduced	the	neurite	length	of	primary	cortical	
mouse	neurons	but	caused	no	significant	decrease	in	cell	body	area.	Plot	box	graph	showing	the	difference	in	the	lengths	of	neurites	between	control	cultured	mice	primary	cortical	neurons	and	those	treated	with	25	µM	AdOx	for	4	days	since	day	10	in	culture	(A).	Plot	box	graph	showing	the	difference	in	the	cell	body	area	of	the	same	cells	measured	in	A	(B).	Data	are	shown	as	range	with	the	black	horizontal	line	indicating	the	mean	and	error	bars	are	standard	deviations.	The	statistical	analysis	was	performed	with	IMB	SPSS	22.		*p<	0.05,	n=105	neurons.	The	lengths	of	neurites	and	the	cell	body	area	were	measured	using	ImageJ	2.		
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Cell	viability	of	AdOx	treated	neurons	was	also	determined	prior	to	cell	lysis.	Primary	cortical	neurons	were	harvested	and	stained	with	trypan	blue	and	the	cells	were	then	counted	using	a	hemocytometer	(Section	2.2).	The	cell	count	results	showed	that	after	four	days	of	AdOx	treatment,	there	were	fewer	total	cells	than	in	control	(approximately	50%)	(Figure	4.5	A)	but	the	percentage	of	the	live	cells	was	similar	to	that	in	the	untreated	cells	(Figure	4.5	B).	The	raw	data	used	to	generate	Figure	4.5	are	displayed	in	the	Appendix	Table	B.5.	
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Figure	4.5	The	effect	of	AdOx	on	cell	viability	of	cultured	primary	cortical	
mouse	neurons.	Bar	graph	of	the	total	number	of	mouse	cortical	neurons	after	25	µM	AdOx	for	four	days	compared	to	control	neurons.	Red	bars	represent	dead	cells	while	blue	represent	live	cells	(A).	Bar	graph	of	percentage	of	live	mouse	cortical	neurons	with	and	without	treatment	with	AdOx	(B).	Error	bars	represent	the	standard	error	of	the	mean	and	n=4.		
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4.4 The	effect	of	methylation	on	the	interaction	of	CRMP-2	and	
tubulin	in	mouse	primary	neurons	
In	Chapter	3,	mass	spectrometry	analysis	detected	the	methylation	of	R390	on	both	tubulin	α	and	β.	R390	is	located	in	the	protein	binding	region	of	tubulin	and	hence	one	of	the	possible	hypotheses	was	that	methylation	might	regulate	the	interaction	between	CRMP-2	and	tubulin.	To	test	this	hypothesis,	tubulin	α	and	β	were	co-immunoprecipitated	using	an	IP	column	cross-linked	with	CRMP-2	antibody.	Whole	cell	lysates	of	AdOx	treated	and	non-treated	primary	cortical	neurons	were	used	to	test	the	effect	of	methylation	inhibition	on	the	binding	of	CRMP-2	to	tubulin	heterodimers.	The	IP	eluted	fractions	were	subjected	to	SDS-PAGE	and	then	immunoblotted	with	anti-CRMP-2	antibody	(as	control	of	the	amount	of	protein	eluted	from	the	column),	anti-tubulin	α	and	anti-tubulin	β	antibodies.	The	same	total	amount	of	protein	was	used	to	load	onto	the	IP	column	from	AdOx	treated	or	non-treated	whole	cell	lysates	(control).	All	elution	volumes	loaded	on	gels	were	identical	between	control	and	AdOx	treated	cells.	
Densitometry	analysis	revealed	a	statistically	significant	decrease	(p<0.05)	in	the	amount	of	both	tubulin	subunits	co-immunoprecipitated	with	CRMP-2	from	the	AdOx	treated	samples	from	three	independent	experiments	(Figure	4.6	A	and	B	and	Appendix	(Figure	B.3	and	Table	B.6).	However,	there	was	no	apparent	change	in	total	amount	of	CRMP-2	eluted	from	both	AdOx	treated	and	control	samples	(Figure	4.6	C)	and	Appendix	Table	B.6.	
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Figure	4.6	AdOx	treatment	of	primary	cortical	neurons	in	vitro	decreases	
the	amount	of	tubulin	heterodimers	co-immunoprecipitated	with	CRMP-2.	Representative	Western	blots	(n=3)	of	CRMP-2	IP	column	eluted	fractions	probed	with	tubulin	α	antibody	(A)	tubulin	β	antibody	(B)		or	CRMP-2	(C)	antibody.	Bar	graphs	of	bands	densitometry	ratio	of	tubulin	α	and	β	to	CRMP-2	(D	and	E).	Error	bars	are	the	standard	error	of	the	mean	and	significance	according	to	t-test	(p<0.05)	is	indicated	by	*.		 	
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4.5 Discussion	
4.5.1 The	effect	of	methylation	inhibition	on	the	cell	cycle	of	Neuro2a	cells		To	determine	whether	the	methylation	of	R276	and	R282	(Chapter	3)	may	be	involved	in	Taxol	binding,	flow	cytometry	analysis	was	performed	on	Neuro2a	cells	treated	with	AdOx	and	Taxol.	Neuro2a	cells	were	used	without	differentiation	in	order	to	utilize	their	proliferating	state	to	test	the	effect	of	methylation	inhibition	due	to	AdOx	treatment	on	the	cell	cycle.	Furthermore,	the	detected	peptides	that	contain	the	di-methylated	R276	and	R282	were	identical	in	both	the	primary	cortical	neuron	and	the	Neuro2a	samples	(Table	3.1)	which	indicates	that	no	mutations	had	occurred	in	this	region	of	the	Neuro2a	cell	line.		
When	the	Neuro2a	cells	were	treated	with	Taxol	at	the	same	time	as	AdOx	for	24	hours,	the	inhibition	of	methylation	has	caused	a	more	significant	number	of	cells	to	be	arrested	in	the	G2/M	phase	compared	to	cells	treated	with	only	Taxol.	This	dual	effect	of	Taxol	and	AdOx	treatment	on	the	cell	cycle	in	Neuro2a	cells	strongly	suggests	that	the	binding	of	Taxol	to	tubulin	β	was	increased	by	the	inhibition	of	methylation.	Although	the	inhibition	of	methylation	by	AdOx	is	not	specific	to	protein	arginine	methylation,	a	specific	protein	or	arginine	residues	within	tubulin	in	the	cells,	the	24	hour	treatment	was	sufficient	to	affect	tubulin	β	methylation,	which	in	turn	had	a	positive	effect	on	Taxol	activity,	presumably	due	to	increased	binding	of	Taxol	to	non-methylated	tubulin.		
Interestingly,	the	effect	of	AdOx	on	the	Neuro2a	cell	cycle	was	very	distinctive	from	that	of	Taxol.	After	24	hr	treatment	with	AdOx	alone,	an	increase	in	the	numbers	of	cells	arrested	in	the	S	phase	was	observed	(Figure	4.1).	This	type	of	
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effect	by	AdOx	on	the	cell	cycle	has	not	previously	been	reported.	However,	others	reported	that	AdOx	causes	a	cell	cycle	arrest	in	the	G2/M	phase	in	cells	such	as	leukaemia	cells,	colon	cancer,	and	cervical	cancer	cells	(Dasgupta	et	al.,	2008,	Heit	et	al.,	2009,	Schwerk	and	Schulze-Osthoff,	2005).	Cell	cycle	arrest	in	the	S	phase	is	mainly	caused	by	the	activation	of	the	S	phase	checkpoint,	when	DNA	damage	is	detected	by	the	cell	during	the	DNA	replication	process	(Abraham,	2001).		
The	activation	of	the	S	phase	checkpoint	due	to	treatment	with	AdOx	could	possibly	be	due	to	inhibition	of	histone	methylation	by	lysine	methyltransferases.	It	has	been	proposed	that	the	methylation	of	K20	on	histone	4	is	required	for	the	recruitment	of	a	DNA	replication	checkpoint	protein	Crb2	(Sanders	et	al.,	2004).	Also,	DNA	repair	proteins	such	as	p53	and	MRE11	are	regulated	by	methylation	(Boisvert	et	al.,	2005),	therefore,	AdOx	treatment	might	have	affected	their	methylation	which	would	lead	to	DNA	damage	and	therefore	a	cell	cycle	arrest	at	the	S	phase.		
Although	AdOx	only	indirectly	affects	arginine	methylation,	tubulin	α	and	β		proteins	immunoprecipitated	from	whole	cell	lysates	of	AdOx	treated	cortical	neurons	exhibited	only	half	the	methylation	of	those	precipitated	from	control	whole	cell	lysates	(Figure	4.2).	This	suggests	that	tubulin	β	methylation	was	indeed	significantly	reduced	by	AdOx,	although	it	can’t	be	ruled	out	that	the	effect	of	AdOx	on	the	cell	cycle	arrest	was	due	to	reduced	methylation	of	residues	other	than	R276	or	R282	or	even	of	other	proteins	than	tubulin	β.		
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4.5.2 The	effect	of	methylation	inhibition	in	primary	cortical	neurons	The	effect	of	inhibition	of	methylation	in	cultured	cells	using	AdOx	was	observed.	In	mouse	primary	cortical	neurons,	after	4	days	of	AdOx	treatment,	the	cells	showed	a	significant	retraction	of	their	neurites,	suggesting	a	potential	link	between	arginine	methylation	and	neurite	growth	(Figure	4.3	and	Figure	4.4).	The	axons	were	visually	identified	(see	Section	2.5),	however	further	tests	were	not	performed	to	confirm	the	identity	of	these	neurites	as	axons.		
The	detection	of	R390	methylation	on	both	tubulin	α	and	β	have	given	rise	to	the	hypothesis	that	arginine	methylation	could	be	a	regulator	of	tubulin	protein-protein	interaction	such	as	its	binding	to	CRMP-2	which	occurs	in	the	C-terminus	where	R390	is	situated	(Lowe	et	al.,	2001).	
To	test	whether	the	methylation	of	R390	on	both	tubulin	α	and	β		has	an	effect	on	its	binding	to	CRMP-2,	which	is	essential	for	axonal	growth	and	elongation	(Fukata	et	al.,	2002),	co-IP	of	tubulin	with	CRMP-2	was	performed	using	a	cross-linked	CRMP-2	IP	column.	Interestingly,	the	amount	of	both	tubulin	subunits	co-immunoprecipitated	with	CRMP-2	was	significantly	reduced	after	AdOx	treatment	(Figure	4.6)	which	suggests	methylation	as	a	promotion	signal	for	tubulin	and	CRMP-2	interaction.	The	methylation	inhibition	by	AdOx	is	not	specific	to	R390	and	it	can’t	be	ruled	out	that	the	decrease	in	binding	of	CRMP-2	to	tubulin	hetero-dimers	may	be	due	to	methylation	inhibition	of	other	residues	within	CRMP-2	or	tubulin.	R390	is	the	most	likely	residue	involved	in	this	interaction	based	on	available	structure	and	function	studies	(see	Section	3.4.3.2).	The	methylation	of	R390	is	a	probable	MT	modification	that,	
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like	glutamylation	(Edde	et	al.,	1990,	Boucher	et	al.,	1994,	Bonnet	et	al.,	2001)	and	glycylation	(Redeker	et	al.,	1994),	may	regulate	the	interaction	to	motor	proteins	and	MAP	such	as	CRMP-2.				  
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Chapter	5 The	Inhibition	of	PRMT1	and	8	and	its	Effect	
on	methylation	in	the	Neuro2a	cell	line	
The	final	aim	of	this	thesis	was	to	determine	which	PRMTs	are	involved	in	the	methylation	of	CRMP-2	and	tubulin.	As	PRMT8	is	a	CNS	only	enzyme	and	PRMT1	is	the	most	abundant	PRMT,	those	two	enzymes	were	targeted	for	inhibition	in	this	chapter	by	using	esiRNA	and	a	novel	inhibitor	that	only	targets	PRMT1	and	PRMT8.	
5.1 Knock-down	of	PRMT1	and	8	with	esiRNA	in	the	Neuro2a	
cell	line	
Neuro2a	cells	were	transfected	with	esiRNA	against	PRMT1	or	8,	and	the	cells	remained	in	culture	for	48	hours	post	transfection. As	control,	KIF11	esiRNA	was	used	and	as	negative	control	the	cells	were	treated	with	the	transfection	reagent	with	no	esiRNA	(Section	2.14).	A	substantial	decrease	in	PRMT1	and	8	or	KIF11	protein	levels	after	transfection	was	detected	by	Western	blot	using	antibodies	against	PRMT1,	8	and	KIF11	(Figure	5.1).	Each	transfection	experiment	was	performed	three	independent	times	(see	Appendix	Figure	C.1).	The	densitometry	analysis	of	the	Western	blot	showing	the	decrease	of	proteins		post	esiRNA	transfection	is	shown	as	bar	graphs	representing	the	average	from	three	independent	experiments	with	the	density	of	the	bands	for	proteins	of	interest	divided	by	the	GAPDH	band	density	(Figure	5.1	D-F	and	Table	C.1).	
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Figure	5.1	PRMT1,	8	and	KIF11	knock-down	with	esiRNA	in	Neuro2a	cells.	PRMT1	(A),	PRMT8	(B)	and	KIF11	as	control	protein	(C)	show	successful	decrease	in	protein	amount	present	after	esiRNA	transfection	as	detected	by	Western	blot.	Arrows	indicate	GAPDH	(which	was	used	as	a	house	keeping	protein	and	loading	control).	Bar	graphs	show	the	densitometry	analysis	(n=3)	(D-F).	*	indicates	a	p	value	<0.05	and	error	bars	represent	the	standard	error	of	the	mean.			
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5.1.1 The	effect	of	the	PRMT1	and	8	knock-down	on	asymmetric	di-
methylation	in	Neuro2a	cells	Whole	cell	lysates	of	Neuro2a	cells	after	transfecting	with	esiRNA,	were	separated	on	SDS-PAGE	and	immunoblotted	with	Asym24	antibody	to	examine	the	effect	of	the	strong	decrease	of	PRMT1	and	8	protein	levels	(see	Figure	5.1)	on	the	general	level	of	asymmetric	arginine	di-methylation. 
PRMT1	and	8	knock-downs	separately	in	Neuro2a	cells	did	not	seem	to	have	a	major	effect	on	the	overall	level	of	asymmetric	di-methylation	detected	by	Asym24	antibody.	One	protein	at	approximately	130	kDa	however,	showed	a	significant	decrease	of	asymmetric	di-methylation	when	PRMT8	was	knocked	down	(Figure	5.2).	However,	noticeable	reductions	of	the	asymmetric	methylation	of	a	few	proteins	appeared	when	both	PRMT1	and	8	were	knocked	down	simultaneously.	The	proteins	that	show	a	major	decrease	in	their	methylation	are	at	approximately	130,	70	and	55	kDa	when	both	PRMT	1	and	8	were	knocked	down	(Figure	5.2).	Densitometry	analysis	was	performed	from	three	different	independent	experiments	(see	Figure	5.2	and	Appendix	Figure	C.2,		Table	C.2	and	Table	C.3).		
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Figure	5.2	Western	blot	of	whole	cell	lysates	of	knocked	down	PRMT1,	8	or	
both	in	Neuro2a	cells.	The	whole	cell	lysates	of	transfected	cells	were	immunoblotted	with	Asym24	antibody	(A).	The	arginine	methylation	of	proteins	at	~130,	70,	and	55	(indicated	by	red	arrows)	was	affected	by	the	knock-down	of	PRMT8	and	both	PRMT1/8	simultaneously	GAPDH	was	used	as	protein	loading	control	(B).	Densitometry	analysis	of	bands	at	130,	70	and	55	kDa.	p	value	<	0.05	according	to	t-test	(n=3)	(C).		
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5.1.2 The	effect	of	PRMT1	and/or	PRMT8	knock-down	on	tubulin	α	
methylation	In	the	previous	Section	(5.1.1),	when	both	PRMT1	and	8	were	knocked	down	simultaneously,	proteins	at	55	kDa	exhibited	a	reduced	asymmetric	di-methylation.	As	tubulin	is	an	abundantly	expressed	protein	in	the	cell,	and	has	been	shown	in	this	thesis	and	by	Guo	et	al	(Guo	et	al.,	2014)	to	be	methylated,	it	was	hypothesized	that	the	methylation	of at	least	one	tubulin	subunit	is	indeed	affected	by	the	double	simultaneous	knock-down	of	PRMT1	and	8.		To	test	whether	it	was	the	methylation	of	tubulin	α	that	was	affected	by	the	simultaneous	knock-down	of	PRMT1	and	8,	300	µg	total	protein	of	each	of	the	cell	lysate	used	in	Figure	5.2	were	immunoprecipitated	using	a	tubulin	α1A		cross-linked	IP	column	(see	Section	2.10).	Western	blots	were	then	performed	with	exactly	the	same	volumes	of	eluted	fractions	from	each	sample,	using	tubulin		α1A		and	Asym24	primary	antibody.	The	amount	of	methylated	tubulin	
α	detected	from	the	PRMT1/8	double	knock-down		was	less	than	that	in	control	(Figure	5.3)	and	(Appendix	Figure	C.3	and	Table	C.4).	
To	confirm	that	the	single	knock-down	of	PRMT1	and	8	did	not	cause	a	decrease	in	tubulin	α	methylation,	the	same	experiments	as	above	were	performed	with	individual	PRMT1	and	PRMT	8	knock-downs	in	Neuro2a	cells.	After	PRMT1	and	PRMT	8	were	knocked	down	Neuro2a	whole	cell	lysates	were	immunoprecipitated	using	a	tubulin	α1A	IP	column,	and	the	eluted	fractions	were	immunoblotted	with	Asym24	to	study	the	level	of	asymmetric	di-methylation	of	tubulin	α.	The	level	of	asymmetric	di-methylation	of	tubulin	α	did	not	show	an	observable	difference	from	control	when	PRMT	1	and	8	were	
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knocked	down	seperately	(Figure	5.4	and	Appendix	Figure	C.4	and	Table	C.5).	The	eluted	fractions	from	each	sample	were	also	immunoblotted	with	tubulin	
α1A	antibody	as	an	indication	of	the	amount	of	tubulin	α	immunoprecipitated.	Similar	amounts	of	tubulin	α	were	immunoprecipitated	in	the	eluted	fraction	of	control	and	PRMT1	or	PRMT8	knocked	down	cells	(Figure	5.4)	Western	blots	shown	in	Figure	5.3	and	Figure	5.4	are	representative	examples	and	the	experiments	were	performed	three	independent	times	(see	Appendix	Figure	C.3,	Figure	C.4,	Table	C.4	and	Table	C.5).	
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Figure	5.3	Tubulin	α	asymmetric	di-methylation	is	decreased	when	
PRMT1	and	8	are	knocked	down	simultaneously	in	Neuro2a	cells.	Western	blot	using	Asym24	antibody	(A)	and	tubulin	α1A	primary	antibody	(B)	of	the	eluted	fractions	from	the	tubulin	α1A		IP	column	of	PRMT1/8	knocked	down	Neuro2a	cell	lysates.	The	same	amount	of	total	protein	was	loaded	onto	the	IP	column	from	each	sample.	Data	in	C	are	averages	of	the	band	intensities	at	55	kDa	as	a	ratio	of	tubulin	from	three	independent	experiments.	Error	bars	are	the	standard	error	of	the	mean.	t-test	was	performed	and	statistical	significance	(p<0.05)	is	indicated	by	*.		
	 132	
	
Figure	5.4	The	effect	of	PRMT1	or	8	knock-down	on	tubulin	α	asymmetric	
di-methylation	.	Western	blot	with	Asym24	antibody	of	the	eluted	fraction	of	the	tubulin	α1A	IP	column	(A)and	with	tubulin	primary	α1A	antibody	(B).	Average	densitometry	(n=3)	as	Asym24:tubulin	α	(C).	Error	bars	represent	the	standard	error	of	the	mean.		
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5.1.3 The	effect	of	PRMT1	and	8	knock-down	on	the	interaction	of	CRMP-2	
and	tubulin	α	To	investigate	whether	reducing	the	amount	of	PRMT1	and/or	8	in	Neuro2a	cells	affects	the	interaction	between	CRMP-2	and	tubulin,	immunoprecipitation	with	the	CRMP-2	antibody	cross-linked	IP	column	was	performed	on	the	PRMT1	or	PRMT8	knocked	down	as	well	as	on	the	PRMT1/8	double	knock-down	cell	lysates.	The	eluted	fractions	were	then	separated	on	SDS-PAGE	and	immunoblotted	with	tubulin	α1A	primary	antibody	or	CRMP-2	primary	antibody	as	control	for	the	amount	of	total	protein	immunoprecipitated	(Figure	5.5).		
The	amount	of	tubulin	α	co-immunoprecipitated	with	CRMP-2	from	the	PRMT1	knock-down	was	slightly	higher	than	that	from	control.	Interestingly,	the	knock-down	of	PRMT8	resulted	in	a	significant	increase	in	the	amount	of	co-immunoprecipitated	tubulin	α	with	CRMP-2,	while	the	amount	of	CRMP-2	immunoprecipitated	was	not	affected	across	all	samples	(Figure	5.5	B).	However,	when	both	PRMT1	and	8	were	knocked	down	simultaneously,	the	amount	of	tubulin	α	co-immunoprecipitated	with	CRMP-2	was	very	similar	to	that	off	PRMT1	knocked	down	samples	(Figure	5.5,	Appendix	Figure	C.5	and	Table	C.6).	The	experiment	was	performed	three	independent	times	with	the	repeats	shown	in	the	Appendix	(Figure	C.5).		
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Figure	5.5	Western	blot	of	PRMT1,	PRMT8	or	both	PRMT1/8	knock-down	
Neuro2a	cell	lysate	fractions	eluted	from	the	CRMP-2	IP	column.	Western	blot	with	anti-tubulin	α1A	primary	antibody	(A)	Western	blot	with	anti-CRMP-2	primary	antibody(B).	Densitometry	analysis	of	the	ratio	of	bands	for	tubulin	α	to	CRMP-2	from	three	separate	Western	blots	of	three	independent	experiments	(C).	Error	bars	represent	the	standard	error	of	the	mean.	t-test	was	performed	and	statistical	significance	(p<0.005)	is	indicated	by	***.		
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5.2 The	inhibition	of	PRMT1	and	PRMT8	using	the	PRMT1/8	
inhibitor	in	Neuro2a	cells	
During	the	course	of	this	thesis,	two	new	chemical	inhibitors	specific	to	PRMT1	and	8	were	described	(Dillon	et	al.,	2012).	One	of	them,	PRMT1/8	inhibitor	(Section	2.3.2),	was	used	to	chemically	block	PRMT1	and	PRMT8	simultaneously	in	Neuro2a	cells	and	the	results	are	shown	in	this	section.	
5.2.1 PRMT1/8	inhibitor	concentrations	in	Neuro2a	cell	culture	
Neuro2a	cells	were	treated	with	10	µM	PRMT1/8	inhibitor	for	24	hrs.	Treated	and	control	cells	(0.1	%	DMSO)	were	first	imaged	and	then	harvested	and	lysed.	Whole	cell	lysates	where	then	separated	on	SDS-PAGE	and	immunoblotted	with	Asym24	and	GAPDH	primary	antibody.	In	the	microscopic	images,	Neuro2a	cells	were	mostly	detached	and	appeared	round	after	the	24	hr	treatment	(Figure	5.6	A	and	B).	The	asymmetric	di-methylation	of	many	proteins	shows	a	decrease	such	as	for	proteins	of	~80,	55,	40	and	15	kDa	size	(Figure	5.6	C	blue	arrows).	However,	two	proteins	(at	~60	kDa	and	10	kDa)	exhibited	an	increase	in	asymmetric	di-methylation	after	treatment	with	the	PRMT1/8	inhibitor	(Figure	5.6	C	red	arrows).	The	Western	blot	represented	in	Figure	5.6	C	was	perfomed	two	independent	times	(see	Appendix	Figure	C.6)		
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Figure	5.6	The	effect	of	10	µM	PRMT1/8	inhibitor	on	Neuro2a	cell	
phenotype	and	asymmetric	arginine	di-methylation.	Microscopic	images	of	Neuro2a	cells	with	0.1%	DMSO	(control)	(A)	or	after	24	hr	treatment	with	10	
µM	of	the	PRMT1/8	inhibitor	for	24	hr	(B).	Scale	bars	are	100	µm.	Western	blot	of	whole	cell	lysates	of	control	and	10	µM	PRMT1/8	inhibitor	treated	Neuro2a	cells	probed	with	Asym24	primary	antibody	(C).	Red	arrows	indicate	proteins	that	showed	an	increase	in	asymmetric	di-methylation	level	while	blue	arrows	indicate	proteins	with	a	decrease	in	asymmetric	di-methylation	level	Western	blot	with	GAPDH	of	the	same	samples	as	in	(C)	as	loading	control	(D).		
	 137	
Next,	Neuro2a	cells	were	treated	with	three	different	lower	concentrations	of	PRMT1/8	inhibitor	(2,	1.5,	1	µM)	to	determine	whether	PRMT1/8	inhibitor	would	cause	the	cells	to	lose	adhesiveness	and	cause	a	major	change	in	morphology	at	lower	concentrations.	The	treated	Neuro2a	cells	were	imaged	after	24	hr	of	treatment	and	the	cells	were	then	harvested	and	counted	using	trypan	blue	staining	prior	to	lysis.		
At	the	concentration	of	2	µM	of	PRMT1/8	inhibitor,	the	majority	of	the	treated	Neuro2a	cells	were	detached	and	round	(Figure	5.7	D).	However,	at	a	concentration	of	1.5	and	1	µM,	PRMT1/8	inhibitor	the	effect	on	cell	morphology	was	different.	Neuro2a	cells	appeared	larger	in	size	and	a	number	of	cells	were	multinucleated	(Figure	5.7	B	and	C).	
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Figure	5.7	Microscopic	images	of	Neuro2a	cells	treated	with	the	PRMT1/8	
inhibitor.	Control	Neuro2a	cells	treated	with	0.1%	DMSO	(A)	or		treated	with	1	
µM	(B),	1.5	µM	(C)	or	2	µM	PRMT1/8	inhibitor	(D).	Scale	bars	are	100	µm.	Red	arrows	point	out	examples	of	multinucleated	cells.		
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The	cell	viability	after	treatment	with	the	different	PRMT1/8	inhibitor	concentrations	was	assessed	by	staining	cells	with	trypan	blue	and	counting	live	and	dead	cells.	After	24	hr	of	1	µM	PRMT1/8	inhibitor	treatment,	the	total	number	of	Neuro2a	cells	was	approximately	80%	of	those	only	treated	with	DMSO,	and	approximately	60%	after	1.5	µM	PRMT1/8	inhibitor	treatment	(Figure	5.8	A).	At	2	µM	the	total	number	of	cells	dropped	to	30%	of	which	only	less	than	20%	were	alive		(Figure	5.8	A).	Furthermore,	the	live	cell	percentage	showed	no	remarkable	difference	from	control	with	1	and	1.5	µM	PRMT1/8	inhibitor,	but	was	reduced	by	approximately	80%	when	Neuro2a	cells	were	treated	with	2	µM	PRMT1/8	inhibitor	(Figure	5.8	B).	The	raw	data	used	to	generate	Figure	5.8	are	displayed	in	the	Appendix	(Table	C.8)	
Therefore,	as	PRMT1/8	inhibitor	at	1.5	µM	showed	more	effect	on	the	morphology	than	at	1	µM	while	not	significantly	affecting	the	viability	of	Neuro2a	cells,	this	concentration	was	chosen	to	further	study	the	effect	on	Neuro2a	cells.		
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Figure	5.8	PRMT1/8	inhibitor	effect	on	Neuro2a	cell	viability.	Bar	graph	of	Neuro2a	cell	count	when	treated	with	DMSO	(control),	1,	1.5	or	2	µM	PRMT1/8	inhibitor.	Blue	section	of	the	bars	represents	the	number	of	live	cells	while	the	red	section	represents	the	dead	cells	(A).	Bar	graph	of	the	percentage	of	live	cells	after	24	hr	treatment	with	DMSO	(control),	1,	1.5	or	2	µM	PRMT1/8	inhibitor	(B).	Data	are	averages	of	3	independent	experiments	and	error	bars	are	the	standard	error	of	the	mean.			
	 141	
5.2.2 The	effect	of	PRMT1/8	inhibitor	on	the	cell	cycle	in	Neuro2a	cells	
At	1.5	µM,	the	PRMT1/8	inhibitor	had	caused	a	decline	in	Neuro2a	cell	growth,	where	cell	numbers	after	24	hours	were	approximately	40%	less	than	in	control	(Figure	5.8	A).	The	decline	in	growth	was	hypothesized	to	be	due	to	an	arrest	in	the	cell	cycle	rather	than	to	cell	toxicity	as	the	percentage	of	live	cells	was	similar	to	control	cells	(Figure	5.8	B).	To	determine	whether	the	cell	cycle	was	affected	and	at	which	cell	cycle	phase	the	PRMT1/8	inhibitor	caused	Neuro2a	cells	to	be	arrested,	flow	cytometry	analysis	was	performed.	Neuro2a	cells	were	treated	with	0.1%	DMSO	(negative	control),	20	nM	Taxol	(positive	control	as	Taxol	is	known	to	arrest	cells	in	the	G2/M	phase	of	the	cell	cycle)	or	1.5	µM,	PRMT1/8	inhibitor	for	24	hr.	After	fixing	the	cells	with	ethanol,	cell	cycle	analysis	was	performed	using	flow	cytometry.	The	data	from	five	independent	experiments	(see	Appendix	Table	C.7)	were	analysed	by	FlowJo	software	(Version	10),	as	described	in	Section	2.13.3	and	Section	2.13.4.		
The	flow	cytometry	analysis	showed	that	PRMT1/8	inhibitor	caused	a	significant	cell	cycle	arrest	at	the	S	phase	after	24	hr	treatment	with	the	number	of	Neuro2a	cells	in	the	S	phase	twice	as	high	as	those	in	the	non-treated	cells	(Figure	5.9	E).	Neuro2a	cells	treated	with	the	anticancer	drug	Taxol	exhibited	the	expected	arrest	cell	cycle	in	the	G2/M	phase.		
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Figure	5.9	Flow	cytometry	and	cell	cycle	analysis	of	Neuro2a	cells.	SSC-A	vs.	FSC-A	was	gated	to	exclude	cell	debris	(P1)	(A).	FSC-H	vs.	FSC-A	was	gated	to	exclude	doublets	(P2)	(B).	Cells	count	vs.	PI	fluorescence	was	used	to	gate	for	live	cells	(P3)	(C).	Cell	cycle	analysis	was	performed	on	P3	(D).	Statistical	analysis	of	six	independent	flow	cytometry	experiments	was	performed	with	IMB	SPSS	22	(E).		*p<	0.05,	**p<0.005	and	error	bars	represent	the	standard	error	of	the	mean.	Raw	data	are	shown	in	the	Appendix	(Table	C.7).		
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5.2.3 The	effect	of	the	PRMT1/8	inhibitor	on	methylation	in	Neuro2a	cells	To	study	the	effect	of	the	PRMT1/8	inhibitor	on	Neuro2a	cell	protein	arginine	methylation	at	1.5	µM,	the	cells	were	treated	with	the	inhibitor	every	24	hours	for	3	days.	The	treated	cells	were	then	harvested	and	lysed	at	24,	48	or	72	hr	after	treatment.	Whole	cell	lysates	where	then	separated	on	SDS-PAGE	and	immunoblotted	with	Sym10	or	Asym24	primary	antibody	in	order	to	observe	possible	changes	on	both	symmetric	and	asymmetric	arginine	di-methylation	of	Neuro2a	cell	proteins,	respectively.	The	effect	of	the	PRMT1/8	inhibitor	induced	a	change	in	the	symmetric	di-methylation	in	Neuro2a	cells	as	detected	by	Sym10	primary	antibody	(Figure	5.10	A).	Interestingly,	the	effect	on	symmetric	di-methylation	was	different	at	24	hr	of	treatment	to	that	at	48	hr	and	72	hr	of	treatment	(Figure	5.10	A).	At	the	24	hr	time	point,	symmetric	di-methylation	showed	a	general	decrease	in	most	proteins	except	for	a	protein	at	35	kDa	for	which	symmetric	di-methylation	was	visibly	increased.	At	48	hrs,	symmetric	di-methylation	of	the	35	kDa	protein	decreased	while	other	proteins,	especially	one	at	55	kDa,	exhibited	increased	methylation.	At	the	72	hr	time	point	of	treatment	with	1.5	µM,	the	symmetric	di-methylation	of	most	of	the	proteins	detected	by	Sym10	antibody	was	increased,	with	the	exception	of	a	protein	at	55	kDa	which	showed	a	marked	decrease	in	symmetric	di-methylation	(Figure	5.10	A	and	independent	repeats	of	this	Western	blot	are	displayed	in	the	Appendix	Figure	C.7).	On	the	other	hand,	the	asymmetric	di-methylation	detected	by	Asym24	antibody	showed	a	slight	decrease	of	most	proteins	at	the	24	hr	time	point	followed	by	a	gradual	increase	in	most	detected	proteins	over	the	next	two	time	points.	At	48	hrs	of	treatment,	two	proteins	of	approximately	20	kDa	and	100	kDa	appeared	to	be	methylated	only	after	48	hr	of	treatment	
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with	the	PRMT1/8	inhibitor.	Only	after	72	hrs,	some	proteins	of	larger	molecular	weight	(approximately	250	kDa)	showed	an	increase	in	asymmetric	di-methylation	(Figure	5.10	B).	Two	independent	repeats	of	this	Western	blot	are	displayed	in	the	Appendix	(Figure	C.8).	
This	unexpected	change	of	the	arginine	di-methylation	profile,	both	in	symmetric	and	asymmetric	di-methylation	of	proteins	in	Neuro2a	cells	after	the	treatment	with	the	PRMT1/8	inhibitor	has	led	to	the	hypothesis	that	treatment	with	the	PRMT1/8	inhibitor	may	have	resulted	in	an	upregulation	of	PRMT	expression.	 
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Figure	5.10	The	effect	of	PRMT1/8	inhibitor	on	symmetric	and	
asymmetric	di-methylation	in	Neuro2a	cells.	Western	blot	with	Sym10	primary	antibody	of	Neuro2a	whole	cell	lysates	treated	with	1.5	µM	at	24,	48	and	72	hrs.	Vehicle	control	was	treated	with	0.1%	DMSO	(A).	Western	blot	with	Asym24	primary	antibody	of	Neuro2a	whole	cell	lysates	treated	with	1.5	µM	at	24,	48	and	72	hrs	(B).	Western	blot	of	same	samples	as	A	and	B	blotted	with	GAPDH	as	housekeeping	protein	and	loading	control	(C).	Red	arrows	point	out	proteins	with	changes	in	their	methylation	levels.	Independent	repeats	of	this	experiment	are	shown	in	the	Appendix	(Figure	C.7	and	C.8).		
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5.2.4 The	effect	of	the	PRMT1/8	inhibitor	on	PRMT1,	8	and	5	protein	level	
in	Neuro2a	cells	In	the	previous	section,	Western	blot	analysis	with	both	Sym10	and	Asym24	primary	antibodies	revealed	that	the	treatment	with	the	PRMT1/8	inhibitor	caused	a	remarkable	and	unexpected	increase	in	the	profile	of	symmetric	and	asymmetric	arginine	di-methylation	in	Neuro2a	cells	(Figure	5.10).	These	results	led	to	the	hypothesis	that	inhibiting	the	action	of	PRMT1	and	8	using	PRMT1/8	inhibitor	could	have	resulted	in	a	compensatory	feedback	mechanism	which	may	have	led	to	increases	in	the	amount	of	PRMT1,	8	and	5	in	the	cells.	This	in	turn	could	have	resulted	in	the	observed	changes	in	the	methylation	profile	of	the	proteins	in	Neuro2a	cells	due	to	the	treatment	with	the	PRMT1/8	inhibitor.	
The	same	samples	used	in	Section	5.2.3	were	analysed	by	Western	blot	using	primary	antibodies	against	PRMT1,	8	or	5.	The	protein	level	of	PRMT1	showed	a	slight	decrease	after	24	hr	treatment	with	the	PRMT1/8	inhibitor	but	then	increased	at	the	48	and	72	hr	time	points	(Figure	5.11).	This	change	was	consistently	noticeable	both	on	the	Western	blots	and	the	densitometry	analysis	in	3	independent	experiments	(Appendix	Figure	C.9,	Table	C.9	and	Table	C.10),	however,	it	did	not	reach	statistical	significance	when	the	t-test	was	performed	with	a	p-value	greater	than	0.05.	
	PRMT8	levels	only	showed	a	slight	increase	24	hrs	post	treatment	but	then	declined	to	levels	similar	to	control	in	the	next	two	time	points	(Figure	5.11,	Figure	C.10,	Table	C.9	and	Table	C.10).	The	small	changes	in	the	PRMT8	levels	
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were	also	not	found	to	be	statistically	significant	according	to	t-test	with	p-values	greater	than	0.05.	
PRMT5	protein	levels	were	minimal	at	the	24	and	48	hr	time	points	of	treatment	with	the	PRMT1/8	inhibitor.	Interestingly,	the	PRMT5	levels	in	Neuro2a	cells	increased	up	to	6	times	compared	to	control	after	72	hrs	of	treatment		with	the	PRMT1/8	inhibitor	which	was	statistically	significant	with	a	
p-value	of	0.041	(Figure	5.11).	Figure	5.11	is	a	representative	Western	blot	and	raw	data	are	shown	in	the	Appendix	Table	C.9,	Table	C.10	and	Figure	C.11.	
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Figure	5.11	The	effect	of	PRMT1/8	inhibitor	on	the	protein	levels	of	
PRMT1,	8	and	5	in	Neuro2a	cells.	Western	blots	with	primary	antibodies	against	PRMT1,	8,	5	or	GAPDH	of	Neuro2a	whole	cell	lysates	treated	with	1.5	
µM	for	24,	48	and	72	hrs	(A).	Vehicle	control	was	treated	with	0.1%	DMSO.	Bar	graph	represents	densitometry	analysis	(n=3)	(B).	Error	bars	are	the	standard	errors	of	the	mean.	t-test	was	performed	and	statistical	significance	(p<0.05)	is	indicated	by	*.	Independent	repeats	are	shown	in	the	Appendix	(Figure	C.9	to	Figure	C.12)		
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5.3 Discussion	
PRMT1	is	vital	for	cell	survival,	and	complete	PRMT1	knock-down	has	been	shown	to	be	lethal	in	mice	embryos	and	is	not	compatible	with	cell	viability	in	culture	(Yu	et	al.,	2009).	In	this	thesis,	when	the	expression	of	PRMT1	was	reduced	approximately	by	70%	using	esiRNA	(Figure	5.1),	the	Neuro2a	cells	survived	for	48	hours,	which	means	there	was	still	enough	functional	PRMT1	for	cell	survival.	This	could	be	the	reason	why	there	were	not	many	changes	to	the	asymmetric	di-methylation	status	of	proteins	as	shown	by	Western	blot	analysis	with	Asym24	(Figure	5.2).	However,	three	proteins	at	55,	70	and	130	kDa	showed	a	slight	decrease	when	PRMT8	was	knocked	down.	The	decrease	of	asymmetric	di-methylation	of	these	three	proteins	became	more	significant	when	both	PRMT1	and	8	were	knocked	down	simultaneously	(Figure	5.2).	PRMT8	function	and	substrates	in	the	neuronal	cells	have	not	yet	been	identified.	EWS	of	90	kDa	is	the	only	known	substrate	of	PRMT8	in	vitro	(Kim	et	al.,	2008).	Here,	the	knock-down	of	PRMT8	in	Neuro2a	cells	has	negatively	affected	the	methylation	of	at	least	three	proteins	which	suggests	that	they	are	potential	substrates	of	PRMT8.	Interestingly,	the	asymmetric	di-methylation	of	proteins	at	55,	70	and	130	kDa	have	dramatically	decreased	in	the	case	of	PRMT1	knock-down	as	well	as	PRMT8	knock-down.	These	results	strongly	suggest	that	PRMT8	action,	at	least	for	these	three	proteins,	may	be	dependent	on	the	presence	of	PRMT1.		PRMT1	and	8	have	been	previously	reported	to	act	as	partners	in	regulating	signalling	pathways	in	the	cell	(Simandi	et	al.,	2014)	and	may	form	heterodimers	to	methylate	certain	proteins	in	neurons. 
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The	protein	at	55	kDa	showed	a	significantly	reduced	level	of	methylation	when	both	PRMT1	and	8	were	knocked	down	simultaneously.	The	molecular	weight	and	predominance	of	the	band	suggested	that	this	protein	could	be	tubulin	atubulin	is	an	abundantly	expressed	protein	in	cells	and	has	previously	been	shown	(see	Section	3.2)	to	be	methylated	(both	subunits	α	and	β).		
In	this	thesis,	the	tubulin	α	subunit	methylation	was	further	investigated	when	PRMT1	and	8	were	knocked	down.	The	decrease	in	tubulin	α	methylation	due	to	the	knocked	down	PRMT1	and	8	was	confirmed	by	immunopreciptating	tubulin	
α	from	Neuro2a	cell	lysates	with	a	tubulin	α1A	IP	column	(Figure	5.3).	The	fractions	from	both	control	and	knocked	down	samples	showed	a	band	at	55	kDa	when	immunoblotted	with	Asym24	antibody	(Figure	5.3)	which	was	strongly	reduced	in	the	PRMT1/8	knocked	down	samples.	This	indicates	that	the	asymmetric	di-methylation	of	at	least	one	tubulin	subunit	(tubulin	α)	may	be	the	product	of	a	combined	PRMT1	and	8	enzymatic	action	rather	than	methylation	by	only	one	of	the	PRMTs	by	itself.	The	amount	of	total	protein	in	the	input	of	the	IP	was	normalised	by	BCA	assay.	
The	effect	of	each	PRMT1	and	PRMT8	individually	on	the	asymmetric	di-methylation	of	the	tubulin	α	subunit	was	then	further	investigated	by	performing	IP	of	the	PRMT1	and	PRMT8	knocked	down	Neuro2a	cell	lysates	using	the	tubulin	α	1A	IP	column.	The	eluted	tubulin	α,	however,	did	not	show	any	reduction	in	methylation	(Figure	5.4),	which	could	be	due	to	three	reasons	assuming	that	PRMT1	and/or	PRMT8	are	the	enzyme	responsible	for	methylating	tubulin.	Firstly,	it	could	be	due	to	differences	in	affinity	of	the	anti-tubulin	α	1A	antibody	to	binding	methylated	versus	non-methylated	tubulin	
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and/or	due	to	larger	amounts	of	non-methylated	tubulin	α	present	in	cell	lysates.	Secondly,	Neuro2a	cells	were	harvested	48	hours	after	transfection	and	longer	times	might	be	needed	to	significantly	affect	the	function	of	PRMT1	and	8	in	the	cells.	Thirdly,	and	most	likely,	PRMT1	and	8	have	recently	been	proposed	to	function	as	a	complex	that	regulates	the	retinoic	acid	(RA)	induced	neuronal	differentiation	in	vitro	(Simandi	et	al.,	2014).	Therefore,	it	is	possible	that	PRMT1	and	8	can	act	as	partners	in	methylating	other	substrates	that	are	yet	to	be	explored.	When	the	expression	of	either	of	them	was	decreased	because	of	esiRNA	transfection,	there	may	have	been	enough	functional	complexes	in	the	cell	to	carry	out	tubulin	methylation.	Indeed,	the	55	kDa-protein	asymmetric	di-methylation	levels	seemed	to	be	affected	only	when	both	PRMT1	and	8	were	knocked	down	at	the	same	time	(Figure	5.2	and	Figure	5.3).	Tubulin	α	methylation,	was	also	observed	to	be	reduced	to	approximately	40%	after	4-day	treatment	with	25	µM	AdOx	in	primary	cortical	neurons	(Figure	4.2	A).	Although	the	action	of	AdOx	is	not	specific	to	blocking	the	action	of	PRMTs,	it	is	possible	as	suggested	by	the	simultaneous	knock-down	experiments	of	both	PRMT1	and	8	(Figure	5.3)	that	AdOx	has	blocked	the	action	of	PRMT1	and	8	after	4-day	treatment	in	primary	cortical	neurons.	
The	effect	of	PRMT1	and	8	knock-downs	on	the	interaction	of	CRMP-2	and	tubulin	was	also	explored	in	Neuro2a	cells	(Figure	5.5).	Curiously,	when	PRMT1	levels	decreased	whether	by	itself	or	accompanied	by	a	PRMT8	decrease,	there	was	only	a	small	increase	in	the	tubulin	α	co-immunoprecipitated	with	CRMP-2	(Figure	5.5	C).	However,	when	PRMT8	levels	were	reduced,	the	amount	of	tubulin	α	co-immunoprecipitated	with	CRMP-2	doubled	in	comparison	to	that	
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in	control.	This	result	was	unexpected	and	raised	the	possibility	that	PRMT1	and	PRMT8	can	possibly	have	antagonistic	functions	in	promoting	specific	protein-protein	interactions	such	as	that	of	CRMP-2	and	tubulin	α	heterodimers.	One	plausible	explanation	for	the	results	is	that	PRMT8	somehow	antagonizes	or	inhibits	the	effect	of	PRMT1.	When	only	PRMT8	levels	decrease,	PRMT1	would	no	longer	be	restricted	by	PRMT8	activity	and	this	could	promote	more	binding	between	CRMP-2	and	tubulin	heterodimer.	However,	this	effect	was	not	seen	when	both	PRMT1	and	8	were	knocked	down	simultaneously,	arguing	against	an	effect	of	PRMT1	and	PRMT8	as	a	heteromeric	complex	such	as	proposed	for	tubulin	α	methylation.	When	both	PRMT1	and	PRMT8	were	knocked	down	according	to	the	hypothesis	above,		the	decreased	levels	of	PRMT1	would	not	be	able	to	up-regulate	the	interaction	between	CRMP2	and	tubulin	α.		
The	newly	discovered	PRMT1/PRMT8	inhibitor	was	also	used	as	a	way	of	specifically	inhibiting	PRMT1	and	PRMT8	functions	simultaneously.	This	inhibitor	has	only	been	used	previously	in	purified	protein	methylation	assays	(Dillon	et	al.,	2012)	but	has	not	yet	been	tested	in	mammalian	cell	culture.	In	the	study	where	this	inhibitor	was	first	described,	the	concentrations	used	were	as	high	as	300	µM	and	the	lowest	concentration	was	10	µM	(Dillon	et	al.,	2012).	When	this	inhibitor	was	tested	on	Neuro2a	cells,	any	concentration	higher	than	10	µM	was	cytotoxic	and	the	cells	did	not	survive	more	than	24	hours	post	treatment	(Figure	5.6	B).		
Western	blotting	with	Asym24	antibody	of	all	cell	lysates	after	inhibitor	treatment	revealed	only	a	few	proteins	that	showed	a	change	in	their	
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asymmetric	di-methylation	(Figure	5.6	C).	The	increase	in	methylation	of	some	proteins	(60	and	10	kDa)	further	confirms	that	blocking	PRMT1	and	PRMT8	action	in	cells	causes	an	increase	in	methylation	of	some	proteins,	most	likely	by	the	action	of	other	PRMTs	(Dhar	et	al.,	2013)	and/or	by	some	feedback	mechanism	which	upregulates	the	protein	expression	levels	of	PRMT1	and	or	PRMT8.	Only	a	few	other	proteins	(80,	55,	40	and	15	kDa)	have	shown	an	expected	decrease	in	methylation	as	detected	by	Asym24	antibody	(Figure	5.6	C).		
As	10	µM	of	PRMT1/8	inhibitor	had	caused	cell	toxicity	after	24	hr	of	treatment,	the	inhibitor	was	then	used	at	lower	concentrations.	Three	lower	concentrations	were	used	to	treat	Neuro2a	cells	including	1,	1.5	and	2	µM.	At	2	
µM,	the	inhibitor	still	caused	toxicity	to	Neuro2a	cells	where	the	cell	number	was	lower	then	in	control	and	the	cells	had	lost	adhesiveness	(Figure	5.7	D).	At	1	and	1.5	µM,	the	PRMT1/8	inhibitor	did	not	cause	a	loss	in	adhesiveness	of	the	cells,	however,	clear	changes	in	morphology	were	visible	where	the	cells	seemed	more	elongated	and	some		also	appeared	multinucleated	(Figure	5.7	B	and	C).	The	changes	observed	in	cell	morphology	due	to	the	PRMT1/8	inhibitor	treatment	at	1	and	1.5	µM	treatment	may	indicate	that	the	cells	were	undergoing	mitosis	but	not	cytokinesis.		Cell	viability	using	trypan	blue	was		measured	and	at	2	µM	inhibitor	treatment,		only	approximately		2%	of	the	original	number	of	Neuro2a	cells	seeded	had	survived	after	24	hr.	Both	1	and	1.5	µM	inhibitor,	however,	caused	no	major	cell	death	but	fewer	cells	were	present	compared	to	control	indicative	of	an	arrest	in	the	cell	cycle.	At	1.5	µM	the	number	of	Neuro2a	cells	was	inhibited	by	approximately	50%.	These	results	
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suggest	that	PRMT1/8	inhibitor	at	a	concentration	of	1.5	µM	can	act	as	a	cytostatic	agent	in	non-differentiated	Neuro2a	cells	possibly	due	to	an	activation	of	a	cell	cycle	check	point.	PRMT1	has	been	reported	to	be	an	indirect	regulator	of	the	cell	cycle	where	it	methylates	the	DNA	repair	proteins	p53	and	MRE11	(Boisvert	et	al.,	2005).	Therefore,	it	is	likely	that	the	inhibition	of	PRMT1	activity	by	the	PRMT1/8	inhibitor	may	indirectly	cause	a	pause	in	the	cell	cycle	due	to	the	dysregulation	of	the	activity	of	PRMT1	substrates	p53	and	MRE11.	This	was	further	tested	using	flow	cytometry	analysis	on	Neuro2a	cells	treated	with	PRMT1/8	inhibitor.	After	treating	the	cells	with	1.5	µM	for	24	hours,	the	number	of	cells	in	S	phase	was	twice	as	much	as	that	in	control	cells	(Figure	5.9	E).	The	arrest	in	S	phase	due	to	arginine	methylation	inhibition	has	already	been	observed	previously	in	Chapter	3.	After	treating	Neuro2a	cells	with	25	µM	AdOx,	the	number	of	cells	arrested	in	S	phase	increased	by	2	fold	(Figure	4.1).	Although	AdOx	is	a	non-specific	arginine	methylation	inhibitor,	it	seems	that	the	effect	on	the	cell	cycle	in	Neuro2a	cells	could	possibly	be	due	to	the	same	mechanism	when	inhibited	by	PRMT1/8	inhibitor	or	by	AdOx.	As	discussed	previously	in	Chapter	4,	cell	cycle	arrest	in	the	S	phase	is	caused	by	S-phase	check	point	activation.	As	both	PRMT1	substrates	p53	and	MRE11	are	DNA	repair	proteins,	their	dysregulation	due	to	the	methylation	inhibition	is	possibly	the	cause	of	S-phase	check	point	activation	and	therefore,	the	observed	S	phase	arrest.	
The	status	of	symmetric	and	asymmetric	di-methylation	of	Neuro2a	cells	when	treated	with	1.5	µM	was	examined	over	a	3	day	experiment.	The	changes	in	symmetric	di-methylation	detected	by	Sym10	antibody	was	very	interesting	
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and	was	in	agreement	with	previous	reports	of	similar	changes	observed	in	mouse	embryonic	fibroblasts	(MEFs)	after	4	days	of	PRMT1	knockout	(Dhar	et	al.,	2013).	The	PRMT1	knockout	MEFs	were	generated	by	treating	with	2	mM	4-Hydroxytamoxifen	(OHT),	which	stabilizes	an	estrogen	receptor	Cre	recombinase	fusion	and	translocates	it	to	the	nucleus,	which	then	excises	the	floxed	prmt1	allele	to	generate	PRMT1	KO	MEFs	(Dhar	et	al.,	2013).	After	24	hr	of	the	PRMT1/8	inhibitor	treatment	there	was	a	general	reduction	in	symmetric	di-methylation	of	those	proteins	also	detected	as	methylated	in	control.	However,	a	protein	at	approximately	42	kDa	and	another	one	at	35	kDa	both	showed	a	visible	increase	in	symmetric	di-methylation	(Figure	5.10	A).	After	48	hr	of	treatment,	the	symmetric	di-methylation	of	the	42	kDa	protein	increased	further,	while	that	of	the	35	kDa	protein	showed	a	decrease.	Noticeably,	a	55	kDa	protein	showed	a	dramatic	increase	in	symmetric	di-methylation	which	diminished	at	72	hr.	At	the	72	hr	time	point,	only	a	few	proteins	exhibited	very	strong	symmetric	di-methylation	including	proteins	at	70,	40,	25	and	15	kDa	(Figure	5.10	A).	Similar	changes	in	symmetric	di-methylation	patterns	in	response	to	loss	of	PRMT1	activity	have	been	observed	previously	by	others	(Dhar	et	al.,	2013).	The	knockout	of	PRMTs	in	mouse	embryonic	fibroblasts	(MEFs)	has	caused	an	increase	in	the	symmetric	di-methylation	of	proteins	however,	this	was	not	observed	until	day	4	post	PRMT1	knockout	(Dhar	et	al.,	2013).		
When	examining	the	asymmetric	di-methylation	in	Neuro2a	cells	detected	by	using	Asym24	antibody,	no	major	changes	were	observed	after	24	hr	of	PRMT1/8	inhibitor	treatment	(Figure	5.10	B).	At	48	and	72	hr	time	points,	the	
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methylation	of	most	of	the	detected	proteins	increased	which	is	in	agreement	with	the	findings	by	Dhar	et	al.	(Dhar	et	al.,	2013).	In	that	study,	the	levels	of	PRMT	3,	4,	5,	6	and	7	were	tested	to	detect	if	the	changes	in	methylation	were	due	to	the	increase	in	their	expression	in	the	PRMT1	knockout	MEFs	(Dhar	et	al.,	2013).	None	of	the	tested	PRMTs	showed	any	change	by	day	4	(Dhar	et	al.,	2013).	However,	a	significant	increase	in	mono-methylation	was	observed	by	Dhar	and	colleagues	(2013)	which	was	not	tested	in	this	thesis.	At	day	8	post	PRMT1	knockout,	an	increased	level	of	PRMT6	and	7	was	observed	(Dhar	et	al.,	2013).	In	this	thesis,	the	protein	levels	of	PRMT1,	8	and	5	were	tested	to	determine	if	the	treatment	with	the	PRMT1/8	inhibitor	may	have	caused	changes	to	the	levels	of	these	PRMTs	in	the	Neuro2a	cells.	Interestingly,	PRMT5	protein	levels	showed	a	significant	increase	at	day	3	of	PRMT1/8	treatment	which	is	highly	likely	to	be	responsible	for	the	observed	increase	in	symmetric	di-methylation	detected	by	Sym10	antibody	at	72	hrs.	The	increase	in	PRMT5	level	due	to	a	change	in	other	PRMTs	level	of	expression	or	activity	has	not	been	observed	before,	however,	it	is	possible	that	at	a	low	level	of	PRMT1	activity,	the	cell	starts	to	compensates	by	increasing	the	expression	of	other	PRMTs	such	as	PRMT5.	PRMT8	protein	levels	remained	unchanged	throughout	the	whole	experiment,	however,	PRMT1	protein	levels	showed	a	slight	increase	at	day	3	(Figure	5.11).	Therefore,	it	is	possible	that	the	increase	in	asymmetric	di-methylation	was	due	to	the	action	of	other	type	I	PRMTs	such	PRMT2,	3,	4	or	6	and	their	levels	in	the	cells	after	treatment	with	PRMT1/8	inhibitor	should	be	further	investigated	in	future	studies.			 	
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Chapter	6 Summary	and	Conclusions	
In	this	thesis,	the	arginine	methylation	of	tubulin	and	CRMP	in	mice	primary	cortical	neurons	and	the	neuronal	cell	line	Neuro2a	was	investigated.	Immunoprecipitation	of	CRMP-2	and	tubulin	α/β	followed	by	Western	blot	analysis	with	Asym24	or	immunoprecipitation	with	Asym24	and	Western	blot	analysis	with	tubulin	antibodies	revealed	that	both	CRMP-2	and	tubulin	α	and	β	subunits	were	asymmetrically	di-methylated	on	some	of	their	arginine	residues.	This	was	then	confirmed	by	mass	spectrometry,	detecting	R173	to	be	mono-methylated	and	R11	and	R62	di-methylated	on	CRMP-2	and	also	revealing	methylated	arginines	on	CRMP-1	and	CRMP-3	(see	Chapter	3).	Six	methylated	arginines	on	the	β	subunit,	R62,	R156,	R276,	R282	(di-methylated)	and,	R241	and	R390	(mono-methylated)	and	two	methylated	arginines	on	the	α	subunit,	R390	(mono-methylated)	and	R79(di-methylated)	were	also	detected	by	mass	spectrometry	(see	Figure	3.3	to	Figure	3.13).	Figure	6.1	shows	a	schematic	summary	of	known	tubulin	α	and	β	PTMs	including	the	newly	identified	methylated	arginine	residues.	
The	intermediate	product	of	both	types	of	PRMTs	(Type	I	and	Type	II)	is	mono-methylated	arginine.	It	is	likely	that	the	final	product	of	some	of	the	arginine	residues	identified	by	mass	spectrometry	to	be	mono-methylated	are	in	fact	di-methylated.	Indeed,	the	identified	proteins	were	detected	in	our	immunoprecipitation	analysis	when	antibodies	specific	for	asymmetric	di-methylation	were	used	(Asym24),	which	suggests	that	at	least	some	of	the	methylated	arginines	are	asymmetrically	di-methylated.	Nevertheless,	PRMT7,	which	was	reported	to	favour	the	catalysis	of	mono-methylated	arginine	
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(Zurita-Lopez	et	al.,	2012),	could	possibly	be	the	enzyme	responsible	for	methylating	some	of	the	residues	identified	to	be	mono-methylated	arginines.	However,	PRMT7	activity	and	localisation	has	not	yet	been	reported	in	the	brain.	
	
Figure	6.1	Schematic	diagram	of	tubulin	α	and	β	showing	the	major	PTM	of	
tubulin.	The	red	CH3	indicate	the	methylated	residues	identified	in	this	thesis.	
6.1 CRMPs	arginine	methylation	
	CRMPs	are	heavily	phosphorylated	and	most	research	has	been	focused	on	the	relationship	between	CRMPs	phosphorylation	and	function	as	mediators	in	the	Sema3A	signalling	pathway	and	neuronal	differentiation,	see	review	by	(Schmidt	and	Strittmatter,	2007).	Recently,	CRMPs	were	classified	as	the	new	MAP	for	their	ability	to	bind	and	modify	MT	functions	(Lin	et	al.,	2011).	However,	the	only	report	of	other	PTM	of	CRMPs	is	by	Guo	and	colleagues	where	a	few	methylated	arginine	residue	were	reported	(Guo	et	al.,	2014).	In	this	thesis,	novel	methylated	arginines	in	CRMP-1,	2	and	3	of	cortical	mouse	primary	neurons	were	identified	(Table	3.1).	The	location	of	CRMP-1	(R226)	and	CRMP-3	methylated	arginines	(R238	and	R270)	appear	to	be	in	the	region	
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where	monomers	bind	to	form	the	CRMP	functional	tetramer	(Wang	and	Strittmatter,	1997).	CRMP-2	methylation	of	R173	could	be	a	potential	regulation	of	the	binding	of	CRMP-2	to	smaller	molecules,	whereas	further	knowledge	of	CRMP-2	structure	is	required	to	understand	the	possible	function	of	R11	and	R63	methylation.	
6.2 Tubulin	α	and	β		R390	methylation-implication	in	neuronal	
disease	
R390	is	located	in	the	C-terminal	domain	of	tubulin,	both	in	the	α	and	β	subunits,	which	is	the	region	where	most	interaction	with	motor	proteins	and	MAPs	such	as	CRMP-2	takes	place	(Nogales,	2001).	Disturbance	of	the	structure	of	this	region	due	to	mutation	may	lead	to	a	reduction	in	the	interaction	of	tubulin	with	such	proteins.	In	the	case	of	CRMP-2,	mutations	in	the	C-terminal	region	of	tubulin	can	lead	to	a	reduction	in	axonal	growth	cone	progress	due	to	reduction	of	CRMP-2	binding	to	tubulin	heterodimers	(Fukata	et	al.,	2002).	In	this	thesis,	the	inhibition	of	methylation	by	AdOx	caused	a	reduction	to	the	amount	of	tubulin	co-immunoprecipitated	with	CRMP-2	(Figure	4.6).	Therefore,	it	is	possible	that	the	inhibition	of	methylation	of	tubulin	α	and	β	R390	was	the	cause	of	the	reduction	in	the	binding	of	CRMP-2	to	tubulin	heterodimers.		
The	implications	of	R390	in	a	range	of	severe	neuronal	disorders	may	possibly	be	due	to	its	sensitive	location	in	the	microtubule-associated	protein	domain.	This	further	emphasizes	that	arginine	methylation	at	this	position	is	one	of	the	cell’s	regulatory	tool	of	MTs	binding	to	other	proteins	such	as	CRMP-2.	Mutation	of	R390	has	been	found	in	a	3-year	old	girl	suffering	from	asymmetrical	polymicrogyria	and	mid-hindbrain	dysgenesis	(Zanni	et	al.,	2013).	In	this	case,	a	
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heterozygous	missense	mutation	in	exon	4	of	tubulin	α1A	resulted	in	R390H	(Table	6.1).	Also,	mutation	of	arginine	390	to	cysteine	in	tubulin	α	has	been	reported	to	cause	resistance	to	MT-destabilizing	drugs	colcemid	and	vinblastine	in	CHO	cells	(Table	6.1)	(Hari	et	al.,	2003).	In	another	study,	mutations	of	arginine	to	histidine	as	well	as	R390C	were	identified	in	patients	with	a	range	of	lissencephalies	(Table	6.1)	(Kumar	et	al.,	2010).	
6.3 Tubulin	α	R79	methylation	
As	discussed	previously	in	Chapter	3,	similar	to	K40,	the	position	of	R79	towards	the	inside	of	the	MT	polymer	suggests	that	it	might	be	involved	in	neuronal	differentiation	by	playing	a	role	as	guidance	cues	to	motor	proteins	(Creppe	et	al.,	2009).	However,	so	far	no	mutations	of	R79	in	neuronal	diseases	have	been	described	and	this	may	indicate	the	importance	of	this	residue.	
6.4 Tubulin	β	R62	methylation-implication	in	neuronal	disease	
Arginine	62	is	located	within	the	region	of	protofilaments	lateral	contact	when	forming	the	MT	polymer	(Nogales,	2001).	The	location	of	R62	suggests	that	disturbance	in	this	position	may	be	involved	in	MT	assembly.	Indeed,	mutation	of	arginine	62	to	glutamine	in	tubulin	βIII	was	one	of	several	other	mutations	identified	in	patients	with	congenital	fibrosis	of	extraocular	muscle	type	3	(CFEOM3)	(Table	6.1),	a	major	neuronal	disease	(Niwa	et	al.,	2013).	In	this	study,	the	mechanism	by	which	the	role	of	R62	mutation	affected	MT	function	was	not	determined.	However,	other	studies	suggested	it	might	be	due	to	its	location	within	the	lateral	contact	of	the	protofilaments	(Tischfield	and	Engle,	
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2010).	These	suggestions	of	the	role	of	R62	in	protofilament	attachment	further	support	methylation	as	a	regulator	of	MT	assembly. 
6.5 R276	and	R282	methylation-implication	in	cancer	drug	
resistance	
Crystallographic	studies	of	tubulin	suggested	that	R276	and		R282	are	part	of	a	flexible	structure	called	the	M	loop	(Nogales,	2001).	The	M	loop	in	tubulin	β,	as	discussed	previously	in	Chapter	3,	forms	part	of	the	binding	site	of	the	anticancer	drug	Taxol.	Mutations	of	R282	were	observed	to	result	in	resistance	to	anticancer	drugs	(Navarrete	et	al.,	2015).	Implication	in	disease	of	R276	has	not	been	reported	yet.	In	this	thesis,	inhibition	of	methylation	in	Neuro2a	cells	increased	the	effect	of	Taxol	by	increasing	the	number	of	cells	arrested	in	the	G2/M	phase	(Figure	4.1).	These	results	strongly	suggest	that	methylation	at	R276	and	R282	may	be	another	cause	of	resistance	to	anticancer	drugs	in	cancer	cells,	particularly	in	neuronal	cancers.	Methylation	of	R282	was	observed	in	Neuro2a	cells	as	well	as	in	primary	cortical	neurons,	suggesting	the	methylation	of	this	particular	arginine	is	indeed	present	in	cortical	neurons	and	it	is	not	a	result	of	the	transformation	into	a	cancerous	cell	line	within	the	Neuro2a	cells.	Therefore,	the	inhibition	of	R276	and	R282	methylation	could	be	a	potential	therapeutic	tool	to	increase	the	efficacy	of	anticancer	drugs	such	as	Taxol.	Although,	no	clinical	abnormalities	have	been	reported	in	relation	to	mutations	of	R282,	it	is	more	likely	that	R282	is	a	key	residue	in	MT	stability	due	to	its	location	in	the	M	loop	that	forms	part	of	the	protofilaments	lateral	contact	(Nogales,	2001).	Recently,	R282,	along	with	T274	and	Q292	were	shown	to	be	critical	for	retaining	the	M	loop	conformation	(Navarrete	et	al.,	2015).	
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Mutations	to	these	residues	caused	drastic	conformational	changes	to	the	M	loop	structure	and	negatively	affected	the	binding	to	epothilone	(Navarrete	et	al.,	2015).	Hence,	developing	a	new	derivative	of	Taxol	or	epothilone	that	does	not	require	R282	as	an	essential	residue	for	binding	to	tubulin	β	could	be	a	possible	solution	for	anticancer	drug	resistance	related	to	R282	and	its	methylation.	Also,	a	derivative	of	Taxol	or	epothilone	that	specifically	binds	to	methylated	R282	would	be	a	more	potent	anticancer	drug.	
6.6 Tubulin	β	R156	methylation	and	implication	in	disease	
Tubulin	β,	R156	has	been	detected	to	be	methylated	in	one	tubulin	β	(TUBBIII)	isotype	by	mass	spectrometry.	Therefore	it	was	hypothesized	that	R156	is	possible	a	specific	PTM	that	occurs	on	TUBBIII	and	this	would	be	consistent	with	the	tubulin	code	(Verhey	and	Gaertig,	2007).	However,	it	was	unclear	if	another	identified	isotype	tubulin	β	4A	(TUBB4A)	chain	contains	methylated	R156	as	that	region	was	not	covered	by	mass	spectrometry.	Nevertheless,	the	mutation	of	R156	to	leucine	has	been	reported	to	be	the	possible	cause	of	hypotonia	and	rotatory	nystagmus	in	a	five	month	old	female	patient	(Purnell	et	al.,	2014).	Although	it	has	not	yet	been	determined	if	R156	mutations	in	other	tubulin	β	isotypes	are	also	pathogenic,	the	discovery	of	its	involvement	in	disease	makes	the	understanding	of	potential	PTMs	of	this	residue	a	high	importance.	
6.7 Tubulin	β	R241	methylation		
Arginine	241	is	a	conserved	residue	in	both	tubulin	subunits	α	and	β,	however,	in	this	thesis	it	was	only	detected	to	be	methylated	in	tubulin	β	(Figure	3.19).	
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Although	an	involvement	of	R241	mutations	in	any	pathologies	has	not	yet	been	reported,	the	conservation	and	the	location	of	this	residue	highlights	its	importance.	R241	is	located	within	the	T7-loop	(Nogales	et	al.,	1998a).	Residues	in	this	loop	are	in	contact	with	the	nucleotide	of	the	next	subunit	in	the	protofilament	structure	and	therefore	important	for	tubulin	heterodimer	stability	(Nogales	et	al.,	1998a).		
6.8 Inhibition	of	methylation	with	AdOx	
AdOx	is	the	most	commonly	used	inhibitor	in	protein	methylation	research.	However,	as	described	previously	in	Section	1.6.2.3,	AdOx	is	an	indirect	inhibitor	of	methylation	that	acts	by	inhibiting	the	enzyme	S-Adenosyl-homocysteine	hydrolase	(SAHh)	that	is	responsible	for	the	hydrolysis	of	SAH	to	adenosine	and	homocysteine.	Homocysteine	is	then	converted	to	methionine	in	the	presence	of	vitamin	B12	(Pahlich	et	al.,	2006,	Hoffman	and	Kunz,	1977).	The	accumulation	of	SAH	therefore,	will	cause	an	inhibition	of	methylation	reactions	in	the	cell	(see	Figure	1.3)	(Pahlich	et	al.,	2006).	In	most	protein	research,	it	is	assumed	that	the	reduction	of	methylated	protein	due	to	AdOx	treatment	is	due	to	the	decrease	of	the	availability	of	methyl	groups	added	to	proteins.	Other	methylation	enzymes,	such	as	DNA	methylases	also	use	SAM	as	the	methyl	donor	(Bedford	and	Richard,	2005).	The	use	of	AdOx	could	affect	other	methylation	in	the	cell	such	as	DNA	methylation	(Bedford	and	Richard,	2005).	Hence,	it	cannot	be	excluded	that	altered	levels	of	methylation	observed	after	AdOx	treatment	are	due	to	changes	in	DNA	methylation	and	altered	protein	expression	levels.	
	 164	
Table	6.1	Summary	of	tubulin	mutations	of	the	identified	methylated	
arginine	residues	
Arginine 
position 
Alpha/ 
Beta Mutation Mutation effect 
Cell 
Type References 
390 Alpha R390C Resistance to MT-
destabilizing drugs 
CHO cell 
line 
(Hari	et	al.,	2003)	
390 Alpha R390C Lissencephalies Human 
patients 
(Kumar	et	al.,	2010)	
390 Alpha R390H Asymmetrical 
polymicrogyria and 
mid-hindbrain 
dysgenesis 
3-year old 
female 
patient 
(Zanni	et	al.,	2013)	
62 Beta R62Q CFEOM3 Human 
patients 
(Niwa	et	al.,	2013)	
156 Beta R156L  5-month 
old female 
patient 
(Purnell	et	al.,	2014)	
282 Beta R282Q Resistance to 
epothilone B 
Human 
ovarian 
cancer 
cell line 
(Giannakakou	et	al.,	2000)	
	
6.9 Future	work	
Although	several	methylation	sites	have	been	positively	identified	in	tubulin	α	and	β,	as	well	as	CRMP-1,	2	and	3	in	this	thesis,	it	is	likely	that	there	are	other	arginines	that	may	be	possible	methylation	sites.	Therefore,	further	mass	spectrometry	studies	of	those	proteins	are	required	in	order	to	obtain	greater	coverage	of	the	protein	sequences	and	determine	whether	any	of	the	remaining	arginines	are	methylated	or	not.	The	use	of	immuno-purified	proteins	can	enhance	the	chances	of	obtaining	better	scores	and	coverage	using	mass	spectrometry	however,	more	specific	antibodies	than	Asym24	need	to	be	utilised.		
Arginine	methylation	of	the	CRMP	family	members	needs	further	investigation.	It	would	be	interesting	to	determine	whether	the	other	members	of	the	CRMP	family	carry	arginine	methylations.	Furthermore,	over	expressing	CRMP-2	with	
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mutated	arginines	would	help	to	determine	the	involvement	of	CRMP-2	methylation	in	CRMP-2/tubulin	binding	and	ultimately	in	axonal	growth.	
It	would	be	of	great	interest	to	determine	whether	the	effect	of	AdOx	on	the	interaction	between	CRMP-2	and	tubulin	heterodimers	and	the	reduction	of	axonal	length	in	primary	neurons	is	due	to	the	methylation	inhibition	rather	than	other	effects	by	AdOx.	This	could	be	achieved	by	performing	site	directed	mutagenesis	to	replace	the	arginine	of	interest	with	another	amino	acid	such	as	alanine	or	cysteine.	Furthermore,	immunostaining	to	distinguish	axons	from	dendrites	could	be	used	to	positively	identify	axons.	
Similarly,	site	directed	mutagenesis	of	R282	and	R276	in	Neuro2a	cells	could	be	used	to	test	the	effect	of	removing	this	arginine	on	Taxol	binding	to	tubulin	β.	It	would	also	be	interesting	to	investigate	the	methylation	status	of	tubulin	in	other	brain	cancer	and	non-neuronal	cancer	cell	lines.		
In	addition,	the	inhibition	of	PRMT1	and	PRMT8	by	PRMT1/8	inhibitor	was	only	performed	in	Neuro2a	cells.	Therefore,	using	this	inhibitor	in	primary	neurons	would	be	the	next	step	to	obtain	a	better	understanding	of	the	function	of	these	two	PRMTs	in	primary	neurons.		
6.10 Conclusion	
This	thesis	has	revealed	several	novel	methylated	arginine	residues	in	three	members	of	the	CRMP	family,	CRMP-1,	2	and	3	and	in	tubulin	α	and	β	subunits	in	mouse	cortical	neurons.	The	methylated	arginines	in	both	tubulin	α	and	β	are	distributed	in	various	functional	regions	of	tubulin.	Tubulin	arginine	methylation	has	been	shown	to	be	a	potential	regulator	of	different	aspects	of	
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MT	function	as	well	as	MT	stability	and	polymerisation.	Three	of	the	four	identified	methylated	arginine	residues	have	been	reported	in	either	drug-resistant	cells	and/or	from	patients	with	neurological	malformations	or	disorders,	suggesting	that	arginine	methylation	might	be	another	important	player	regulating	both	MT	dynamics	and	tubulin	protein-protein	interactions.	Therefore,	considering	tubulin	arginine	methylation	will	be	essential	in	any	future	attempts	to	untangle	the	tubulin	code	and	in	the	design	of	novel	anti-cancer	drugs.		
The	relationship	between	PRMT1	and	PRMT8	and	tubulin	α	methylation	was	investigated	and	it	was	shown	that	PRMT1	and	8	could	possibly	work	as	a	complex	that	methylates	tubulin	α.	Identifying	tubulin	α	as	a	possible	substrate	of	PRMT1	or	PRMT8	will	further	broaden	the	knowledge	in	the	relationship	between	arginine	methylation	and	MT	function.	This	knowledge	will	create	new	targets	for	developing	drugs	that	may	regulate	the	specific	PRMT	by	regulating	its	own	substrate,	in	this	case,	tubulin	α.	
Also,	identifying	methylated	arginine	residues	in	CRMPs	will	shed	more	light	on	the	function	of	this	family	of	proteins	in	regulating	axonal	growth	and	provide	a	better	understanding	of	neuronal	function	and	neurodegenerative	disease.		 	
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Appendix	A Chapter	2	and	3	supporting	data	
	
Figure	A.1	The	effect	of	AdOx	treatment	on	primary	cortical	neurons.	Western	blot	of	whole	cell	lysates	treated	with	AdOx	(5,	25	and	50	µM	using	Asym24	primary	antibody	specific	for	proteins	with	asymmetrically	di-methylated	arginines	(A)	GAPDH	(as	housekeeping	protein)	(B).	Non-relevant	lanes	contained	samples	not	relevant	to	this	experiment.		
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Figure	A.2	CRMP-2	is	asymmetrically	di-methylated.		Independent	repeat	Western	blot	with	Asym24	primary	antibody	of	mouse	primary	cortical	whole	cell	lysate	used	as	an	IP	input	and	the	elution	fraction	off	the	CRMP-2	IP	column	(A).	Western	blot	with	CRMP-2	primary	antibody	of	mouse	primary	cortical	whole	cell	lysate	(IP	input)	and	the	elution	fraction	off	the	Asym24	IP	column	(B).	Both	elution	fractions	in	A	and	B	show	a	single	band	at	approximately	62	kDa	(see	arrow).		
	 192	
	
Figure	A.3	Tubulin	α	and	β	are	asymmetrically	di-methylated.	Independent	Western	blot	of	mouse	primary	cortical	neuronal	whole	cell	lysates	input	and	eluted	fractions	from	tubulin	α1A	antibody	IP	column	probed	with	Asym24	antibody	and	Western	blot	of	Asym24	IP	column	eluted	fraction	probed	with	tubulin	β	antibody	(A).	From	tubulin	βIII	antibody	IP	column	probed	with	Asym24	antibody	and	Western	blot	of	Asym24	IP	column	eluted	fraction	probed	with	tubulin	βIII	antibody	(B).	Black	arrow	indicates	tubulin	at	55	kDa.	(A)	and	(B)	are	independent	repeats	of	the	data	displayed	in	Figure	3.14	and	3.15.		
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Figure	A.4	Mass	spectrum	of	methylated	R267	in	CRMP-1.	MS/MS	spectrum	of	methylated	R267	identified	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	70	kDa	was	digested	with	chymotrypsin.	Mass	of	the	neutral	peptide	was	2996.4913	kDa	and	the	ion	score	was	13.	
	
	
Figure	A.5	Mass	spectrum	of	methylated	R238	and	R270	in	CRMP-3.		MS/MS	spectrum	of	methylated	R238	and	R270	identified	from	mouse	primary	cortical	neurons	using	whole	cell	lysate	separated	on	SDS-PAGE.	The	excised	band	at	70	kDa	was	digested	with	chymotrypsin.	Mass	of	the	neutral	peptide	was	4247.3585	kDa	and	the	ion	score	was	10.	 	
	 194	
Table	A.1	Proteins	identified	by	mass	spectrometry	to	contain	methylated	
arginines	
Protein MS score Coverage % 
Peptide with methylated 
arginine 
ATP synthase 
subunit beta 1018 32-56 
95LVLEVAQHLGESSVR109 
352GSITSVQAIYVPADDLTDPAPA 
TSFAHLDATTVLSR388        
ATP synthase 
subunit alpha 643 20-33 
403GIRPAINAGISVSR316 
Pyruvate kinase 
isozymes 
M1/M2 
891 20-41 93TATESFASDPILYRPVAVALDTK115 *The	methylated	arginine	are	shown	as	underlined	(R).				 	
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Appendix	B Chapter	4	supporting	data			
Table	B.1	Percentage	of	Neuro2a	cells	in	cell	cycle	phases	as	obtained	from	
flow	cytometry	analysis	used	to	generate	Figure	4.1.	
Number of 
experiment Treatment 
Phase (%) 
G1 S G2/M 
1 DMSO 44.1 43 10.2 
1 DMSO 34.8 52 9.83 
1 Taxol 34 5.3 57.5 
1 Taxol 31 11 54 
1 Both 4 17.4 67 
1 AdOx 28 55 8 
1 AdOx 22 63 10 
2 DMSO 40 44 14 
2 DMSO 39 35 16 
2 Taxol 16 12 65 
2 Taxol 23 9 67 
2 Taxol and AdOx 10 15 71 
2 Taxol and AdOx 8 13.5 65 
2 AdOx 12 75 8 
2 AdOx 20 52 2 
3 DMSO 50 39 10 
3 DMSO 43 35 14 
3 Taxol 24 27 41 
3 Taxol 25 28 38 
3 Taxol and AdOx 21 24 52 
3 Taxol and AdOx 22 24 54 
3 AdOx 11 84 5 
3 AdOx 13.5 82 6 
4 DMSO 52 39 4 
4 DMSO 55 32 10 
4 Taxol 20 13 63 
4 Taxol 23 10 65 
4 Taxol and AdOx 10 6 77 
4 Taxol and AdOx 11 12 75 
4 AdOx 10.8 62.4 24.1 
4 AdOx 12 55 20 
5 DMSO 72 13 13 
5 DMSO 73 15 10 
5 Taxol 21 12.4 54.3 
5 Taxol 10.6 13 55 
5 Taxol and AdOx 8 13 70 
5 Taxol and AdOx 9 11 76 
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Number of 
experiment Treatment 
Phase (%) 
G1 S G2/M 
5 AdOx 24 41 20 
5 AdOx 24 43 18 
6 DMSO 75 15 12 
6 DMSO 77 18 0 
6 Taxol 21 37 43 
6 Taxol 23 39 40 
6 Taxol and AdOx 23 9 77 
6 Taxol and AdOx 17 8 80 		 	
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Figure	B.1	AdOx	treatment	reduces	asymmetric	arginine	di-methylation	of	
tubulin	α	in	primary	mouse	cortical	neurons.	Independent	repeat	Western	blot	using	Asym24	and	tubulin	α1A	primary	antibodies	of	the	eluted	fractions	from	the	tubulin	α1A		IP	column	of	primary	mouse	cortical	neuronal	cell	lysate	treated	with	25	µM	AdOx	for	4	days.	The	band	correspondent	to	tubulin	at	approximately	55	kDa	is	indicated	by	the	black	arrows.		 	
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Table	B.2	Band	density	calculated	by	ImageJ	from	Western	blots	in	
Figure	B.1	and	figure	Figure	4.2	
 Asym24 
Repeat # Control AdOx 
1 3505.16 1621.889 
2 2060 528.388 
 Tubulin α 
Repeat # Control AdOx 
1 3758.401 3123.338 
2 1508.539 1575.459 
 Asym24/ Tubulin α 
Repeat # Control AdOx 
1 0.932620016 0.519280654 
2 1.365559657 0.335386703 
Average 1.149089837 0.427333679 
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Figure	B.2	AdOx	treatment	reduces	asymmetric	arginine	di-methylation	of	
tubulin	β	in	primary	mouse	cortical	neurons.	Independent	repeat	Western	blots	using	Asym24	and	tubulin	βIII	primary	antibodies	of	the	eluted	fractions	from	the	tubulin	βIII	IP	column	of	primary	mouse	cortical	neuronal	cell	lysates	treated	with	25	µM	AdOx	for	4	days.	The	band	correspondent	to	tubulin	at	approximately	55	kDa	is	indicated	by	the	black	arrows.				 	
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Table	B.3	Band	density	calculated	by	ImageJ	from	Western	blots	in	
Figure	B.2	and	Figure	4.2		
 Asym24 
Repeat # Control AdOx 
1 3500.19 1003.62 
2 2941.061 1506.06 
 Tubulin β 
Repeat # Control AdOx 
1 1696.163 1291.991 
2 1523.7096 1585.6166 
 Asym24/Tubulin β 
Repeat # Control AdOx 
1 2.063592945 0.776801077 
2 1.930197854 0.94982608 
Average 1.996895399 0.863313579 		 	
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Table	B.4	Axonal	length	measurements	obtained	by	Simple	Neurite	Tracer	
and	used	in	Figure	4.4	
Neuron 
No. Treatment Axonal Length (µm) Cell body area (µm
2) 
1 Control 122.64 311.765 
2 Control 100.787 331.401 
3 Control 98.117 211.332 
4 Control 116.126 265.225 
5 Control 122.114 352.855 
6 Control 76.014 303.633 
7 Control 44.796 333.91 
8 Control 76.081 197.232 
9 Control 90.867 297.405 
10 Control 109.208 313.062 
11 Control 100.97 255.969 
12 Control 174.764 311.505 
13 Control 232.494 337.63 
14 Control 331.066 399.135 
15 Control 217.669 204.239 
16 Control 217.665 227.336 
17 Control 154.547 327.595 
18 Control 106.081 339.446 
19 Control 176.26 451.99 
20 Control 267.357 310.208 
21 Control 116.429 267.647 
22 Control 335.854 348.183 
23 Control 37.915 300.173 
24 Control 101.739 290.571 
25 Control 77.141 283.651 
26 Control 47.314 310.208 
27 Control 44.216 267.647 
28 Control 227.911 348.183 
29 Control 210.116 300.173 
30 Control 217.942 290.571 
31 Control 142.941 283.651 
32 Control 263.545 276.99 
33 Control 122.177 323.875 
34 Control 182.039 270.761 
35 Control 185.056 307.093 
36 Control 85.031 297.664 
37 Control 151.685 370.242 
38 Control 166.288 263.754 
39 Control 170.184 262.63 
40 Control 86.701 244.377 
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Neuron 
No. Treatment Axonal Length (µm) Cell body area (µm
2) 
41 Control 121.742 294.031 
42 Control 131.861 290.484 
43 Control 47.746 429.412 
44 Control 123.421 273.356 
45 Control 78.547 348.097 
46 Control 247.425 281.142 
47 Control 208.877 247.232 
48 Control 295.556 350.865 
49 Control 199.128 266.609 
50 Control 126.072 233.737 
51 Control 83.482 286.851 
52 Control 71.638 278.201 
53 Control 98.898 314.273 
54 Control 40.241 321.453 
55 Control 134.613 233.737 
56 Control 147.824 286.851 
57 Control 176.139 278.201 
58 Control 120.913 314.273 
59 Control 227.703 321.453 
60 Control 137.823 441.003 
61 Control 181.573 291.522 
62 Control 117.705 239.706 
63 Control 110.341 265.138 
64 Control 139.662 368.772 
65 Control 126.914 238.581 
66 Control 141.057 340.398 
67 Control 141.231 266.696 
68 Control 173.349 445.761 
69 Control 164.886 352.855 
70 Control 191.339 392.993 
71 Control 250.578 456.834 
72 Control 336.753 360.813 
73 Control 233.273 343.166 
74 Control 229.882 297.059 
75 Control 163.049 274.913 
76 Control 81.249 237.803 
77 Control 117.719 393.339 
78 Control 167.352 266.955 
79 Control 269.875 253.633 
80 Control 167.055 257.266 
81 Control 172.829 375.346 
82 Control 91.564 342.042 
83 Control 249.564 289.706 
84 Control 238.218 330.623 
85 Control 410.802 279.325 
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Neuron 
No. Treatment Axonal Length (µm) Cell body area (µm
2) 
86 Control 184.430 330.277 
87 Control 147.980 309.602 
88 Control 268.421 336.851 
89 Control 171.555 369.723 
90 Control 111.015 348.875 
91 Control 95.458 383.997 
92 Control 115.22 375.26 
93 Control 81.722 343.426 
94 Control 211.959 386.592 
95 Control 174.362 286.505 
96 Control 174.835 266.955 
97 Control 177.323 253.633 
98 Control 110.962 257.213 
99 Control 210.474 392.993 
100 Control 51.674 456.834 
101 Control 238.591 360.813 
102 Control 145.58 238.571 
103 Control 87.743 340.698 
104 Control 134.943 346.842 
105 Control 102.453 395.891 
106 AdOx (25µM) 41.778 291.696 
107 AdOx (25µM) 65.424 299.870 
108 AdOx (25µM) 46.703 450.000 
109 AdOx (25µM) 62.223 379.152 
110 AdOx (25µM) 35.018 304.412 
111 AdOx (25µM) 41.274 272.880 
112 AdOx (25µM) 51.808 465.182 
113 AdOx (25µM) 43.887 263.669 
114 AdOx (25µM) 76.754 280.017 
115 AdOx (25µM) 79.451 312.197 
116 AdOx (25µM) 43.523 242.648 
117 AdOx (25µM) 73.344 219.551 
118 AdOx (25µM) 27.605 267.431 
119 AdOx (25µM) 10.081 212.933 
120 AdOx (25µM) 10.746 216.437 
121 AdOx (25µM) 27.418 248.616 
122 AdOx (25µM) 27.658 366.306 
123 AdOx (25µM) 19.170 382.266 
124 AdOx (25µM) 8.937 413.409 
125 AdOx (25µM) 14.004 217.475 
126 AdOx (25µM) 30.415 369.551 
127 AdOx (25µM) 21.606 359.559 
128 AdOx (25µM) 11.427 313.106 
129 AdOx (25µM) 7.633 323.357 
130 AdOx (25µM) 41.279 258.218 
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Neuron 
No. Treatment Axonal Length (µm) Cell body area (µm
2) 
131 AdOx (25µM) 116.735 339.707 
132 AdOx (25µM) 28.217 313.625 
133 AdOx (25µM) 43.561 298.703 
134 AdOx (25µM) 69.262 302.726 
135 AdOx (25µM) 36.590 336.722 
136 AdOx (25µM) 80.122 238.625 
137 AdOx (25µM) 93.446 260.424 
138 AdOx (25µM) 25.764 315.182 
139 AdOx (25µM) 72.871 263.409 
140 AdOx (25µM) 79.005 316.350 
141 AdOx (25µM) 33.755 300.000 
142 AdOx (25µM) 50.0316 401.471 
143 AdOx (25µM) 87.923 380.45 
144 AdOx (25µM) 76.941 389.274 
145 AdOx (25µM) 91.899 305.450 
146 AdOx (25µM) 38.507 350.217 
147 AdOx (25µM) 75.238 315.572 
148 AdOx (25µM) 32.802 305.321 
149 AdOx (25µM) 123.223 488.798 
150 AdOx (25µM) 108.780 305.321 
151 AdOx (25µM) 66.050 488.798 
152 AdOx (25µM) 80.090 314.144 
153 AdOx (25µM) 88.060 368.642 
154 AdOx (25µM) 115.120 346.194 
155 AdOx (25µM) 87.160 358.781 
156 AdOx (25µM) 68.220 223.659 
157 AdOx (25µM) 65.570 393.167 
158 AdOx (25µM) 136.140 505.536 
159 AdOx (25µM) 101.170 209.732 
160 AdOx (25µM) 182.360 254.152 
161 AdOx (25µM) 80.490 395.243 
162 AdOx (25µM) 50.790 380.969 
163 AdOx (25µM) 130.220 254.844 
164 AdOx (25µM) 126.183 399.783 
165 AdOx (25µM) 40.174 327.553 
166 AdOx (25µM) 11.022 392.388 
167 AdOx (25µM) 90.594 324.914 
168 AdOx (25µM) 52.341 455.061 
169 AdOx (25µM) 55.131 430.926 
170 AdOx (25µM) 95.568 356.705 
171 AdOx (25µM) 80.932 327.899 
172 AdOx (25µM) 65.110 298.572 
173 AdOx (25µM) 41.643 386.289 
174 AdOx (25µM) 23.527 382.526 
175 AdOx (25µM) 86.485 407.570 
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Neuron 
No. Treatment Axonal Length (µm) Cell body area (µm
2) 
176 AdOx (25µM) 162.651 448.443 
177 AdOx (25µM) 89.323 363.063 
178 AdOx (25µM) 92.854 378.633 
179 AdOx (25µM) 49.275 246.150 
180 AdOx (25µM) 42.416 330.148 
181 AdOx (25µM) 26.750 408.996 
182 AdOx (25µM) 55.110 199.017 
183 AdOx (25µM) 158.893 370.848 
184 AdOx (25µM) 147.459 294.464 
185 AdOx (25µM) 160.743 304.975 
186 AdOx (25µM) 86.432 249.222 
187 AdOx (25µM) 140.033 303.591 
188 AdOx (25µM) 118.113 259.732 
189 AdOx (25µM) 121.757 273.097 
190 AdOx (25µM) 93.065 359.688 
191 AdOx (25µM) 114.825 324.914 
192 AdOx (25µM) 126.144 255.061 
193 AdOx (25µM) 96.983 330.926 
194 AdOx (25µM) 39.680 356.705 
195 AdOx (25µM) 63.361 327.899 
196 AdOx (25µM) 105.683 398.572 
197 AdOx (25µM) 45.434 314.144 
198 AdOx (25µM) 51.366 368.642 
199 AdOx (25µM) 96.535 346.194 
200 AdOx (25µM) 68.160 358.781 
201 AdOx (25µM) 58.664 323.659 
202 AdOx (25µM) 81.734 293.167 
203 AdOx (25µM) 66.722 215.536 
204 AdOx (25µM) 99.320 287.573 
205 AdOx (25µM) 59.178 212.266 
206 AdOx (25µM) 31.221 207.308 
207 AdOx (25µM) 51.925 362.333 
208 AdOx (25µM) 62.577 301.358 
209 AdOx (25µM) 72.000 335.667 
210 AdOx (25µM) 48.020 220.341 			 	
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Table	B.5	Cell	count	of	primary	cortical	neurons	after	4-day	treatment	
with	AdOx	used	in		Figure	4.5		
 Control (x1000) 
Repeat # Live Dead 
1 530 115 
2 405 95 
3 500 110 
4 365 90 
Average 450 102.5 
STDEV 77.78 11.90 
SEM 38.89 5.95 
 AdOx (x1000) 
Repeat # Live Dead 
1 190 50 
2 155 75 
3 210 55 
4 185 50 
Average 185 57.5 
STDEV 22.73 11.90 
SEM 11.37 5.95 		
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Figure	B.3	AdOx	treatment	reduces	the	binding	of	tubulin	to	CRMP-2.	Two	independent	experiments	of	Western	blots	with	CRMP-2,	tubulin	α	and	tubulin	
β	primary	antibodies	(A	and	B).	In	each	Western	blot	control	represents	the	elution	fraction	of	the	non-treated	primary	cortical	neuronal	whole	cell	lysates	from	the	CRMP-2	IP	column	and	AdOx	represents	the	elution	fraction	of	the	25	
µM	AdOx	treated	ones	from	the	same	CRMP-2	column.				 	
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Table	B.6	Band	density	calculated	by	ImageJ	from	Western	blots	in	
Figure	B.3	and	Figure	4.6	
Tubulin α 
Repeat # Control AdOx 
1 7266.841 2722.477 
2 9858.347 3963.326 
3 8901.154 3519.962 
Tubulin β 
Repeat # Control AdOx 
1 5984.648 2655.284 
2 6570.79 1933.284 
3 5478.255 2236.305 
CRMP-2 
Repeat # Control AdOx 
1 6311.154 6298.447 
2 4273.577 5017.941 
3 2815.92 3313.698 
Tubulin α/CRMP 
Repeat # Control AdOx 
1 1.151428249 0.432245758 
2 2.306813941 0.789831128 
3 3.161010966 1.062245865 
Average 2.206417719 0.761440917 
STDEV 1.008546095 0.315958125 
SEM 0.582284359 0.182418509 
Tubulin β/CRMP 
Repeat # Control AdOx 
1 0.948265246 0.421577573 
2 1.537538694 0.385274359 
3 1.945458323 0.674866871 
Average 1.477087421 0.493906267 
STDEV 0.501337487 0.157764178 
SEM 0.289447333 0.091085191 
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Appendix	C Chapter	5	supporting	data		
	
Figure	C.1	PRMT1,	8	and	KIF	11	knock-down	with	esiRNA	in	Neuro2a	cells.	Two	independent	repeats	of	Western	blots	with	PRMT1,	8,	KIF11	and	GAPDH	primary	antibodies	which	all	show	successful	decrease	in	the	respective	protein	amount	present	after	esiRNA	treatment	(A	and	B).	GAPDH	was	used	as	a	house	keeping	protein	and	loading	control.		
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Table	C.1	Band	density	calculated	using	ImageJ	from	Western	blots	in	
Figure	C.1	and	Figure	5.1	
 Control esiRNA Control esiRNA Control esiRNA 
Repeat # PRMT1 PRMT8 KIF11 
1 5644.43 1776.77 2647.75 702.41 1642.75 988.11 
2 1715.04 707.34 6445.18 1320.82 2570.92 264.97 
3 5310.01 1763.48 6127.06 4885.72 7735.84 4322.89 
 GAPDH 
Repeat # PRMT1 PRMT8 KIF11 
1 1081.70 1325.11 1004.82 812.11 3744.94 4139.16 
2 411.68 379.09 3665.50 3298.50 3657.70 3943.92 
3 2305.72 2674.48 2063.00 1948.45 3112.75 3298.94 
 RPRMT/GAPDH 
Repeat # PRMT1 PRMT8 KIF11 
1 5.22 1.34 2.64 0.86 0.44 0.24 
2 4.17 1.87 1.76 0.40 0.70 0.07 
3 2.30 0.66 2.97 2.51 2.49 1.31 
Average 3.90 1.29 2.45 1.26 1.21 0.54 
STDEV 1.48 0.60 0.63 1.11 1.11 0.67 
SEM 0.85 0.35 0.36 0.64 0.64 0.39 	
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Figure	C.2	Western	blot	of	whole	cell	lysates	from	Neuro2a	cells	with	
knocked	down	PRMT1,	8	or	both.	Independent	repeats	of	Western	blots	with	Asym24	and	GAPDH	primary	antibodies.	In	the	repeats	there	is	a	visible	decrease	in	the	intensity	of	bands	at	130,	70	and	55	kDa	(A	and	B).	These	are	independent	repeats	of	data	shown	in	Figure	5.2.		
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Table	C.2	Band	density	of	bands	at	130,	70	and	55	kDa	calculated	using	
ImageJ	from	Western	blots	in	Figure	C.2	and	Figure	5.2	
				 	
Band at 55 kDa 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 468.80 551.21 226.85 111.90 
2 974.80 525.09 578.97 254.14 
3 776.11 627.65 504.92 172.85 
Band at 70 kDa 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 1261.50 1607.91 663.52 292.58 
2 439.63 450.11 319.99 226.63 
3 690.41 638.69 664.11 153.82 
Band at 130 kDa 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 1017.65 968.34 313.82 293.73 
2 613.63 465.53 317.58 262.26 
3 655.00 644.27 342.66 179.46 
GAPDH 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 4084.60 5156.89 5246.89 5525.53 
2 6160.21 4508.59 5158.40 6186.62 
3 2577.97 1962.60 2162.52 3889.53 
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Table	C.3	The	ratio	of	band	densities	of	proteins	at	55,	70	and	130	kDa	to	
that	of	GAPDH	calculated	from	Table	C.2	
55 kDa/GAPDH 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 0.11 0.11 0.04 0.02 
2 0.16 0.12 0.11 0.04 
3 0.30 0.32 0.23 0.04 
Average 0.19 0.18 0.13 0.04 
STDEV 0.10 0.12 0.10 0.01 
SEM 0.06 0.07 0.06 0.01 
70 kDa/GAPDH 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 0.31 0.31 0.13 0.05 
2 0.07 0.10 0.06 0.04 
3 0.27 0.33 0.31 0.04 
Average 0.22 0.25 0.17 0.04 
STDEV 0.13 0.13 0.13 0.01 
SEM 0.07 0.07 0.07 0.01 
130 kDa/GAPDH 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 0.25 0.19 0.06 0.05 
2 0.10 0.10 0.06 0.04 
3 0.25 0.33 0.16 0.05 
Average 0.20 0.21 0.09 0.05 
STDEV 0.09 0.11 0.06 0.01 
SEM 0.05 0.07 0.03 0.00 			 	
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Figure	C.3	Asymmetric	arginine	di-methylation	of	tubulin	α1A	is	reduced	
when	both	PRMT1	and	8	are	knocked	down	simltaneously.	Independent	repeats	with	Asym24	and	tubulin	α1A	primary	antibodies	of	the	eluted	fractions	from	the	tubulin	α1A		IP	column	of	PRMT1/8	knock-down	Neuro2a	cell	lysates	and	control	(A	and	B).	In	the	repeats	there	is	a	visible	decrease	in	the	intensity	of	tubulin	α	band	in	the	esiRNA	treated	sample.		
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Table	C.4	Methylated	tubulin	α	and	GAPDH	band	densities	calculated	using	
ImageJ	from	Western	blots	in	Figure	C.3	and	Figure	5.3	
Asym24 
Repeat # Control esiRNA PRMT1/8 
1 2267.477 1109.335 
2 2663.761 1336.761 
3 513.584 318.424 
Tubulin α 
Repeat # Control esiRNA PRMT1/8 
1 4563.82 4708.991 
2 5784.335 6030.284 
3 2054.335 2273.698 
Asym24/ Tubulin α 
Repeat # Control esiRNA PRMT1/8 
1 0.50 0.24 
2 0.46 0.22 
3 0.25 0.14 
Average 0.40 0.20 
STDEV 0.13 0.05 
SEM 0.08 0.03 		
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Figure	C.4	Tubulin	α1A	asymmetric	arginine	di-methylation	is	not	affected	
by	the	knock-down	of	PRMT1	or	8.	Independent	repeats	of	Western	blots	of	the	eluted	fractions	from	the	tubulin	α1A		IP	column	of	PRMT1	or	8	knocked	down	Neuro2a	cell	lysates	using	Asym24	and	Tubulin	α1A	primary	antibodies.	(A	and	B).	Black	arrows	indicate	tubulin	α	at	approximately	55	kDa.			 	
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Table	C.5	Tubulin	α	and	Asym24	band	densitiesC.	calculated	using	ImageJ	
from	Western	blots	in	Figure	C.4	and	Figure	5.4	
 Tubulin α 
Repeat # Control PRMT1 PRMT8 
1 22096.439 20765.125 20740.468 
2 5430.062 6270.77 6012.376 
3 8722.065 7542.120 7704.014 
 Asym24 
Repeat # Control PRMT1 PRMT8 
1 3210.598 2586.062 2640.648 
2 4996.770 4518.527 5338.841 
3 3728.134 4572.093 3313.105 
 Asym24/Tubulin α 
Repeat # Control PRMT1 PRMT8 
1 0.14529934 0.124538716 0.127318631 
2 0.920204963 0.720569723 0.887975236 
3 0.427437081 0.606207936 0.430049193 
Average 0.497647128 0.483772125 0.48178102 
STDEV 0.39219481 0.316316513 0.382957901 
SEM 0.083616214 0.067438907 0.081646899 		 	
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Figure	C.5	The	effect	of	PRMT1,	PRMT8	or	both	PRMT1/8	knock-down	on	
CRMP-2	and	tubulin	α	binding	in	Neuro2a	cell.	Independent	Western	blots	(A	and	B)	with	CRMP-2	and	tubulin	α1A	primary	antibodies	of	PRMT1,	PRMT8	or	both	PRMT1/8	knock-down	Neuro2a	cell	lysate	fractions	eluted	from	the	CRMP-2	IP	column.	These	are	independent	repeats	of	the	data	shown	in	Figure	5.5.				 	
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Table	C.6	Tubulin	α	and	CRMP2	band	densities	calculated	using	ImageJ	
from	Western	blots	in	Figure	C.5	and	Figure	5.5	
 Tubulin α 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 2534.13 6198.50 9710.50 6969.79 
2 3641.96 2689.38 5574.50 2621.96 
3 986.58 1440.70 4354.18 1732.36 
 CRMP-2 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 2449.41 3222.70 3211.46 3357.28 
2 2314.58 3121.99 1981.99 2927.82 
3 2182.82 2507.62 1734.39 2683.43 
 Tubulin α/CRMP-2 
Repeat # Control PRMT1 KD PRMT8 KD PRMT1/8 KD 
1 1.49 1.92 3.02 2.08 
2 1.09 0.86 3.21 0.90 
3 0.45 0.57 2.51 0.65 
Average 1.01 1.12 2.92 1.21 
STDEV 0.52 0.71 0.36 0.76 
SEM 0.30 0.41 0.21 0.44 
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Table	C.7	Flow	Percentage	of	Neuro2a	cells	in	the	cell	cycle	phases	as	
obtained	from	flow	cytometery	and	used	to	generate	Figure	5.9	
  Phase (%) Folds 
Repeat # Treatment G1 S G2/M G1 S G2/M 
1 DMSO 75 15 12 1.00 1.00 1.00 
1 Inhibitor 36 53 7 0.48 3.53 0.58 
1 taxol 21 37 43 0.28 2.47 3.58 
2 DMSO 77 18 11 1.00 1.00 1.00 
2 Inhibitor 38 36 14 0.49 2.00 1.27 
2 taxol 23 39 40 0.30 2.17 3.64 
3 DMSO 72 13 13 1.00 1.00 1.00 
3 Inhibitor 59 30 6 0.82 2.31 0.46 
3 taxol 21 12.4 54.3 0.29 0.95 4.18 
4 DMSO 73 15 10 1.00 1.00 1.00 
4 Inhibitor 39 33 17 0.53 2.20 1.70 
4 taxol 10.6 13 55 0.27 0.39 3.24 
5 DMSO 38 49 9 1.00 1.00 1.00 
5 Inhibitor 38 53 7 1.00 1.08 0.78 
5 taxol 11 35 39 0.29 0.66 5.57 
6 DMSO 39 50 10 1.00 1.00 1.00 
6 Inhibitor 39 47 9 1.00 0.94 0.90 
6 taxol 10 31 47 0.26 0.66 5.22 	 	
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Table	C.8	Cell	count	of	Neuro2a	cells	treated	with	and	PRMT1/8	inhibitor	
used	to	generate	Figure	5.8	
DMSO 
Repeat # Live Dead 
1 2955 75 
2 2065 20 
3 2505 50 
Average 2508.33 48.33 
STDEV 445.01 27.54 
SEM 256.93 15.90 
1 µM PRMT1/8 inhibitor 
Repeat # Live Dead 
1 1740 165 
2 1995 35 
3 2025 75 
Average 1920.00 91.67 
STDEV 156.60 66.58 
SEM 90.42 38.44 
1.5 µM PRMT1/8 inhibitor 
Repeat # Live Dead 
1 1305 85 
2 1445 70 
3 1225 65 
Average 1325.00 73.33 
STDEV 111.36 10.41 
SEM 64.29 6.01 
2 µM PRMT1/8 inhibitor 
Repeat # Live Dead 
1 145 470 
2 160 745 
3 110 550 
Average 138.33 588.33 
STDEV 25.66 141.45 
SEM 14.81 81.67 	
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Figure	C.6	The	effect	of	10	µM	PRMT1/8	inhibitor	on	Neuro2a	cell	
phenotype	and	asymmetric	arginine	di-methylation.		Microscopic	images	of	Neuro2a	cells	with	0.1%	DMSO	(control)	(A)	or	after	24	hr	treatment	with	10	
µM	of	the	PRMT1/8	inhibitor	for	24	hr	(B).	Scale	bars	are	100	µm.	Western	blot	of	whole	cell	lysates	of	control	and	10	µM	PRMT1/8	inhibitor	treated	Neuro2a	cells	probed	with	Asym24	primary	antibody	(C).	GAPDH	Western	blot	of	the	same	samples	as	in	(C)	used	as	loading	control	(D).	These	images	and	Western	blots	are	independent	repeats	of	Figure	5.6.			 	
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Figure	C.7	The	effect	of	PRMT1/8	inhibitor	on	the	symmetric	methylation	
in	Neuro2a	cells.	Independent	Western	blots	(A	and	B)	with	Sym10	primary	antibody	of	Neuro2a	cell	whole	cell	lysates	treated	with	1.5	µM	PRMT1/8	inhibitor	or	3	days.	These	Western	blots	are	independent	repeats	of	the	data	shown	in	Figure	5.10	A.	
		 	
	 224	
	
Figure	C.8	The	effect	of	PRMT1/8	inhibitor	on	the	asymmetric	di-
methylation	in	Neuro2a	cells.	Independent	Western	blots	(A	and	B)	with	Asym24	primary	antibody	of	Neuro2a	cell	whole	cell	lysates	treated	with	1.5	
µM	PRMT1/8	inhibitor	for	3	days.	These	Western	blots	are	independent	repeats	of	the	data	shown	in	Figure	5.10	B.	
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Figure	C.9	The	effect	of	PRMT1/8	inhibitor	on	the	PRMT1	protein	level	in	
Neuro2a	cells.	Independent	Western	blots	(A	and	B)	with	PRMT1	primary	antibody	of	Neuro2a	cell	whole	cell	lysates	treated	with	1.5	µM	PRMT1/8	inhibitor	for	3	days.	These	Western	blots	are	independent	repeats	of	the	data	shown	in	Figure	5.11	A.		
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Figure	C.10	The	effect	of	PRMT1/8	inhibitor	on	the	PRMT8	protein	level	in	
Neuro2a	cells.	Independent	Western	blots	(A	and	B)	with	PRMT8	primary	antibody	of	Neuro2a	cell	whole	cell	lysates	treated	with	1.5	µM	PRMT1/8	inhibitor	for	3	days.	These	Western	blots	are	independent	repeats	of	data	shown	in	Figure	5.11	A.			 	
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Figure	C.11	The	effect	of	PRMT1/8	inhibitor	on	the	PRMT5	protein	levels	
in	Neuro2a	cells.	Independent	Western	blots	(A	and	B)	with	PRMT5	antibody	of	Neuro2a	cell	whole	cell	lysates	treated	with	1.5	µM	PRMT1/8	for	3	days.	These	Western	blots	are	independent	repeats	of	data	shown	in	Figure	5.11	A.			
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Figure	C.12	GAPDH	protein	levels	in	Neuro2a	cells	in	Neuro2a	cells	after	
treatment	with	PRMT1/8	inhibitor.	Independent	Western	blots	(A	and	B)	with	GAPDH	primary	antibody	of	Neuro2a	cell	whole	cell	lysates	treated	with	1.5	µM	PRMT1/8	inhibitor	for	3	days.	These	Western	blots	are	independent	repeats	of	the	data	shown	in	Figure	5.11	A.		
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Table	C.9	PRMT1,	5,	8	and	GAPDH	band	densities	calculated	using	ImageJ	
from	Western	blots	in	Figure	C.9	to	Figure	C.12	and	Figure	5.11	
PRMT5 
Repeat # Control 24hr 48hr 72hr 
1 312.849 463.092 1395.627 2414.619 
2 559.506 506.749 335.335 2897.255 
3 890.799 853.042 946.456 6137.397 
PRMT8 
Repeat # Control 24hr 48hr 72hr 
1 1403.092 1841.092 1121.092 1393.021 
2 808.989 2260.749 1481.456 1756.406 
3 680.08 1267.356 738.77 1855.982 
PRMT1 
Repeat # Control 24hr 48hr 72hr 
1 2986.87 2920.598 3873.012 5104.376 
2 5390.64 4574.74 4433.619 8388.175 
3 3444.77 3403.891 3892.891 5999.719 
GAPDH 
Repeat # Control 24hr 48hr 72hr 
1 3971.782 4696.782 3271.782 4513.641 
2 3101.841 3622.184 4063.033 4181.246 
3 3763.296 4823.953 5020.024 4595.418 
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Table	C.10	The	ratio	of	band	densities	of	PRMT5,	1	and	8	to	that	of	GAPDH	
calculated	from	Table	C.9.	
PRMT5/GAPDH 
Repeat # Control 24hr 48hr 72hr 
1 0.078767918 0.098597721 0.426564789 0.534960357 
2 0.180378685 0.139901507 0.082533172 0.692916657 
3 0.236707131 0.176834642 0.18853615 1.33554706 
Average 0.165284578 0.138444623 0.232544704 0.854474691 
STDEV 0.080044193 0.039138802 0.176187409 0.424040701 
SEM 0.046213536 0.022596798 0.101721848 0.244820013 
 PRMT8/GAPDH 
Repeat # Control 24hr 48hr 72hr 
1 0.353265109 0.39199009 0.342654859 0.308624678 
2 0.260809306 0.624139746 0.364618254 0.420067607 
3 0.180713927 0.262721465 0.147164635 0.403876644 
Average 0.264929448 0.426283767 0.284812583 0.377522976 
STDEV 0.086349344 0.183133382 0.119711386 0.060214354 
SEM 0.049853817 0.105732107 0.069115401 0.034764774 
 PRMT1/GAPDH 
Repeat # Control 24hr 48hr 72hr 
1 0.752022644 0.621829585 1.183762243 1.13087771 
2 1.73788405 1.262978358 1.091209203 2.006142427 
3 0.915359834 0.705622754 0.775472587 1.305587218 
Average 1.135088842 0.863476899 1.016814678 1.480869118 
STDEV 0.528385566 0.348505933 0.214070128 0.463211496 
SEM 0.305063549 0.201209994 0.123593446 0.267435282 	
	
